

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 38/00, C07K 5/00, 7/00, 17/00, C07D 211/40, 211/54, 207/12, 207/24, 207/36</p>	A1	<p>(11) International Publication Number: WO 95/09001</p> <p>(43) International Publication Date: 6 April 1995 (06.04.95)</p>
<p>(21) International Application Number: PCT/US94/11071</p> <p>(22) International Filing Date: 29 September 1994 (29.09.94)</p> <p>(30) Priority Data: 129,868 30 September 1993 (30.09.93) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 129,868 (CIP) Filed on 30 September 1993 (30.09.93)</p> <p>(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): DESOLMS, S., Jane [US/US]; 735 Port Indian Road, Norristown, PA 19403 (US). GARSKY, Victor, M. [US/US]; 752 Palmer Place, Blue Bell, PA 19422 (US). GIULLANI, Elizabeth, A. [US/US]; 1333 Gwynedale Way, Lansdale, PA 19446 (US). GOMEZ, Robert, P. [US/US]; 307 Victoria Lane, Perkasie, PA 18944 (US). GRAHAM, Samuel, L. [US/US]; 325</p>		<p>Widlund Drive, Schwenksville, PA 19473 (US). STOKKER, Gerald, E. [US/US]; 212 Plymouth Road, Gwynedd Valley, PA 19437 (US). WISCOUNT, Catherine, M. [US/US]; 3096 Lindberg Avenue, Allentown, PA 18103 (US).</p> <p>(74) Common Representative: MERCK & CO., INC.; Patent Dept., 126 East Lincoln Avenue, Rahway, NJ 07065 (US).</p> <p>(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).</p> <p>Published With international search report.</p>
<p>(54) Title: INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE</p> <p>(57) Abstract</p> <p>The present invention comprises analogs of the CAAX motif of the protein Ras that is modified by farnesylation <i>in vivo</i>. These CAAX analogs inhibit the farnesylation of Ras. Furthermore, these CAAX analogs differ from those previously described as inhibitors of Ras farnesyl transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autooxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LJ	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

TITLE OF THE INVENTION
INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

RELATED APPLICATION

5 The present patent application is a continuation-in-part application of copending application Serial No. 08/129,868, filed September 30, 1993.

BACKGROUND OF THE INVENTION

10 The *Ras* gene is found activated in many human cancers, including colorectal carcinoma, exocrine pancreatic carcinoma, and myeloid leukemias. Biological and biochemical studies of Ras action indicate that Ras functions like a G-regulatory protein, since Ras must be localized in the plasma membrane and must bind with GTP in order
15 to transform cells (Gibbs, J. *et al.*, *Microbiol. Rev.* 53:171-286 (1989). Forms of Ras in cancer cells have mutations that distinguish the protein from Ras in normal cells.

 At least 3 post-translational modifications are involved with Ras membrane localization, and all 3 modifications occur at the C-terminus of Ras. The Ras C-terminus contains a sequence motif termed
20 a "CAAX" or "Cys-Aaa¹-Aaa²-Xaa" box (Aaa is an aliphatic amino acid, the Xaa is any amino acid) (Willumsen *et al.*, *Nature* 310:583-586 (1984)). Other proteins having this motif include the Ras-related GTP-binding proteins such as Rho, fungal mating factors, the nuclear lamins,
25 and the gamma subunit of transducin.

 Farnesylation of Ras by the isoprenoid farnesyl pyrophosphate (FPP) occurs *in vivo* on Cys to form a thioether linkage (Hancock *et al.*, *Cell* 57:1167 (1989); Casey *et al.*, *Proc. Natl. Acad. Sci. USA* 86:8323 (1989)). In addition, Ha-Ras and N-Ras are palmitoylated
30 via formation of a thioester on a Cys residue near a C-terminal Cys farnesyl acceptor (Gutierrez *et al.*, *EMBO J.* 8:1093-1098 (1989); Hancock *et al.*, *Cell* 57:1167-1177 (1989)). Ki-Ras lacks the palmitate acceptor Cys. The last 3 amino acids at the Ras C-terminal end are removed proteolytically, and methyl esterification occurs at the new C-

- 2 -

terminus (Hancock *et al.*, *ibid*). Fungal mating factor and mammalian nuclear lamins undergo identical modification steps (Anderegg *et al.*, *J. Biol. Chem.* 263:18236 (1988); Farnsworth *et al.*, *J. Biol. Chem.* 264:20422 (1989)).

5 Inhibition of Ras farnesylation *in vivo* has been demonstrated with lovastatin (Merck & Co., Rahway, NJ) and compactin (Hancock *et al.*, *ibid*; Casey *et al.*, *ibid*; Schafer *et al.*, *Science* 245:379 (1989)). These drugs inhibit HMG-CoA reductase, the rate limiting enzyme for the production of polyisoprenoids and the farnesyl
10 pyrophosphate precursor. It has been shown that a farnesyl-protein transferase using farnesyl pyrophosphate as a precursor is responsible for Ras farnesylation. (Reiss *et al.*, *Cell*, 62:81-88 (1990); Schaber *et al.*, *J. Biol. Chem.*, 265:14701-14704 (1990); Schafer *et al.*, *Science*, 249:1133-1139 (1990); Manne *et al.*, *Proc. Natl. Acad. Sci USA*,
15 87:7541-7545 (1990)).

 Inhibition of farnesyl-protein transferase and, thereby, of farnesylation of the Ras protein, blocks the ability of Ras to transform normal cells to cancer cells. The compounds of the invention inhibit Ras farnesylation and, thereby, generate soluble Ras which, as indicated
20 *infra*, can act as a dominant negative inhibitor of Ras function. While soluble Ras in cancer cells can become a dominant negative inhibitor, soluble Ras in normal cells would not be an inhibitor.

 A cytosol-localized (no Cys-Aaa¹-Aaa²-Xaa box membrane domain present) and activated (impaired GTPase activity, staying bound
25 to GTP) form of Ras acts as a dominant negative Ras inhibitor of membrane-bound Ras function (Gibbs *et al.*, *Proc. Natl. Acad. Sci. USA* 86:6630-6634(1989)). Cytosollocalized forms of Ras with normal GTPase activity do not act as inhibitors. Gibbs *et al.*, *ibid*, showed this effect in *Xenopus* oocytes and in mammalian cells.

30 Administration of compounds of the invention to block Ras farnesylation not only decreases the amount of Ras in the membrane but also generates a cytosolic pool of Ras. In tumor cells having activated Ras, the cytosolic pool acts as another antagonist of membrane-bound Ras function. In normal cells having normal Ras, the cytosolic pool of

- 3 -

Ras does not act as an antagonist. In the absence of complete inhibition of farnesylation, other farnesylated proteins are able to continue with their functions.

5 Farnesyl-protein transferase activity may be reduced or completely inhibited by adjusting the compound dose. Reduction of farnesyl-protein transferase enzyme activity by adjusting the compound dose would be useful for avoiding possible undesirable side effects resulting from interference with other metabolic processes which utilize the enzyme.

10 These compounds and their analogs are inhibitors of farnesyl-protein transferase. Farnesyl-protein transferase utilizes farnesyl pyrophosphate to covalently modify the Cys thiol group of the Ras CAAX box with a farnesyl group. Inhibition of farnesyl pyrophosphate biosynthesis by inhibiting HMG-CoA reductase blocks
15 Ras membrane localization *in vivo* and inhibits Ras function. Inhibition of farnesyl-protein transferase is more specific and is attended by fewer side effects than is the case for a general inhibitor of isoprene biosynthesis.

Previously, it has been demonstrated that tetrapeptides
20 containing cysteine as an amino terminal residue with the CAAX sequence inhibit Ras farnesylation (Schaber *et al.*, *ibid*; Reiss *et al.*, *ibid*; Reiss *et al.*, *PNAS*, 88:732-736 (1991)). Such inhibitors may inhibit while serving as alternate substrates for the Ras farnesyl-transferase enzyme, or may be purely competitive inhibitors (U.S.
25 Patent 5,141,851, University of Texas).

It has also been demonstrated that certain inhibitors of farnesyl-protein transferase selectively block the processing of Ras oncoprotein intracellularly (N.E. Kohl *et al.*, *Science*, 260:1934-1937 (1993) and G.L. James *et al.*, *Science*, 260:1937-1942 (1993).

30 Recently, it has been shown that an inhibitor of farnesyl-protein transferase blocks the growth of *ras*-dependent tumors in nude mice (N.E. Kohl *et al.*, *Proc. Natl. Acad. Sci U.S.A.*, 91:9141-9145 (1994)).

- 4 -

Inhibitors of Ras farnesyl-protein transferase (FPTase) have been described in two general classes. The first are analogs of farnesyl diphosphate (FPP), while the second class of inhibitors is related to the protein substrate for the enzyme, Ras. Almost all of the peptide derived inhibitors that have been described are cysteine containing molecules that are related to the CAAX motif that is the signal for protein prenylation. The exception to this generalization is a class of natural products known as the peptidocinnamins (Omura, *et al.*, *J. Antibiotics* 46:222 (1993)). In general, deletion of the thiol from a CAAX derivative dramatically reduces the inhibitory potency of these compounds. However, the thiol group potentially places limitations on the therapeutic application of FPTase inhibitors with respect to pharmacokinetics, pharmacodynamics and toxicity. Therefore, a functional replacement for the thiol is desirable. With the exception of the peptidocinnamins, non-thiol FPTase inhibitors that are competitive with the Ras substrate have not been described and are the subject of this invention.

It is, therefore, an object of this invention to develop tetrapeptide-based compounds which do not have a thiol moiety, and which will inhibit farnesyl transferase and the post-translational functionalization of the oncogene Ras protein. It is a further object of this invention to develop chemotherapeutic compositions containing the compounds of this invention and methods for producing the compounds of this invention.

SUMMARY OF THE INVENTION

The present invention comprises analogs of the CAAX motif of the protein Ras that is modified by farnesylation *in vivo*. These CAAX analogs inhibit the farnesylation of Ras. Furthermore, these CAAX analogues differ from those previously described as inhibitors of Ras farnesyl transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide

- 5 -

formation with endogenous thiols, and reduced systemic toxicity.
Further contained in this invention are chemotherapeutic compositions
containing these farnesyl transferase inhibitors and methods for their
production.

5

10

15


20

25

30

- 6 -


The compounds of this invention are illustrated by the formulae:



I


10

15



II

20




25

III

and

30




IV

- 7 -

DETAILED DESCRIPTION OF THE INVENTION

The compounds of this invention inhibit the farnesylation of Ras. In a first embodiment of this invention, the Ras farnesyl transferase inhibitors are illustrated by the formula I:



wherein:

R¹ is selected from:

- a) heterocycle, and
- b) C₁-C₁₀ alkyl, which is substituted with heterocycle and which is optionally substituted with one or more of C₁-C₄ alkyl, hydroxy or amino groups;

R^{2a} and R^{2b} are independently selected from:

- a) a side chain of a naturally occurring amino acid,
- b) an oxidized form of a side chain of a naturally occurring amino acid which is:
 - i) methionine sulfoxide, or
 - ii) methionine sulfone,
- c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
- d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocycle and C₃-C₁₀ cycloalkyl; or

R^{2a} and R^{2b} are combined to form - (CH₂)_s -;

- 8 -

R³ and R⁴ are independently selected from:

- 5 a) a side chain of a naturally occurring amino acid,
 b) an oxidized form of a side chain of a naturally occurring
 amino acid which is:
 i) methionine sulfoxide, or
 ii) methionine sulfone, and
 c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀
10 alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,
 wherein the substituent is selected from F,
 Cl, Br, N(R⁸)₂, NO₂, R⁸O-, R⁹S(O)_m-,
 R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-,
 R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂,
 R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
15 d) C₁-C₆ alkyl substituted with an unsubstituted or
 substituted group selected from aryl, heterocyclic and C₃-
 C₁₀ cycloalkyl; or

20 R³ and R⁴ are combined to form - (CH₂)_s - ;

R^{5a} and R^{5b} are independently selected from:

- a) a side chain of a naturally occurring amino acid,
 b) an oxidized form of a side chain of a naturally occurring
 amino acid which is:
25 i) methionine sulfoxide, or
 ii) methionine sulfone,
 c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀
 alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocycle group,
 wherein the substituent is selected from F, Cl, Br,
30 N(R⁸)₂, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-,
 CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃,
 -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and


- 9 -

d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl; or


5 R^{5a} and R^{5b} are combined to form $-(CH_2)_8-$ wherein one of the carbon atoms is optionally replaced by a moiety selected from: O, S(O)_m, -NC(O)-, and -N(COR⁸)-;

X-Y is



10




15



20



25



30 R^{7a} is selected from

- a) hydrogen,
- b) unsubstituted or substituted aryl,
- c) unsubstituted or substituted heterocyclic,
- d) unsubstituted or substituted cycloalkyl, and

- 10 -

e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

5 R^{7b} is selected from

- a) hydrogen,
- b) unsubstituted or substituted aryl,
- c) unsubstituted or substituted heterocyclic,
- d) unsubstituted or substituted cycloalkyl,
- 10 e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl,
- f) a carbonyl group which is bonded to an unsubstituted or substituted group selected from aryl, heterocyclic, cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
- 15 unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl, and
- g) a sulfonyl group which is bonded to an unsubstituted or substituted group selected from aryl, heterocyclic, cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
- 20 unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

25 R⁸ is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

R⁹ is independently selected from C₁-C₆ alkyl and aryl;


R¹⁰ is independently selected from hydrogen and C₁-C₆ alkyl;

30 Z is independently H₂ or O;
m is 0, 1 or 2; and
s is 4 or 5;

or the pharmaceutically acceptable salts thereof.

- 11 -

In a second embodiment of this invention the prodrugs of compounds of formula I are illustrated by the formula II:



10 wherein:

R¹ is selected from:

- 15 a) heterocycle, and
b) C₁-C₁₀ alkyl, which is substituted with heterocycle and which is optionally substituted with one or more of C₁-C₄ alkyl, hydroxy or amino groups;

R^{2a} and R^{2b} are independently selected from:

- 20 a) a side chain of a naturally occurring amino acid,
b) an oxidized form of a side chain of a naturally occurring amino acid which is:
i) methionine sulfoxide, or
ii) methionine sulfone,
c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,
25 wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocycle and C₃-C₁₀ cycloalkyl; or
- 30

R^{2a} and R^{2b} are combined to form - (CH₂)_s - ;

- 12 -

R³ and R⁴ are independently selected from:

- a) a side chain of a naturally occurring amino acid,
- b) an oxidized form of a side chain of a naturally occurring amino acid which is:
 - 5 i) methionine sulfoxide, or
 - ii) methionine sulfone, and
- c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br,
 - 10 N(R⁸)₂, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
 - d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl; or

R³ and R⁴ are combined to form - (CH₂)_s - ;

R^{5a} and R^{5b} are independently selected from:

- 20 a) a side chain of a naturally occurring amino acid,
- b) an oxidized form of a side chain of a naturally occurring amino acid which is:
 - i) methionine sulfoxide, or
 - 25 ii) methionine sulfone,
- c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocycle group, wherein the substituent is selected from F, Cl, Br,
 - 30 N(R⁸)₂, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
 - d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl; or

- 13 -


R5a and R5b are combined to form $-(CH_2)_s-$ wherein one of the carbon atoms is optionally replaced by a moiety selected from: O, S(O)_m, -NC(O)-, and -N(COR⁸)-;

5 R⁶ is

a) substituted or unsubstituted C₁-C₈ alkyl, wherein the substituent on the alkyl is selected from:


- 1) aryl,
- 2) heterocycle,
- 10 3) -N(R⁹)₂,
- 4) -OR⁸, or

b)




X-Y is

20




25





30

- 14 -



5



10

R7a is selected from

- a) hydrogen,
- b) unsubstituted or substituted aryl,
- c) unsubstituted or substituted heterocyclic,
- d) unsubstituted or substituted cycloalkyl, and
- e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

15

20 R7b is selected from

- a) hydrogen,
- b) unsubstituted or substituted aryl,
- c) unsubstituted or substituted heterocyclic,
- d) unsubstituted or substituted cycloalkyl,
- e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl,
- f) a carbonyl group which is bonded to an unsubstituted or substituted group selected from aryl, heterocyclic, cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl, and
- g) a sulfonyl group which is bonded to an unsubstituted or substituted group selected from aryl, heterocyclic,

25

30

- 15 -

cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

5 R⁸ is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

R⁹ is independently selected from C₁-C₆ alkyl and aryl;

10 R¹⁰ is independently selected from hydrogen and C₁-C₆ alkyl;

R¹¹ is independently selected from C₁-C₆ alkyl;


Z is independently H₂ or O;

15 m is 0, 1 or 2; and

s is 4 or 5;

or the pharmaceutically acceptable salts.

20 In a third embodiment of this invention, the inhibitors of farnesyl transferase are illustrated by the formula III:



III

wherein:

30 R¹ is selected from:

- a) heterocycle, and
- b) C₁-C₁₀ alkyl, which is substituted with heterocycle and which is optionally substituted with one or more of C₁-C₄ alkyl, hydroxy or amino groups;

- 16 -

R2a and R2b are independently selected from:

- a) a side chain of a naturally occurring amino acid,
- b) an oxidized form of a side chain of a naturally occurring amino acid which is:
 - i) methionine sulfoxide, or
 - ii) methionine sulfone,
- c) substituted or unsubstituted C1-C20 alkyl, C2-C20 alkenyl, C3-C10 cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C1-C20 alkyl, and
- d) C1-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocycle and C3-C10 cycloalkyl; or

R2a and R2b are combined to form - (CH₂)_s -;

R3 and R4 are independently selected from:


- a) a side chain of a naturally occurring amino acid,
- b) an oxidized form of a side chain of a naturally occurring amino acid which is:
 - i) methionine sulfoxide, or
 - ii) methionine sulfone, and
- c) substituted or unsubstituted C1-C20 alkyl, C2-C20 alkenyl, C3-C10 cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, N(R⁸)₂, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C1-C20 alkyl, and
- d) C1-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C3-C10 cycloalkyl; or

R3 and R4 are combined to form - (CH₂)_s -;


- 17 -

X-Y is


5





10



15



20



R^{7a} is selected from

25

- a) hydrogen,
- b) unsubstituted or substituted aryl,
- c) unsubstituted or substituted heterocyclic,
- d) unsubstituted or substituted cycloalkyl, and
- e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

30

R^{7b} is selected from

- a) hydrogen,

- 18 -

- b) unsubstituted or substituted aryl,
c) unsubstituted or substituted heterocyclic,
d) unsubstituted or substituted cycloalkyl,
5 e) C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl,
f) a carbonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
10 unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl, and
g) a sulfonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
15 unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl;

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

20 R⁹ is independently selected from C₁-C₆ alkyl and aryl;

R¹⁰ is independently selected from hydrogen and C₁-C₆ alkyl;

Z is H₂ or O;

25

m is 0, 1 or 2;


n is 0, 1 or 2; and

s is 4 or 5;

30 or the pharmaceutically acceptable salts thereof.

In a fourth embodiment of this invention the prodrugs of
compounds of formula III are illustrated by the formula IV:

- 19 -



IV

wherein:

R1 is selected from:

- a) heterocycle, and
- b) C1-C10 alkyl, which is substituted with heterocycle and which is optionally substituted with one or more of C1-C4 alkyl, hydroxy or amino groups;

R2a and R2b are independently selected from:

- a) a side chain of a naturally occurring amino acid,
- b) an oxidized form of a side chain of a naturally occurring amino acid which is:
 - i) methionine sulfoxide, or
 - ii) methionine sulfone,
- c) substituted or unsubstituted C1-C20 alkyl, C2-C20 alkenyl, C3-C10 cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C1-C20 alkyl, and
- d) C1-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocycle and C3-C10 cycloalkyl; or

R2a and R2b are combined to form - (CH₂)_s -;

R3 and R4 are independently selected from:

- a) a side chain of a naturally occurring amino acid,

- 20 -

b) an oxidized form of a side chain of a naturally occurring amino acid which is:

i) methionine sulfoxide, or

ii) methionine sulfone, and

5 c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,

wherein the substituent is selected from F, Cl, Br,

N(R⁸)₂, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-,

10 CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃,


-N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and

d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl; or


15 R³ and R⁴ are combined to form - (CH₂)_s - ;

X-Y is

20




25




30



- 21 -



5



10 R7a is selected from

- 15 a) hydrogen,
b) unsubstituted or substituted aryl,
c) unsubstituted or substituted heterocyclic,
d) unsubstituted or substituted cycloalkyl, and
e) C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl;

20 R7b is selected from

- 25 a) hydrogen,
b) unsubstituted or substituted aryl,
c) unsubstituted or substituted heterocyclic,
d) unsubstituted or substituted cycloalkyl,
e) C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl,
f) a carbonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
30 unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl, and
g) a sulfonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an

- 22 -

unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl;

R^8 is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

R^9 is independently selected from C₁-C₆ alkyl and aryl;

R^{10} is independently selected from hydrogen and C₁-C₆ alkyl;
Z is H₂ or O;


m is 0, 1 or 2;

n is 0, 1 or 2; and

s is 4 or 5;

or the pharmaceutically acceptable salts.

In a more preferred embodiment of this invention, the Ras
farnesyl transferase inhibitors are illustrated by the formula I:



wherein:

R^1 is selected from:

- a) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and isoquinolinyl, and
- b) C₁-C₁₀ alkyl, which is substituted with a heterocycle and which is optionally substituted with one or more of C₁-C₄ alkyl, hydroxy or amino groups;

wherein the heterocycle is selected from
pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl,

- 23 -

pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and isoquinolinyl;

R^{2a} is selected from:

- 5 a) a side chain of a naturally occurring amino acid,
 wherein the amino acid is selected from alanine,
 leucine, isoleucine and valine; and
 b) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀
10 alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,
 wherein the substituent is selected from F, Cl, Br,
 NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN,
 (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃,
 -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
15 c) C₁-C₆ alkyl substituted with an unsubstituted or
 substituted group selected from aryl, heterocyclic and C₃-
 C₁₀ cycloalkyl;

R^{2b} is selected from hydrogen and C₁-C₆ alkyl; or

20 R^{2a} and R^{2b} are combined to form - (CH₂)_s -;

R³ and R⁴ are independently selected from:

- 25 a) a side chain of a naturally occurring amino acid,
 b) an oxidized form of a side chain of a naturally occurring
 amino acid which is:
 i) methionine sulfoxide, or
 ii) methionine sulfone,
 c) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀
30 alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,
 wherein the substituent is selected from F,
 Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-,
 R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-,
 R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂,
 R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and

- 24 -

d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl;

5 R_{5a} is selected from:

a) a side chain of a naturally occurring amino acid, wherein the amino acid is selected from methionine and glutamine,

10

b) an oxidized form of a side chain of a naturally occurring amino acid which is:

i) methionine sulfoxide, or

ii) methionine sulfone, and

15

c) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,

wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and

20

d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl;;

R_{5b} is selected from:

25

a) hydrogen, and


b) C₁-C₃ alkyl;

30


- 25 -

X-Y is


5




10



15



20

R^{7a} is selected from

25

- a) hydrogen,
- b) unsubstituted or substituted aryl,
- c) unsubstituted or substituted heterocyclic,
- d) unsubstituted or substituted cycloalkyl, and
- e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

30

wherein heterocycle is selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl;

- 26 -

R^{7b} is selected from

- 5 a) hydrogen,
 b) unsubstituted or substituted aryl,
 c) unsubstituted or substituted heterocyclic,
 d) unsubstituted or substituted cycloalkyl,
 e) C₁-C₆ alkyl substituted with hydrogen or an
 unsubstituted or substituted group selected from aryl,
 heterocyclic and cycloalkyl,
10 f) a carbonyl group which is bonded to an unsubstituted or
 substituted group selected from aryl, heterocyclic,
 cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
 unsubstituted or substituted group selected from aryl,
 heterocyclic and cycloalkyl, and
15 g) a sulfonyl group which is bonded to an unsubstituted or
 substituted group selected from aryl, heterocyclic,
 cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
 unsubstituted or substituted group selected from aryl,
 heterocyclic and cycloalkyl;
20 wherein heterocycle is selected from pyrrolidinyl,
 imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-
 oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl,
 and thienyl;

25 R⁸ is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

 R⁹ is independently selected from C₁-C₆ alkyl and aryl;

 R¹⁰ is independently selected from hydrogen and C₁-C₆ alkyl;

30 Z is independently H₂ or O;


 m is 0, 1 or 2; and

 s is 4 or 5;

- 27 -

or the pharmaceutically acceptable salts thereof.

In a second more preferred embodiment of this invention,
the prodrugs of the preferred compounds of formula I are illustrated by
the formula II:



II

wherein:

R¹ is selected from:

- a) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and isoquinolinyl, and
- b) C₁-C₁₀ alkyl, which is substituted with a heterocycle and which is optionally substituted with one or more of C₁-C₄ alkyl, hydroxy or amino groups;

wherein the heterocycle is selected from
pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl,
pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and
isoquinolinyl;

R^{2a} is selected from:

- a) a side chain of a naturally occurring amino acid,
wherein the amino acid is selected from alanine,
leucine, isoleucine and valine; and
- b) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,
wherein the substituent is selected from F, Cl, Br,
NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN,

- 28 -

(R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃,
-N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
c) C₁-C₆ alkyl substituted with an unsubstituted or
substituted group selected from aryl, heterocyclic and C₃-
C₁₀ cycloalkyl;

R_{2b} is selected from hydrogen and C₁-C₆ alkyl; or

R_{2a} and R_{2b} are combined to form - (CH₂)_s -;

R₃ and R₄ are independently selected from:

a) a side chain of a naturally occurring amino acid,
b) an oxidized form of a side chain of a naturally occurring
amino acid which is:

i) methionine sulfoxide, or
ii) methionine sulfone,

c) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀
alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,

wherein the substituent is selected from F, Cl, Br,

NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN,
(R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃,

-N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and

d) C₁-C₆ alkyl substituted with an unsubstituted or
substituted group selected from aryl, heterocyclic and C₃-
C₁₀ cycloalkyl;

R_{5a} is selected from:

a) a side chain of a naturally occurring amino acid,
wherein the amino acid is selected from methionine
and glutamine,

b) an oxidized form of a side chain of a naturally occurring
amino acid which is:

i) methionine sulfoxide, or
ii) methionine sulfone, and

- 29 -

c) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
 d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl;

R^{5b} is selected from:


- a) hydrogen, and
- b) C₁-C₃ alkyl;

R⁶ is



a) substituted or unsubstituted C₁-C₈ alkyl, wherein the substituent on the alkyl is selected from:

- 1) aryl,
- 2) heterocycle,
- 3) -N(R⁹)₂,
- 4) -OR⁸, or


b)




X-Y is



- 30 -



5



10

R7a is selected from

- 15 a) hydrogen,
 b) unsubstituted or substituted aryl,
 c) unsubstituted or substituted heterocyclic,
 d) unsubstituted or substituted cycloalkyl, and
 e) C₁-C₆ alkyl substituted with hydrogen or an
 unsubstituted or substituted group selected from aryl,
 heterocyclic and cycloalkyl;

20

wherein heterocycle is selected from pyrrolidinyl,
 imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-
 oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl,
 and thienyl;

25

R7b is selected from

- 30 a) hydrogen,
 b) unsubstituted or substituted aryl,
 c) unsubstituted or substituted heterocyclic,
 d) unsubstituted or substituted cycloalkyl,
 e) C₁-C₆ alkyl substituted with hydrogen or an
 unsubstituted or substituted group selected from aryl,
 heterocyclic and cycloalkyl,
 f) a carbonyl group which is bonded to an unsubstituted or
 substituted group selected from aryl, heterocyclic,
 cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an

- 31 -

unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl, and
g) a sulfonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
5 cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl;

wherein heterocycle is selected from pyrrolidinyl,
imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-
10 oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl,
and thienyl;

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

15 R⁹ is independently selected from C₁-C₆ alkyl and aryl;

R¹⁰ is independently selected from hydrogen and C₁-C₆ alkyl;

20 R¹¹ is independently selected from C₁-C₆ alkyl;

Z is independently H₂ or O;

m is 0, 1 or 2; and

s is 4 or 5;


25

or the pharmaceutically acceptable salts thereof.

In a third more preferred embodiment of this invention,
the inhibitors of farnesyl transferase are illustrated by the formula III:

30

- 32 -



III

wherein:

10 R¹ is selected from:

- a) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and isoquinolinyl, and
 b) C₁-C₁₀ alkyl, which is substituted with a heterocycle and which is optionally substituted with one or more of C₁-C₄ alkyl, hydroxy or amino groups;

wherein the heterocycle is selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and isoquinolinyl;

20 R^{2a} is selected from:

- a) a side chain of a naturally occurring amino acid, wherein the amino acid is selected from alanine, leucine, isoleucine and valine; and

b) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and

c) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl;

- 33 -

R2b is selected from hydrogen and C1-C6 alkyl; or

R2a and R2b are combined to form - (CH2)_s -;

5

R3 and R4 are independently selected from:

- a) a side chain of a naturally occurring amino acid,
- b) an oxidized form of a side chain of a naturally occurring amino acid which is:

10

- i) methionine sulfoxide, or
- ii) methionine sulfone,

15

- c) substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, C3-C10 cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C1-C20 alkyl, and
- d) C1-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C3-C10 cycloalkyl;


20

25

30

- 34 -

X-Y is



20

R7a is selected from

- a) hydrogen,
 b) unsubstituted or substituted aryl,
 c) unsubstituted or substituted heterocyclic,
 d) unsubstituted or substituted cycloalkyl, and
 e) C1-C6 alkyl substituted with hydrogen or an
 unsubstituted or substituted group selected from aryl,
 heterocyclic and cycloalkyl;

25

30

wherein heterocycle is selected from pyrrolidinyl,
 imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-
 oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl,
 and thienyl;

R7b is selected from

- a) hydrogen,

- 35 -

- 5 b) unsubstituted or substituted aryl,
 c) unsubstituted or substituted heterocyclic,
 d) unsubstituted or substituted cycloalkyl,
 e) C₁-C₆ alkyl substituted with hydrogen or an
 unsubstituted or substituted group selected from aryl,
 heterocyclic and cycloalkyl,
 f) a carbonyl group which is bonded to an unsubstituted or
 substituted group selected from aryl, heterocyclic,
10 cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
 unsubstituted or substituted group selected from aryl,
 heterocyclic and cycloalkyl, and
 g) a sulfonyl group which is bonded to an unsubstituted or
 substituted group selected from aryl, heterocyclic,
15 cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
 unsubstituted or substituted group selected from aryl,
 heterocyclic and cycloalkyl;

 wherein heterocycle is selected from pyrrolidinyl,
 imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-
20 oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl,
 and thienyl;

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

25 R⁹ is independently selected from C₁-C₆ alkyl and aryl;

R¹⁰ is independently selected from hydrogen and C₁-C₆ alkyl;


Z is independently H₂ or O;

30 m is 0, 1 or 2;
 n is 0, 1 or 2; and
 s is 4 or 5;

or the pharmaceutically acceptable salts thereof.

- 36 -

In a fourth more preferred embodiment of this invention,
the prodrugs of the preferred compounds of formula III are illustrated
by the formula IV:



IV

wherein:

R¹ is selected from:

- a) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and isoquinolinyl, and
- b) C₁-C₁₀ alkyl, which is substituted with a heterocycle and which is optionally substituted with one or more of C₁-C₄ alkyl, hydroxy or amino groups;

wherein the heterocycle is selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and isoquinolinyl;

R^{2a} is selected from:

- a) a side chain of a naturally occurring amino acid, wherein the amino acid is selected from alanine, leucine, isoleucine and valine; and
- b) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN,

- 37 -

(R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃,
-N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
c) C₁-C₆ alkyl substituted with an unsubstituted or
substituted group selected from aryl, heterocyclic and C₃-
C₁₀ cycloalkyl;

R_{2b} is selected from hydrogen and C₁-C₆ alkyl; or

R_{2a} and R_{2b} are combined to form - (CH₂)_s -;

R₃ and R₄ are independently selected from:

a) a side chain of a naturally occurring amino acid,
b) an oxidized form of a side chain of a naturally occurring
amino acid which is:

i) methionine sulfoxide, or

ii) methionine sulfone,

c) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀
alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,

wherein the substituent is selected from F, Cl, Br,

NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN,





(R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃,

-N(R⁸)₂, R⁹OC(O)NR⁸-, C₁-C₂₀ alkyl, and

d) C₁-C₆ alkyl substituted with an unsubstituted or
substituted group selected from aryl, heterocyclic and C₃-
C₁₀ cycloalkyl;

- 38 -

X-Y is

R^{7a} is selected from

- a) hydrogen,
- b) unsubstituted or substituted aryl,
- c) unsubstituted or substituted heterocyclic,
- d) unsubstituted or substituted cycloalkyl, and
- e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

wherein heterocycle is selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl;

R^{7b} is selected from

- a) hydrogen,

- 39 -

- 5 b) unsubstituted or substituted aryl,
 c) unsubstituted or substituted heterocyclic,
 d) unsubstituted or substituted cycloalkyl,
 e) C₁-C₆ alkyl substituted with hydrogen or an
 unsubstituted or substituted group selected from aryl,
 heterocyclic and cycloalkyl,
 f) a carbonyl group which is bonded to an unsubstituted or
 substituted group selected from aryl, heterocyclic,
10 cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
 unsubstituted or substituted group selected from aryl,
 heterocyclic and cycloalkyl, and
 g) a sulfonyl group which is bonded to an unsubstituted or
 substituted group selected from aryl, heterocyclic,
15 cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
 unsubstituted or substituted group selected from aryl,
 heterocyclic and cycloalkyl;
 wherein heterocycle is selected from pyrrolidinyl,
 imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-
20 oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl,
 and thienyl;

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

25 R⁹ is independently selected from C₁-C₆ alkyl and aryl;

R¹⁰ is independently selected from hydrogen and C₁-C₆ alkyl;

30 Z is independently H₂ or O;

m is 0, 1 or 2;

n is 0, 1 or 2; and

s is 4 or 5;

- 40 -

or the pharmaceutically acceptable salts thereof.

The preferred compounds of this invention are as follows:

- 5 Pyroglutamyl-valyl-phenylalanyl-methionine; (SEQ.ID.NO.: 1)
- Pyroglutamyl-valyl-phenylalanyl-methionine methyl ester;
 (SEQ.ID.NO.: 1)
- 10 Pyroglutamyl-valyl-isoleucyl-methionine; (SEQ.ID.NO.: 2)
- Pyroglutamyl-valyl-isoleucyl-methionine methyl ester; (SEQ.ID.NO.:
 2)
- 15 Nicotinoyl-isoleucyl-phenylalanyl-methionine;
- Nicotinoyl-isoleucyl-phenylalanyl-methionine methyl ester;
- 20 N-[2(S)-(L-Pyroglutamylamino)-3-methylbutyl]phenylalanyl-
 methionine;
- N-[2(S)-(L-Pyroglutamylamino)-3-methylbutyl]phenylalanyl-methionine
 methyl ester;
- 25 N-[5(S)-(L-Pyroglutamylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-
 octenoyl]-methionine;
- N-[5(S)-(L-Pyroglutamylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-
 octenoyl]-methionine methyl ester;
- 30 N-[5(S)-((Imidazol-4-yl)acetyl-amino)-6(S)-methyl-2(R)-butyl-3,4(E)-
 octenoyl]-methionine;

- 41 -

N-[5(S)-((Imidazol-4-yl)acetylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine methyl ester;

5 N-[5(S)-((Imidazol-4-yl)carbonylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine;

N-[5(S)-((Imidazol-4-yl)carbonylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine methyl ester;

10 N-[2(S)-(2(S)-(Imidazol-4-yl)acetylamino)-3(S)-methylpentyl-3-phenylpropionyl]-methionine;

15 N-[2(S)-(2(S)-(Imidazol-4-yl)acetylamino)-3(S)-methylpentyl-3-phenylpropionyl]-methionine methyl ester;

N-[2(S)-(2(S)-Pyroglutamylamino)-3(S)-methylpentyl-3-phenylpropionyl]-methionine;

20 N-[2(S)-(2(S)-Pyroglutamylamino)-3(S)-methylpentyl-3-phenylpropionyl]-methionine methyl ester;

N-[2(S)-(2(S)-Imidazol-4-ylcarbonylamino)-3(S)-methylpentyl-3-phenylpropionyl]-methionine;

25 N-[2(S)-(2(S)-Imidazol-4-ylcarbonylamino)-3(S)-methylpentyl-3-phenylpropionyl]-methionine methyl ester;

30 N-[2(S)-(2(S)-((3-Picolinyl)amino)-3(S)-methylpentyl-3-phenylpropionyl]-methionine;

N-[2(S)-(2(S)-((3-Picolinyl)amino)-3(S)-methylpentyl-3-phenylpropionyl]-methionine methyl ester;

- 42 -

N-[2(S)-(2(S)-((Histidyl)amino)-3(S)-methylpentyl)-3-phenylpropionyl]-methionine;

5 N-[2(S)-(2(S)-((Histidyl)amino)-3(S)-methylpentyl)-3-phenylpropionyl]-methionine methyl ester;

N-Benzyl-N-[2(S)-((Imidazol-4-ylcarbonyl)amino)-3(S)-methylpentyl]-glycyl-methionine;

10 N-Benzyl-N-[2(S)-((Imidazol-4-ylcarbonyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester;

N-Benzyl-N-[2(S)-((Imidazol-4-ylacetyl)amino)-3(S)-methylpentyl]-glycyl-methionine;

15 N-Benzyl-N-[2(S)-((Imidazol-4-ylacetyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester;

20 N-Benzyl-N-[2(S)-((Pyroglutamyl)amino)-3(S)-methylpentyl]-glycyl-methionine;

N-Benzyl-N-[2(S)-((Pyroglutamyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester;

25 N-(1-Naphthylmethyl)-N-[2(S)-((imidazol-4-ylcarbonyl)amino)-3(S)-methylpentyl]-glycyl-methionine;

N-(1-Naphthylmethyl)-N-[2(S)-((imidazol-4-ylcarbonyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester;

30 N-(1-Naphthylmethyl)-N-[2(S)-((imidazol-4-ylacetyl)amino)-3(S)-methylpentyl]-glycyl-methionine;

- 43 -

N-(1-Naphthylmethyl)-N-[2(S)-((imidazol-4-ylacetyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester;

5 N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)amino-3(S)-methylpentyl)-glycyl-methionine; and

N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)amino-3(S)-methylpentyl)-glycyl-methionine methyl ester;

10 N-[1-(Pyroglutamylamino)cyclopent-1-ylmethyl]-N-(1-naphthylmethyl)-glycyl-methionine methyl ester

15 N-[1-(Pyroglutamylamino)-cyclopent-1-ylmethyl]-N-(1-naphthylmethyl)-glycyl-methionine

N-(2(S)-L-Histidylamino-3(S)-methylpentyl)-N-(benzylmethyl)glycyl-methionine methyl ester

20 N-(2(S)-L-Histidylamino-3(S)-methylpentyl)-N-(benzylmethyl)glycyl-methionine

N-(2(S)-L-Histidylamino-3(S)-methylpentyl)-N-(1-naphthylmethyl)-glycyl-methionine methyl ester

25 N-(2(S)-L-Histidylamino-3(S)-methylpentyl)-N-(1-naphthylmethyl)-glycyl-methionine

30 2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyloxy]-3-methylbutanoyl-methionine methyl ester

2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyloxy]-3-methylbutanoyl-methionine

- 44 -

- 2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyloxy]-3-methylbutanoyl-methionine methyl ester
- 5 2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyloxy]-3-methylbutanoyl-methionine
- N-(Benzyl)-N-[2(S)-(2-oxopyrrolidin-5(R,S)-ylmethyl)amino-3(S)-methylpentyl]-glycyl-methionine methyl ester
- 10 N-(Benzyl)-N-[2(S)-(2-oxopyrrolidin-5(R,S)-ylmethyl)amino-3(S)-methylpentyl]-glycyl-methionine
- N-(Benzyl)-N-{2(S)-[((D,L)-2-thiazolyl)alanyl]amino}-3(S)-methylpentyl}-glycyl-methionine methyl ester
- 15 N-(Benzyl)-N-{2(S)-[((D,L)-2-thiazolyl)alanyl]amino}-3(S)-methylpentyl}-glycyl-methionine
- N-(Benzyl)-N-[2(S)-(3-pyridylmethyl)amino-3(S)-methylpentyl]-glycyl-methionine methyl ester
- 20 N-(Benzyl)-N-[2(S)-(3-pyridylmethyl)amino-3(S)-methylpentyl]-glycyl-methionine
- 25 2(S)-[2(S)-(2-Oxopyrrolidin-5(S)-ylmethyl)amino-3(S)-methylpentyloxy]-3-phenylpropionyl-methionine methyl ester
- 2(S)-[2(S)-(2-Oxopyrrolidin-5(S)-ylmethyl)amino-3(S)-methylpentyloxy]-3-phenylpropionyl-methionine
- 30 2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyloxy]-3-(1-naphthyl)propionyl-methionine sulfone methyl ester
- 2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyloxy]-3-(1-naphthyl)propionyl-methionine sulfone

- 45 -

- 2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl]oxy]-3-(2-naphthyl)propionyl-methionine sulfone methyl ester
- 5 2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl]oxy]-3-(2-naphthyl)propionyl-methionine sulfone
- 2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]oxy]-3-(1-naphthyl)propionyl-methionine sulfone methyl ester
- 10 2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]oxy]-3-(1-naphthyl)propionyl-methionine sulfone
- 15 2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]oxy]-3-(2-naphthyl)propionyl-methionine sulfone methyl ester
- 2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]oxy]-3-(2-naphthyl)propionyl-methionine sulfone
- 20 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(3-quinolylmethyl)glycyl-methionine methyl ester
- N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(3-quinolylmethyl)glycyl-methionine
- 25 N-(Benzyl)-N-[2(S)-(tetrazol-1-ylacetyl)amino-3(S)-methylpentyl]-glycyl-methionine methyl ester
- 30 N-(Benzyl)-N-[2(S)-(tetrazol-1-ylacetyl)amino-3(S)-methylpentyl]-glycyl-methionine
- N-(Benzyl)-N-[2(S)-nicotinoylamino-3(S)-methylpentyl]-glycyl-methionine methyl ester

- 46 -

N-(Benzyl)-N-[2(S)-nicotinoylamino-3(S)-methylpentyl]-glycyl-methionine

5 N-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)-glycyl-methionine sulfoxide methyl ester

N-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)-glycyl-methionine sulfoxide

10 2(S)-{2(S)-[2(S,R)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl-oxy}-3-phenylpropionyl-methionine sulfone methyl ester

15 2(S)-{2(S)-[2(S,R)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl-oxy}-3-phenylpropionyl-methionine sulfone

2(S)-{2(S)-[2(R,S)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl-oxy}-3-phenylpropionyl-methionine sulfone methyl ester

20 2(S)-{2(S)-[2(R,S)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl-oxy}-3-phenylpropionyl-methionine sulfone

N-{2(S)-[2(S,R)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl)-N-(1-naphthylmethyl)-glycyl-methionine methyl ester

25 N-{2(S)-[2(S,R)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl)-N-(1-naphthylmethyl)-glycyl-methionine

30 N-{2(S)-[2(R,S)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl)-N-(1-naphthylmethyl)-glycyl-methionine methyl ester

N-{2(S)-[2(R,S)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl)-N-(1-naphthylmethyl)-glycyl-methionine

- 47 -

N-{2(S)-[(Imidazol-4-yl)methyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)-glycyl-methionine methyl ester

5 N-{2(S)-[(Imidazol-4-yl)methyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)-glycyl-methionine

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine isopropyl ester

10 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine t-butyl ester

15 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(4-quinolylmethyl)glycyl-methionine methyl ester

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(4-quinolylmethyl)glycyl-methionine

20 N-{2(S)-[3-(Imidazol-4-yl)propyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)glycyl-methionine methyl ester

N-{2(S)-[3-(Imidazol-4-yl)propyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)glycyl-methionine

25 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-norleucine

30 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-norleucine methyl ester

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-glutamine

- 48 -

- N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-glutamine t-butyl ester
- 5 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-[5-(dimethyl-amino)naphthylsulfonyl]glycyl-methionine methyl ester
- N-[2(S)-(3-pyridylmethyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-methionine
- 10 2(S)-{2(S)-[2-(Imidazol-4-yl)ethyl]amino-3(S)-methylpentyloxy}-3-phenylpropionyl-methionine sulfone methyl ester
- 2(S)-{2(S)-[2-(Imidazol-4-yl)ethyl]amino-3(S)-methylpentyloxy}-3-phenylpropionyl-methionine sulfone
- 15 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-serine methyl ester
- 20 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-(D,L)-serine
- N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-(L,D)-serine
- 25 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-homoserine lactone
- N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-homoserine
- 30 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(cinnamyl)-glycyl-methionine methyl ester

- 49 -

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(cinnamyl)-glycyl-methionine

5 N-{2(S)-[2-(Imidazol-4-yl)ethyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)glycyl-methionine methyl ester

N-{2(S)-[2-(Imidazol-4-yl)ethyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)glycyl-methionine

10 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-alanine methyl ester

15 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-alanine

N-[2(S)-(D-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine methyl ester

20 N-[2(S)-(D-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine

2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyloxy]-3-phenylpropionyl-methionine sulfone methyl ester

25 2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyloxy]-3-phenylpropionyl-methionine sulfone

30 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-methylenedioxybenzyl)glycyl-methionine methyl ester

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-methylenedioxybenzyl)glycyl-methionine

- 50 -

N-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]-N-(2,3-dihydrobenzofuran-7-ylmethyl)glycyl-methionine methyl ester

5 N-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]-N-(2,3-dihydrobenzofuran-7-ylmethyl)glycyl-methionine

N-{2(S)-[3-(3-indolyl)propionyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)glycyl-methionine methyl ester

10 N-{2(S)-[3-(3-indolyl)propionyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)glycyl-methionine

15 N-{2(S)-[3-(1-indolyl)propionyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)glycyl-methionine methyl ester

N-{2(S)-[3-(1-indolyl)propionyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)glycyl-methionine

20 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-histidine methyl ester

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-histidine

25 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(cyclopropylmethyl)glycyl-methionine methyl ester

30 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(cyclopropylmethyl)glycyl-methionine

N-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]-N-(cyclopropylmethyl)glycyl-methionine methyl ester

- 51 -

N-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]-N-(cyclopropylmethyl)glycyl-methionine

5 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-dihydrobenzofuran-7-ylmethyl)glycyl-methionine methyl ester

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-dihydrobenzofuran-7-ylmethyl)glycyl-methionine

10 2(S)-[2(S)-N-(L-Pyroglutamyl)-N-methylamino-3(S)-methylpentyloxy]-3-phenylpropionyl-methionine methyl ester

15 2(S)-[2(S)-N-(L-Pyroglutamyl)-N-methylamino-3(S)-methylpentyloxy]-3-phenylpropionyl-methionine

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-O-methylserine methyl ester

20 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-O-methylserine

N-(1-Naphthylmethyl)-N-[2(S)-(N'-(L-pyroglutamyl)-N'-methylamino)-3(S)-methylpentyl]-glycyl-methionine methyl ester

25 N-(1-Naphthylmethyl)-N-[2(S)-(N'-(L-pyroglutamyl)-N'-methylamino)-3(S)-methylpentyl]-glycyl-methionine

30 N-[1-(Pyroglutamylamino)cyclopent-1-ylmethyl]-N-(1-naphthylmethyl)-glycyl-methionine methyl ester

N-[1-(Pyroglutamylamino)-cyclopent-1-ylmethyl]-N-(1-naphthylmethyl)-glycyl-methionine

N-[2(S)-(Pyridin-2-on-6-ylcarbonyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine methyl ester

- 52 -

N-[2(S)-(Pyridin-2-on-6-ylcarbonyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine

5 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(3-chloro-benzyl)glycyl-methionine methyl ester

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(3-chloro-benzyl)glycyl-methionine

10 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-O-methylhomoserine methyl ester

15 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-O-methylhomoserine

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-dimethyl-benzyl)glycyl-methionine methyl ester

20 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-dimethyl-benzyl)glycyl-methionine

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-(2-thienyl)alanine methyl ester

25 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-(2-thienyl)alanine

or the pharmaceutically acceptable salts thereof.


30

- 53 -

The most preferred compounds of the invention are:

N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)amino-3(S)-methyl-pentyl)]-glycyl-methionine


5



10

N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)amino-3(S)-methyl-pentyl)]-glycyl-methionine methyl ester


15



20

N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)amino-3(S)-methyl-pentyl)]-glycyl-methionine isopropyl ester


25




30

N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)amino-3(S)-methyl-pentyl)]-glycyl-methionine t-butyl ester


- 54 -



N-(1-Naphthylmethyl)-N-[2(S)-((imidazol-4-ylacetyl)amino)-3(S)-methylpentyl]-glycyl-methionine



N-(1-Naphthylmethyl)-N-[2(S)-((imidazol-4-ylacetyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester



or the pharmaceutically acceptable salts thereof.

30

- 55 -

In the present invention, the amino acids which are disclosed are identified both by conventional 3 letter and single letter abbreviations as indicated below:

5	Alanine	Ala	A
	Arginine	Arg	R
	Asparagine	Asn	N
	Aspartic acid	Asp	D
	Asparagine or		
10	Aspartic acid	Asx	B
	Cysteine	Cys	C
	Glutamine	Gln	Q
	Glutamic acid	Glu	E
	Glutamine or		
15	Glutamic acid	Glx	Z
	Glycine	Gly	G
	Histidine	His	H
	Isoleucine	Ile	I
	Leucine	Leu	L
20	Lysine	Lys	K
	Methionine	Met	M
	Phenylalanine	Phe	F
	Proline	Pro	P
	Serine	Ser	S
25	Threonine	Thr	T
	Tryptophan	Trp	W
	Tyrosine	Tyr	Y
	Valine	Val	V

The compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention.

- 56 -

The compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention.

5 As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.

As used herein, "cycloalkyl" is intended to include non-aromatic cyclic hydrocarbon groups having the specified number of
10 carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

"Alkenyl" groups include those groups having the specified number of carbon atoms and having one or several double bonds. Examples of alkenyl groups include vinyl, allyl, isopropenyl, pentenyl,
15 hexenyl, heptenyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, isoprenyl, farnesyl, geranyl, geranylgeranyl and the like.

As used herein, "aryl" is intended to include any stable monocyclic, bicyclic or tricyclic carbon ring(s) of up to 7 members in
20 each ring, wherein at least one ring is aromatic. Examples of aryl groups include phenyl, naphthyl, anthracenyl, biphenyl, tetrahydronaphthyl, indanyl, phenanthrenyl and the like.

The term heterocycle or heterocyclic, as used herein, represents a stable 5- to 7-membered monocyclic or stable 8- to 11-
25 membered bicyclic or stable 11-15 membered tricyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
30 The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl,

- 57 -

benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydro-
 benzothienyl, dihydrobenzothiopyranyl, dihydrobenzothio-pyranyl
 sulfone, furyl, imidazolidinyl, imidazolyl, imidazolyl, indolinyl,
 indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl,
 5 isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl,
 2-oxoazepinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl,
 piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, pyridonyl, pyrazinyl,
 pyrazolidinyl, pyrazolyl, pyrimidinyl, pyrrolidinyl, pyrrolyl,
 10 quinazolinyl, quinolinyl, quinolinyl N-oxide, quinoxalyl,
 tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydro-quinolinyl,
 thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl,
 thienofuryl, thienothienyl, and thienyl.


As used herein, the terms "substituted aryl", "substituted
 heterocycle" and "substituted cycloalkyl" are intended to include the
 15 cyclic group which is substituted with 1 or 2 substituents selected from
 the group which includes but is not limited to F, Cl, Br, CF₃, NH₂,
 N(C₁-C₆ alkyl)₂, NO₂, CN, (C₁-C₆ alkyl)O-, -OH, (C₁-C₆
 alkyl)S(O)_m-, (C₁-C₆ alkyl)C(O)NH-, H₂N-C(NH)-, (C₁-C₆
 alkyl)C(O)-, (C₁-C₆ alkyl)OC(O)-, N₃, (C₁-C₆ alkyl)OC(O)NH- and
 20 C₁-C₂₀ alkyl.

When R^{2a} and R^{2b} and R³ and R⁴ are combined to form -
 (CH₂)_s -, cyclic moieties are formed. Examples of such cyclic moieties
 include, but are not limited to:



25
 30 When R^{5a} and R^{5b} are combined to form - (CH₂)_s -, cyclic
 moieties as described hereinabove for R^{2a} and R^{2b} and R³ and R⁴ are
 formed. In addition, such cyclic moieties may optionally include a
 heteroatom(s). Examples of such heteroatom-containing cyclic moieties
 include, but are not limited to:

- 58 -



The pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed, e.g., from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like: and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenyl-acetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like.

The pharmaceutically acceptable salts of the compounds of this invention can be synthesized from the compounds of this invention which contain a basic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents.

It is intended that the definition of any substituent or variable (e.g., R⁸, Z, m, etc.) at a particular location in a molecule be independent of its definitions elsewhere in that molecule. Thus, -N(R⁸)₂ represents -NHH, -NHCH₃, -NHC₂H₅, etc. It is understood

- 59 -

that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth below.

The compounds of the invention can be synthesized from their constituent amino acids by conventional peptide synthesis techniques, and the additional methods described below. Standard methods of peptide synthesis are disclosed, for example, in the following works: Schroeder *et al.*, *"The Peptides"*, Vol. I, Academic Press 1965, or Bodanszky *et al.*, *"Peptide Synthesis"*, Interscience Publishers, 1966, or McOmie (ed.) *"Protective Groups in Organic Chemistry"*, Plenum Press, 1973, or Barany *et al.*, *"The Peptides: Analysis, Synthesis, Biology"* 2, Chapter 1, Academic Press, 1980, or Stewart *et al.*, *"Solid Phase Peptide Synthesis"*, Second Edition, Pierce Chemical Company, 1984. The teachings of these works are hereby incorporated by reference.

Abbreviations used in the description of the chemistry and in the Examples that follow are:

Ac ₂ O	Acetic anhydride;
Boc	t-Butoxycarbonyl;
DBU	1,8-diazabicyclo[5.4.0]undec-7-ene;
DMAP	4-Dimethylaminopyridine;
DME	1,2-Dimethoxyethane;
DMF	Dimethylformamide;
EDC	1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride;
HOBT	1-Hydroxybenzotriazole hydrate;
Et ₃ N	Triethylamine;
EtOAc	Ethyl acetate.
FAB	Fast atom bombardment;
HOBT	3-Hydroxy-1,2,2-benzotriazin-4(3H)-one;
HPLC	High-performance liquid chromatography;

- 60 -

	MCPBA	m-Chloroperoxybenzoic acid;
	MsCl	Methanesulfonyl chloride;
	NaHMDS	Sodium bis(trimethylsilyl)amide
	Py	Pyridine;
5	TFA	Trifluoroacetic acid;
	THF	Tetrahydrofuran;

Compounds of this invention are prepared by employing the reactions shown in the following Reaction Schemes A-J, in addition to other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures. Some key bond-forming and peptide modifying reactions are:

Reaction A. Amide bond formation and protecting group cleavage using standard solution or solid phase methodologies.

Reaction B. Preparation of a reduced peptide subunit by reductive alkylation of an amine by an aldehyde using sodium cyanoborohydride or other reducing agents.


Reaction C. Alkylation of a reduced peptide subunit with an alkyl or aralkyl halide or, alternatively, reductive alkylation of a reduced peptide subunit with an aldehyde using sodium cyanoborohydride or other reducing agents.

Reaction D. Peptide bond formation and protecting group cleavage using standard solution or solid phase methodologies.


Reaction E. Preparation of a reduced subunit by borane reduction of the amide moiety.

These reactions may be employed in a linear sequence to provide the compounds of the invention or they may be used to synthesize fragments which are subsequently joined by the alkylation reactions described in the Reaction Schemes.



- 61 -

REACTION SCHEME AReaction A. Coupling of residues to form an amide bond



20

REACTION SCHEME BReaction B. Preparation of reduced peptide subunits by reductive alkylation

- 62 -

REACTION SCHEME CReaction C. Alkylation/reductive alkylation of reduced peptide subunitsREACTION SCHEME DReaction D. Coupling of residues to form an amide bond

- 63 -

REACTION SCHEME D (CONTD)REACTION SCHEME EReaction E. Preparation of reduced dipeptides from peptides

where RA and RB are R2a, R2b, R3, R4 R5a and R5b as previously defined; XL is a leaving group, e.g., Br⁻, I⁻ or MsO⁻; and RC is defined such that R7b is generated by the reductive alkylation process.

25 Certain compounds of this invention wherein X-Y is an ethenylene or ethylene unit are prepared by employing the reaction sequences shown in Reaction Schemes F and G. Reaction Scheme F outlines the preparation of the alkene isosteres utilizing standard manipulations such as Weinreb amide formation, Grignard reaction, acetylation, ozonolysis, Wittig reaction, ester hydrolysis, peptide


30 coupling reaction, mesylation, cleavage of peptide protecting groups, reductive alkylation, etc., as may be known in the literature or exemplified in the Experimental Procedure. The key reactions are: stereoselective reduction of the Boc-amino-enone to the corresponding syn amino-alcohol (Scheme F, Step B, Part 1), and stereospecific boron

- 64 -


trifluoride or zinc chloride activated organo-magnesium, organo-lithio, or organo-zinc copper(I) cyanide S_N2' displacement reaction (Scheme F, Step G). Through the use of optically pure N-Boc amino acids as starting material and these two key reactions, the stereo-chemistry of the final products is well defined. In Step H of Scheme F, R^1 is incorporated using coupling reaction A and R^1COOH ; the alkylation reaction C using R^1CHO and a reducing agent; or alkylation reaction C using R^1CH_2XL .

The alkane analogs are prepared in a similar manner by including an additional catalytic hydrogenation step as outlined in Reaction Scheme G.


REACTION SCHEME F




- 65 -

REACTION SCHEME F (CONT'D)

- 66 -

REACTION SCHEME F (CONT'D)


- 67 -

REACTION SCHEME G

- 68 -

REACTION SCHEME G (CONTD)


5



10

1. R³MgCuCNCl·BF₃
 2. H₂, 5% Pd/C
- Step K


15



20


1. HCl
2. NaCNBH₃,
R¹CHO

25




30

NaOH



- 69 -

REACTION SCHEME G (CONTD)

25

The oxa isostere compounds of this invention are prepared according to the route outlined in Scheme H. An aminoalcohol **1** is acylated with alpha-chloroacetyl chloride in the presence of trialkylamines to yield amide **2**. Subsequent reaction of **2** with a deprotonation reagent (e.g., sodium hydride or potassium t-butoxide) in an ethereal solvent such as THF provides morpholinone **3**. The N-Boc derivative **4** is then obtained by the treatment of **3** with BOC anhydride and DMAP (4-dimethylaminopyridine) in methylene chloride.

30

Alkylation of **4** with R³XL, where XL is a leaving group such as Br⁻, I⁻ or Cl⁻ in THF/DME (1,2-dimethoxyethane) in the presence of a suitable base, preferably NaHMDS [sodium bis(trimethylsilyl)amide], affords **5**, which is retreated with NaHMDS followed by either protonation or the addition of an alkyl halide R⁴X to give **6a** or **6b**, respectively.

- 70 -


Alternatively, 6a can be prepared from 4 via an aldol condensation approach. Namely, deprotonation of 4 with NaHMDS followed by the addition of a carbonyl compound R^xRYCO gives the adduct 7 (wherein R^x and RY are selected so that R^3 is eventually formed). Dehydration of 7 can be effected by mesylation and subsequent elimination catalyzed by DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) or the direct treatment of 7 with phosphorus oxychloride in pyridine to give olefin 8. Then, catalytic hydrogenation of 8 yields 6a. Direct hydrolysis of 6 with lithium hydrogen peroxide in aqueous THF will produce acid 9b. Sometimes, it is more efficient to carry out this conversion via a 2-step sequence, namely, hydrolysis of 6 in hydrochloric acid to afford 9a, which is then derivatized with BOC-ON or BOC anhydride to give 9b. The peptide coupling of acid 9b with either an alpha-aminolactone (e.g., homoserine lactone, etc.) or the ester of an amino acid is carried out under the conditions exemplified in the previously described references to yield derivative 10. Treatment of 10 with gaseous hydrogen chloride gives 11, which undergoes reductive alkylation in the presence of an aldehyde R^1CHO (12) and a reducing agent (e.g., sodium cyanoborohydride); or acylation in the presence of R^1COOH (13) and a peptide coupling reagent affording the products 14a and b. Hydrolysis of compounds 14 to the corresponding hydroxy acids and acids, respectively, is accomplished by standard methods such as treatment with NaOH in alcoholic or aqueous milieu followed by careful acidification with dilute HCl.

25


30

- 71 -

SCHEME H




- 72 -


SCHEME H (CONT'D)9a, $\text{R}^Z = \text{H}$ b, $\text{R}^Z = \text{BOC}$

10

15

10

20


11

25

30

- 73 -

SCHEME H (CONT'D)



The thia, oxothia and dioxothia isostere compounds of this invention are prepared in accordance to the route depicted in Scheme I.

25 Aminoalcohol 1 is derivatized with BOC₂O to give 15. Mesylation of 15 followed by reaction with methyl alpha-mercaptoacetate in the presence of cesium carbonate gives sulfide 16. Removal of the BOC group in 16 with TFA followed by neutralization with di-isopropylethylamine leads to lactam 17. N-BOC derivative 18 is

30 obtained via the reaction of 17 with BOC anhydride in THF catalyzed by DMAP. Sequential alkylation of 18 with the alkyl halides R³X and R⁴X in THF/DME using NaHDMS as the deprotonation reagent produces 19. Hydrolysis of 19 in hydrochloride to yield 20a, which is derivatized with Boc anhydride to yield 20b. The coupling of 20b with an alpha-aminolactone (e.g., homoserine lactone, etc.) or the ester of an

- 74 -

amino acid is carried out under conventional conditions as exemplified in the previously described references to afford 21. Sulfide 21 is readily oxidized to sulfone 22 by the use of MCPBA (m-chloroperoxybenzoic acid). The N-BOC group of either 21 or 22 is readily removed by treatment with gaseous hydrogen chloride. The resultant amine hydrochloride 23 undergoes reductive alkylation in the presence of an aldehyde R^1CHO (12) and a reducing agent (e.g., sodium cyanoborohydride); or acylation in the presence of R^1COOH (13) and a peptide coupling reagent to afford the products 24 and 25.

10

15


20

25


30

- 75 -

SCHEME I



- 76 -

SCHEME I (CONT'D)

- 77 -

The compounds of this invention inhibit Ras farnesyl transferase which catalyzes the first step in the post-translational processing of Ras and the biosynthesis of functional Ras protein. These compounds are useful as pharmaceutical agents for mammals, especially for humans. These compounds may be administered to patients for use in the treatment of cancer. Examples of the type of cancer which may be treated with the compounds of this invention include, but are not limited to, colorectal carcinoma, exocrine pancreatic carcinoma, and myeloid leukemias.

The compounds of this invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers or diluents, optionally with known adjuvants, such as alum, in a pharmaceutical composition, according to standard pharmaceutical practice. The compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.

For oral use of a chemotherapeutic compound according to this invention, the selected compound may be administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch, and lubricating agents, such as magnesium stearate, are commonly added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents may be added. For intramuscular, intraperitoneal, subcutaneous and intravenous use, sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled in order to render the preparation isotonic.

The present invention also encompasses a pharmaceutical composition useful in the treatment of cancer, comprising the

- 78 -

administration of a therapeutically effective amount of the compounds of this invention, with or without pharmaceutically acceptable carriers or diluents. Suitable compositions of this invention include aqueous solutions comprising compounds of this invention and
5 pharmacologically acceptable carriers, e.g., saline, at a pH level, e.g., 7.4. The solutions may be introduced into a patient's intramuscular blood-stream by local bolus injection.

When a compound according to this invention is administered into a human subject, the daily dosage will normally be
10 determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.

In one exemplary application, a suitable amount of compound is administered to a mammal undergoing treatment for
15 cancer. Administration occurs in an amount between about 0.1 mg/kg of body weight to about 20 mg/kg of body weight per day, preferably of between 0.5 mg/kg of body weight to about 10 mg/kg of body weight per day.

The compounds of the instant invention are also useful
20 as a component in an assay to rapidly determine the presence and quantity of farnesyl-protein transferase (FPTase) in a composition. Thus the composition to be tested may be divided and the two portions contacted with mixtures which comprise a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine
25 terminus) and farnesyl pyrophosphate and, in one of the mixtures, a compound of the instant invention. After the assay mixtures are incubated for an sufficient period of time, well known in the art, to allow the FPTase to farnesylate the substrate, the chemical content of the assay mixtures may be determined by well known
30 immunological, radiochemical or chromatographic techniques. Because the compounds of the instant invention are selective inhibitors of FPTase, absence or quantitative reduction of the amount of substrate in the assay mixture without the compound of the instant invention relative to the presence of the unchanged substrate in the

- 79 -

assay containing the instant compound is indicative of the presence of FPTase in the composition to be tested.

5 It would be readily apparent to one of ordinary skill in the art that such an assay as described above would be useful in identifying tissue samples which contain farnesyl-protein transferase and
10 quantitating the enzyme. Thus, potent inhibitor compounds of the instant invention may be used in an active site titration assay to determine the quantity of enzyme in the sample. A series of samples composed of aliquots of a tissue extract containing an unknown amount of farnesyl-protein transferase, an excess amount of a known substrate
15 of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and farnesyl pyrophosphate are incubated for an appropriate period of time in the presence of varying concentrations of a compound of the instant invention. The concentration of a sufficiently potent inhibitor (i.e., one that has a K_i substantially smaller than the
20 concentration of enzyme in the assay vessel) required to inhibit the enzymatic activity of the sample by 50% is approximately equal to half of the concentration of the enzyme in that particular sample.

EXAMPLES

25 Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species and conditions are intended to be further illustrative of the invention and not limitative of the reasonable scope thereof.

30 The standard workup referred to in the examples refers to solvent extraction and washing the organic solution with 10% citric acid, 10% sodium bicarbonate and brine as appropriate. Solutions were dried over sodium sulfate and evaporated *in vacuo* on a rotary evaporator.

- 80 -

EXAMPLE 1Preparation of pyroglutamyl-valyl-phenylalanyl-methionine

5 The title compound was assembled using standard solid phase synthetic methods on an automated peptide synthesizer. The product was cleaved from the resin with HF and purified by reverse-phase HPLC. The title compound was obtained as a lyophilized powder and characterized by amino acid analysis (found: 1.73 $\mu\text{mol}/\text{mg}$) and
10 FAB mass spectrum, $m/z = 507$ (M+1).

EXAMPLE 2Preparation of pyroglutamyl-valyl-isoleucyl-methionine

15 This compound was prepared using the method of Example 1. Amino acid analysis. Found 1.65 $\mu\text{mol}/\text{mg}$. FAB mass spectrum, $m/z = 473$ (M+1).

EXAMPLE 3

20 Preparation of nicotinoyl-valyl-phenylalanyl-methionine

Standard solution phase peptide synthesis methods were employed to prepare the title compound.

Anal. Calcd for $\text{C}_{26}\text{H}_{34}\text{N}_4\text{O}_5\text{S} \cdot 1.75\text{H}_2\text{O}$:

25 C, 57.17; H, 6.92; N, 10.26.

Found: C, 57.11; H, 6.63; N, 10.35.

EXAMPLE 4

30 Preparation of N-[2(S)-(L-Pyroglutamylamino)-3-methylbutyl]-phenylalanyl-methionine

Step A: Preparation of N-(3-methyl-2(S)-(t-butoxycarbonyl-amino)-but-1-yl)phenylalanine methyl ester

- 81 -

Sodium cyanoborohydride (2.0 g, 0.03 mole) was added portionwise (one hour) to a solution of the known compound 2(S)-t-butoxycarbonylamino-3-methylbutyraldehyde (5.8 g, 0.029 mole) and phenylalanine methyl ester hydrochloride (6.1 g, 0.028 mole) in methanol (150 ml) and acetic acid (1.5 ml). The clear reaction mixture was stirred at room temperature under argon for 2 hours and concentrated *in vacuo*. The residue was cooled in an ice bath, neutralized with saturated NaHCO₃ and extracted (3X) with ethyl acetate. The organic phase was dried (Na₂SO₄), filtered and evaporated to give a pale yellow residue, which was purified by column chromatography on silica gel using 20% ethyl acetate-hexane. The title compound (8.4 g) was obtained as a pale yellow oil.

Step B: Preparation of N-(3-methyl-2(S)-(t-butoxycarbonylamino)but-1-yl)phenylalanine

A solution of lithium hydroxide (1.63 g, 0.068 mole) in water (70 ml) was added to a solution of the product of Step A (7.6 g, 0.021 mole) in ethylene glycol dimethyl ether (100 ml) with cooling in an ice bath. The reaction mixture was stirred at room temperature under Ar for 2 hours, concentrated *in vacuo*, and extracted (2X) with ethyl acetate. The aqueous phase was neutralized with 10% of citric acid, cooled and filtered to give the product as a white solid (6.6 g), mp >193° (dec).

Step C: Preparation of N-(3-methyl-2(S)-(t-butoxycarbonylamino)but-1-yl)phenylalanine-methionine-methyl ester

N-Methyl morpholine (4.0 ml) and 1-ethyl-3-(3-dimethylaminopropyl) carbodimide (EDC) hydrochloride (0.96 g, 0.005 mole) were added to a solution of the product of Step B (1.76 g, 0.005 mole), methionine methyl ester hydrochloride (1.0 g, 0.005 mole) and 1-hydroxybenzotriazole hydrate (HOBT, 0.677 g, 0.005 mole) in dimethylformamide (DMF, 30 ml) the reaction mixture was stirred at room temperature over the weekend, concentrated *in vacuo* and taken up in ice, water, and ethyl acetate. After addition of 10% aqueous citric

- 82 -

acid, the ethyl acetate solution was separated, washed with water (2X), aqueous NaHCO₃ and brine, and dried over sodium sulfate. Filtration and evaporation of the ethyl acetate solution gave a pale yellow residue, which was purified by column chromatography (silica gel) using 35% ethyl acetate-hexane. The title compound (1.97 g) was obtained as a white solid.

Step D: Preparation of N-(3-methyl-2(S)-aminobut-1-yl)phenylalanyl-methionine methyl ester hydrochloride

The product of Step C (0.74 g, 0.0015 mole) in ethyl acetate (25 ml) was treated with HCl gas at -25°C for 30 min. The solution was stirred at room temperature for 1 hour and concentrated *in vacuo* to provide the title compound as a white solid (~0.79 g).

Step E: Preparation of N-[2(S)-(L-Pyroglutamylamino)-3-methylbutyl]phenylalanyl-methionine methyl ester

N-methylmorpholine (1.0 mL) and EDC hydrochloride (0.252 g, 1.3 mmol) were added to a solution of L-pyroglutamic acid (0.17 g, 1.3 mmol), the product of Step D (0.60 g, 1.3 mmol), and HOBT (1.18 g, 1.3 mmol) in 10 mL of DMF. The reaction mixture was stirred at room temperature for 27 h, concentrated *in vacuo* and the product was isolated as the free base following a standard workup.

Chromatography on silica gel (6% isopropanol in methylene chloride) gave the pure title compound (0.36 g) as an oil.

Step F: Preparation of N-[2(S)-(L-Pyroglutamylamino)-3-methylbutyl]phenylalanyl-methionine

The product of Step E was dissolved in 15 mL of methanol and a solution of 60 mg of LiOH in 7 mL of water added. The mixture was stirred for 3 h at room temperature under argon, diluted with water and filtered. The filtrate was neutralized with 10% citric acid and cooled. The product was isolated by filtration and further purified by reverse phase HPLC. Lyophilization gave the title compound as a white solid. ¹H-NMR (D₂O) δ 7.40 (3H, m), 7.29 (2H, m), 4.36 (1H,

- 83 -

dd, J=4.9, 8.5 Hz), 4.29 (1H, m), 4.22 (1H, dd, J = 6.2, 8.7 Hz), 3.96 (1H, dd, J = 7, 13 Hz), 3.33 (1H, dd, J = 6.4, 14.3 Hz), 3.20 (3H, m), 2.54 (1H, m), 2.44 (2H, m), 2.39 (1H, m), 2.32 (1H, m), 2.09 (2H, m), 2.06 (3H, s), 1.92 (1H, m), 1.87 (1H, m), 0.92 (3H, d, J=7.8 Hz), 0.90 (3H, d, J=7.8 Hz).

Anal. Calcd for C₂₄H₃₆N₄O₅S•1.4 TFA:

C, 49.35; H, 5.78; N, 8.59.

Found: C, 49.23; H, 5.79; N, 8.64.

EXAMPLE 5

Preparation of N-[5(S)-(L-Pyroglutamylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine methyl ester

Step A: Preparation of 4(S)-N-tert-(butyloxy)carbonylamino-3(S),7-dimethyl-6,7-octen-5-one

To a cold (0°C) solution of N-t-(butoxy)carbonyl-L-isoleucine hemihydrate (6.01 g, 25 mmol) in ethyl acetate (90 mL), N-methyl morpholine (2.75 mL, 25 mmol) and isobutyl chloroformate (3.25 mL, 25.1 mmol) were added successively. The resultant white suspension was stirred at 0°C for 15 minutes treated with N,O-dimethylhydroxylamine hydrochloride (2.52 g, 25.8 mmol) and N-methylmorpholine (2.75 mL, 25 mmol), and then stirred at room temperature overnight. The resultant mixture was washed successively with water, 10% aqueous citric acid, brine, and was dried over anhydrous magnesium sulfate, filtered and concentrated. The residual oil was chromatographed on silica gel eluting with 30% ethyl acetate in hexane. Collection and concentration of appropriate fractions provided 5.0 g (73%) of the corresponding amide.

A 1 liter three neck round bottom flask was charged with magnesium turnings (44 g, 1.8 mol) and flamed dried under a steady stream of dry argon. The turnings were activated by stirring under an atmosphere of argon for an additional 3 to 4 hours at room temperature. Tetrahydrofuran (450 mL), freshly distilled from sodium

- 84 -

5 benzophenone ketyl, 2-methylpropenyl bromide (50 g, 0.37 mol), and a crystal of iodine were added. The mixture was warmed gently with a mantle until slight reflux occurred. Without removing the mantle heating was discontinued, and the mixture was stirred overnight under an atmosphere of argon. The resultant Grignard reagent was used as described in the following.

10 To a cold (-50°C) solution of N-tert-(butyloxy)carbonyl-isoleucine N,O-dimethylhydroxylamide (17.2 g, 63 mmol) in tetrahydrofuran (400 mL), the above Grignard reagent in tetrahydrofuran (prepared from 50 g of 2-methylpropenyl bromide) was added over a period of 20 min., with the temperature of the reacting solution maintained below -40°C. The mixture was then allowed to warm up slowly to room temperature. The resultant solution was diluted with diethyl ether, treated with 10% aqueous citric acid, 15 washed with brine, dried over magnesium sulfate, filtered, and concentrated under vacuo. The residual oil was chromatographed on silica gel eluting with 7% ethyl acetate in hexane. Collection and concentration of appropriate fractions provided 12.6 g (74%) of the ketone.

20

Step B: Preparation of 4(S)-N-tert-(butyloxy)carbonylamino-5(R)-acetoxy-3(S),7-dimethyl-6,7-octene

25 To a cold (0°C) solution of 4(S)-N-tert-(butyloxy)-carbonyl-amino-3(S),7-dimethyl-6,7-octen-5-one (12.57 g, 46.7 mmol) in methanol (200 mL), sodium borohydride was added portionwise until reaction was complete as monitored by TLC on silica gel eluting with 20% ethyl acetate in hexane. The resultant mixture was concentrated under vacuo. The residue was suspended in diethyl ether, washed successively with 1M aqueous hydrochloric acid and brine, dried over 30 magnesium sulfate, filtered and concentrated under vacuo to provide the corresponding alcohol (11.93 g).

Without further purification, the crude alcohol, 4-N,N-dimethyl-aminopyridine (0.132 g), and pyridine (17 mL) were dissolved in dichloromethane (48 mL), cooled to 0°C and treated with

- 85 -

acetic anhydride (18.8 mL, 199 mmol). The resultant mixture was stirred at room temp for 2 hours and concentrated under vacuo. The residual oil was chromatographed on silica gel eluting with 20% ethyl acetate in hexane. Collection and concentration of appropriate fractions
5 provided 10.7 g (73%) of the acetate as a white solid.

Step C: Preparation of methyl 5(S)-N-tert-(butyloxy)carbonyl-
amino-4(R)-acetoxy-6(S)-methyl-2,3-E-octenoate

To a cold (-78°C) solution of 4(S)-N-tert-(butyloxy)-
10 carbonyl-amino-5(R)-acetoxy-3(S),7-dimethyl-6,7-octene (6.5 g, 20.7 mmol) in dichloromethane (100 mL), a steady stream of ozone was bubbled through until a blue color persisted. The mixture was stirred for an additional 5 min and purged with argon to remove excess ozone.
15 Then dimethyl sulfide (15 mL) was added and the reaction mixture was allowed to warm to room temperature. The resultant mixture was cooled back to -78°C, and (carbomethoxymethylene)-triphenylphosphorane (15.3 g, 45.7 mmol) was added. The mixture was stirred at room temp overnight and concentrated onto silica gel (20 g). The
20 resultant solid was loaded on a column of silica gel and the product was eluted with 15% EtOAc in hexane. Collection and concentration of appropriate fractions provided 6.5 (91%) of the octenoate.

Step D: Preparation of 5(S)-N-tert-(butyloxy)carbonylamino-4(R)-
hydroxy-6(S)-methyl-2,3-E-octenoic acid

To a solution of methyl 5(S)-N-tert-(butyloxy)-carbonyl-
25 amino-4(R)-acetoxy-6(S)-methyl-2,3-E-octenoate (1 g, 2.9 mmol) in tetrahydrofuran (2 mL), a solution of lithium hydroxide (0.5 g, 12 mmol) in methanol-water (3:1 v/v) was added. The mixture was made homogenous by addition of a minimum amount of a methanol-water
30 (3:1 v/v) and stirred at room temp for 2 days. The resultant solution was acidified with aqueous hydrochloric acid to pH 5 and concentrated under vacuo. The residue was subjected to column chromatography on silica gel eluting with 20% methanol in chloroform. Collection and

- 86 -

concentration of appropriate fractions provided 0.71 g (87%) of the corresponding hydroxy-acid.

5 **Step E:** Preparation of 5(S)-N-tert-(butyloxy)carbonylamino-4(R)-hydroxy-6(S)-methyl-2,3-E-octenoyl methionine methyl ester

 To a solution of 5(S)-N-tert-(butyloxy)carbonylamino-4(R)-hydroxy-6(S)-methyl-2,3-E-octenoyl acid (1.91 g, 6.65 mmol) in dimethyl-formamide (28 mL), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.91 g, 9.98 mmol), 1-hydroxybenzotriazole hydrate (1.35 g, 9.98 mmol), L-methionine methyl ester hydrochloride (3.98, 19.95 mmol), and diisopropylethylamine (2.41 mL, 18.62 mmol) were added. The resultant mixture was stirred at room temperature overnight, and concentrated under vacuo. The residue was diluted with ethyl acetate, and the organic solution washed successively with water, 10% aqueous citric acid, brine, dried over magnesium sulfate, filtered and concentrated. The residue was then subjected to column chromatography on silica gel eluting with 80% ethyl acetate in hexane. Collection and concentration of appropriate fractions provided 1.0 g (35%) of the coupled product.

Step F: Preparation of 5(S)-N-tert-(butyloxy)carbonylamino-4(R)-(methylsulfonyl)oxy-6(S)-methyl-2,3-E-octenoyl methionine methyl ester

 To a cold (-20°C) solution of 5(S)-N-tert-(butyloxy)-carbonylamino-4(R)-hydroxy-6(S)-methyl-2,3-E-octenoyl methionine methyl ester (0.80 g, 1.85 mmol) in a mixture of dichloromethane (12 mL) and pyridine (6 mL), methanesulfonyl chloride (0.8 mL) was added. The resultant mixture was kept at 0°C overnight, and concentrated under vacuo. The residue was diluted with dichloromethane, washed successively with sat. sodium bicarbonate, and brine. The organic phase was dried over magnesium sulfate, filtered and concentrated. The residue was subjected to column chromatography on silica gel eluting with a mixture of ethyl acetate and

- 87 -

hexane, 8:2 v/v. Collection and concentration of appropriate fractions provided 0.67 g (71%) of the mesylate, which is stable for storage at -10°C.

5 **Step G:** Preparation of 5(S)-N-tert-(butyloxy)carbonylamino-6(S)-methyl-2(R)-n-butyl-3,4-E-octenoyl-methionine methyl ester

 To a cold (-78°C) suspension of copper(I) cyanide (0.17 g, 1.9 mmol) in tetrahydrofuran (25 mL, freshly distilled from sodium benzophenone ketyl), a solution of n-butylmagnesium chloride (1 mL, 2.0 M, 1.9 mmol) in tetrahydrofuran was added. The mixture was stirred at 0°C until a homogeneous solution was formed. Once a solution was formed, it was cooled to -78°C, boron-trifluoride etherate (0.24 mL, 1.9 mmol) was added, and the resulting mixture was stirred at -78°C for 5 min. A solution of 5(S)-N-tert-(butyloxy)carbonylamino-4(R)-(methylsulfonyl)oxy-6(S)-methyl-2,3-E-octenoyl methionine methyl ester (0.24 g, 0.48 mmol) in tetrahydrofuran (25 mL) was added dropwise to the above mixture. The resultant solution was stirred at -78°C for 3h, quenched with sat. aqueous ammonium chloride (pH 8) and diluted with diethyl ether. The organic solution was washed with brine, dried over magnesium sulfate, filtered, and concentrated. The residue was chromatographed on silica gel eluting with 60% ethyl acetate in hexane. Collection and concentration of appropriate fractions provided 0.18 g (80%) of the 3,4-E-octenoyl-methionine methyl ester.

Step H: 5(S)-amino-6(S)-methyl-2(R)-n-butyl-3,4-E-octenoyl-methionine methyl ester hydrochloride

 To a cold (0°C) solution of 5(S)-N-tert-(butyloxy)-carbonylamino-6(S)-methyl-2(R)-n-butyl-3,4-E-octenoyl-methionine methyl ester (0.18 g, 0.38 mmol) in a mixture of ethyl acetate (20 mL) and dichloromethane (20 mL), a steady stream of anhydrous hydrogen chloride gas was bubbled through for a period of 10 min. The mixture was capped and stirred for an additional 40 min at 0°C. The resultant

- 88 -

solution was then purged with a stream of argon and concentrated under vacuum to provide the corresponding hydrochloride salt.

5 Step I: Preparation of N-[5(S)-(L-Pyroglutamylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine methyl ester

The product of Step H was coupled to pyroglutamic acid under standard conditions.

Anal. Calcd for $C_{24}H_{40}N_3O_4S \cdot 0.3 \text{ TFA} \cdot 0.2 \text{ H}_2\text{O}$:

10 C, 58.57; H, 8.13; N, 8.33.

Found: C, 58.50; H, 8.09; N, 8.20.

EXAMPLE 6

15 Preparation of N-[5(S)-(L-Pyroglutamylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine

The methyl ester of the product of Example 5 was saponified as described for Example 3, Step B.

20 EXAMPLE 7

Preparation of N-[5(S)-((Imidazol-4-yl)acetylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine and N-[5(S)-((Imidazol-4-yl)acetyl-
25 amino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine methyl ester

Using the methods of Examples 5 and 6, substituting imidazole-4-acetic for pyroglutamic acid, the title compounds were obtained. The compound was characterized as the ester, and the corresponding acid was generated by in situ hydrolysis.

30 Anal. Calcd for $C_{24}H_{40}N_4O_4S \cdot 1.3 \text{ TFA}$:

C, 50.80; H, 6.62; N, 8.91.

Found: C, 50.65; H, 6.57; N, 8.74.

- 89 -

EXAMPLE 8

Preparation of N-[5(S)-(Imidazol-4-ylcarbonylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine and N-[5(S)-(Imidazol-4-ylcarbonylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine methyl ester

Using the methods of Examples 5 and 6, substituting imidazole-4-carboxylic acid for pyroglutamic acid, the title compounds were obtained. The compound was characterized as the ester and the carboxylic acid was prepared by in situ hydrolysis.

Anal. Calcd for $C_{23}H_{38}N_4O_4S \cdot 1.1$ TFA:

C, 51.12; H, 6.66; N, 9.46.

Found: C, 50.84; H, 6.74; N, 9.65.

EXAMPLE 9

Preparation of N-[2(S)-(2(S)-(Imidazol-4-yl)acetyl-amino)-3(S)-methylpentyl-oxy]-3-phenylpropionyl]-methionine methyl ester

Step A: Preparation of N-(alpha-chloroacetyl)-L-isoleucinol

To a stirred solution of L-isoleucinol (20 g, 0.17 mol) and triethylamine (28.56 ml, 0.204 mol) in CH_2Cl_2 (500 ml) at $-78^\circ C$ was added chloroacetyl chloride (16.3 ml, 0.204 mol) over 5 minutes. The cooling bath was removed and the solution allowed to warm to $-20^\circ C$. The mixture was diluted with EtOAc and washed sequentially with 1 M HCl, and brine and dried (Na_2SO_4). Evaporation *in vacuo* afforded the amide title compound (35 g, 100%).

$R_f = 0.3$ CH_2Cl_2 : MeOH (95:5);

1H NMR ($CDCl_3$) δ 6.80 (1H, brd, $J = 5$ Hz), 4.10 (2H, s), 3.84 (1H, m), 3.79 (2H, m), 2.65 (1H, brs), 1.72 (1H, m), 1.55 (1H, m), 1.17 (1H, m), 0.96 (3H, d, $J = 6$ Hz) 0.90 (3H, t, $J = 6$ Hz).

- 90 -

Step B: Preparation of 5(S)-[1(S)-methyl]propyl-2,3,5,6-tetrahydro-4H-1,4-oxazin-3-one

To a stirred solution of N-(α -chloroacetyl)-L-isoleucinol (7.4 g, 0.038 mol) in THF (125 ml) under argon at 0°C was slowly
5 added sodium hydride (2.2 g of a 60% dispersion in mineral oil, 0.055 mol) with concomitant gas evolution. After completing the addition, the mixture was warmed to room temperature (R.T.) and stirred for 16 hr. Water (2.8 ml) was added and the solvents evaporated *in vacuo*. The residue was dissolved in CHCl₃ (70 ml) and washed with water and
10 saturated NaCl solution. The organic layer was dried (Na₂SO₄) and evaporated *in vacuo*. The residue was chromatographed using silica gel eluting with CH₂Cl₂:MeOH (96:4) to afford the lactam title compound (4.35 g, 72%) as a white solid.
R_f = 0.35 CH₂Cl₂:MeOH (95:5);
15 ¹H NMR δ (CDCl₃) 6.72 (1H, brs), 4.20 (1H, d, J = 14.5 Hz), 4.10 (1H, d, J = 14.5 Hz), 3.88 (1H, dd, J = 9 and 3.5 Hz), 3.58 (1H, dd, J = 9 and 6.5 Hz), 3.45 (1H, brqt, J = 3.5 Hz), 1.70-1.45 (2H, m), 1.34-1.15 (1H, m), 0.96 (3H, t, J = 6.5 Hz), 0.94 (3H, d, J = 6.5 Hz).

20 Step C: Preparation of N-(tert-butoxycarbonyl)-5(S)-[1(S)-methyl]propyl-2,3,5,6-tetrahydro-4H-1,4-oxazin-3-one

5(S)-[1(S)-Methyl]propyl-2,3,5,6-tetrahydro-4H-1,4-oxazin-3-one (12.2 g, 0.0776 mol) and DMAP (18.9 g, 0.155 mol) were dissolved in methylene chloride (120 ml) under argon at R.T. Boc
25 anhydride (33.9 g, 0.155 mol) was added to the stirred solution in one portion, with concomitant gas evolution and the mixture was stirred at R.T. for 16 hr. The solvent was evaporated *in vacuo* and the residue was taken up in ethyl acetate and washed sequentially with 10% citric acid, 50% NaHCO₃ and finally brine. The organic extract was dried
30 (Na₂SO₄) and evaporated *in vacuo*. Chromatography of the residue over silica gel eluting with 20% EtOAc in hexanes afforded the title compound (14.1 g, 71%) as a white solid.
R_f = 0.75 EtOAc:hexanes (20:80); mp 59-60°C

- 91 -

Anal. Calcd for C₁₃H₂₃O₄N

C, 60.68; H, 9.01; N, 5.44

Found: C, 60.75; H, 9.01; N, 5.58

¹H NMR (CDCl₃) δ 4.25 (1H, d, J = 15 Hz), 4.15 (1H, d, J = 15 Hz),
5 4.15-4.00 (2H, m), 3.73 (1H, dd, J = 10 and 2 Hz), 1.88 (1H, qt, J = 6
Hz), 1.55 (9H, s), 1.50-1.36 (1H, m), 1.35-1.19 (1H, m) 1.00 (3H, d, J =
6 Hz) 0.95 (3H, d, J = 6.5 Hz).

Step D: Preparation of N-(tert-Butoxycarbonyl)-2(S)-benzyl-5(S)-
10 [1(S)-methyl]propyl-2,3,5,6-tetrahydro-4H-1,4-oxazin-3-
one

A solution of N-(tert-butoxycarbonyl)-5(S)-[1(S)-methyl]-
propyl-2,3,5,6-tetrahydro-4H-1,4-oxazin-3-one (5.75 g, 22.3 mmol) in
DME (100 ml) under argon was cooled to -60°C. The cold solution was
15 transferred via canula to a second flask containing sodium
bis(trimethylsilyl)amide (24.6 ml of a 1M solution in THF, 24.6 mmol)
at -78°C under argon. After stirring for 10 minutes, benzyl bromide
(2.25 ml, 19 mmol) was added over 5 minutes and the resulting mixture
was stirred at -78°C for 3 hours. After this time, the reaction mixture
20 was transferred via cannula to another flask containing sodium
bis(trimethylsilyl)amide (24.6 ml of a 1M solution in THF, 24.6 mmol)
at -78°C, under argon. After stirring for a further 5 minutes, the
reaction was quenched by the addition of saturated aqueous ammonium
chloride solution (24.6 ml) and allowed to warm to room temperature.
25 This mixture was diluted with brine (50 ml) and water (20 ml) and then
extracted with ethyl acetate (2 x 100 ml). The organic extracts were
washed with brine (50 ml) and evaporated *in vacuo* to afford an oil.
Chromatography of the residue over silica gel (230-400 mesh, 300 g)
eluting with 10-20% ethyl acetate in hexanes afforded the title
30 compound (5.12 g, 67%) as a clear oil.

R_f = 0.25 EtOAc:Hexanes (20:80);

¹H NMR (CDCl₃) δ 7.35-7.15 (5H, m), 4.31 (1H, dd, J = 6 and 2 Hz),
4.03 (1H, d, J = 12 Hz), 3.88 (1H, dd, J = 6 and 1 Hz), 3.66 (1H, dd, J =
12 and 2 Hz), 3.29 (1H, dd, J = 12 and 3 Hz), 1.54 (9H, s), 3.12 (1H,

- 92 -

dd, J = 12 and 7 Hz), 1.47 (1H, m), 1.25 (1H, m), 1.10 (1H, m), 0.83 (3H, d, J = 6 Hz), 0.80 (3H, t, J = 6 Hz).

5 Step E: Preparation of N-(tert-butoxycarbonyl)-2(S)-[2(S)-amino-3(S)-methyl]pentyloxy-3-phenylpropionic acid

To a stirred solution of N-(tert-butoxycarbonyl)-2(S)-benzyl-5(S)-[1(S)-methyl]-propyl-2,3,5,6-tetrahydro-4H-1,4-oxazin-3-one (5.1 g, 14.7 mmol) in THF (150 ml) and water (50 ml) at 0°C was added hydrogen peroxide (15 ml of a 30% aqueous solution, 132 mmol) and lithium hydroxide (3.0 g, 63.9 mmol). After stirring for 30 minutes, the reaction was quenched with a solution of sodium sulfite (28.25 g, 0.224 mol) in water (70 ml). The THF was evaporated *in vacuo* and the aqueous phase was acidified to pH 3-4 by addition of 10% citric acid solution and extracted with EtOAc. The organic extracts were dried (Na₂SO₄), evaporated *in vacuo* and the residue purified by chromatography over silica gel eluting with 4% MeOH in CH₂Cl₂ to give the lactam 2(S)-benzyl-5(S)-[1(S)-methyl]propyl-2,3,5,6-tetrahydro-4H-1,4-oxazin-3-one (0.82 g 22%) and then with 20% MeOH in CH₂Cl₂ to afford the title compound (4.03 g, 75%) as a viscous oil.

R_f = 0.4 MeOH:CH₂Cl₂ (5:95) + 0.3% AcOH;

¹H NMR (d₆ DMSO) δ 7.35-7.10 (5H, m), 6.68 (1H, br, s), 3.75 (1H, dd, J = 7.5 and 2.5 Hz) 3.54 (1H, m), 3.5-3.2 (2H, m) 2.99 (1H, dd, J = 12.5 and 2.5 Hz), 2.75 (1H, dd, J = 12.5 and 7.5 Hz), 1.50-1.35 (11H, m), 0.98 (1H, sept, J = 6 Hz), 0.78 (3H, t, J = 6 Hz), 0.65 (3H, d, J = 6 Hz);

FAB MS 366 (MH⁺) 266 (MH₂⁺ - CO₂tBu).

30 Step F: Preparation of N-(tert-Butoxycarbonyl)-2(S)-[2(S)-amino-3(S)-methyl]-pentyloxy-3-phenylpropionyl-methionine methyl ester

To a stirred solution of N-(tert-butoxycarbonyl)-2(S)-[2(S)-amino-3(S)-methyl]-pentyloxy-3-phenylpropionic acid (0.200 g, 0.53 mmol) and EDC (0.158 g, 0.82 mmol) in DMF (15 ml) at room

- 93 -

temperature was added HOBT (0.89 mg 0.66 mmol) and methionine methyl ester hydrochloride (0.131 g, 0.66 mmol). The pH was adjusted to pH= 6.5 by addition of NEt₃ (0.18 mL) (the pH was monitored by application of an aliquot of the reaction mixture to a moist strip of pH paper). After stirring at room temperature for 16 hr, the reaction was diluted with EtOAc and washed with saturated NaHCO₃ and then brine and dried (NaSO₄). Evaporation *in vacuo* (sufficient to remove DMF) and chromatography over silica gel eluting with EtOAc/hexane (25%-50%) afforded the title compound (240 mg).

NMR (CD₃OD) δ 0.78 (3H, d, J=6Hz), 0.89 (3H, t, J=6Hz), 1.11 (H, m), 1.47 (9H, s), 2.06 (3H, s), 2.2~2.4 (2H, m), 2.90 (H, d of d, J=14, 7Hz), 3.05 (H, d of d, J=14, 5Hz), 3.38 (H, d of d, J=8, 6Hz), 3.5~3.55 (2H, m), 3.71 (3H, s), 3.97 (H, d of d, J=7, 5Hz), 6.60 (H, d, J=10Hz), 7.24 (5H, m).

Step G: Preparation of 2(S)-[2(S)-Amino-3(S)-methyl]-pentyloxy-3-phenylpropionyl-methionine methyl ester hydrochloride

Anhydrous HCl gas was bubbled through a cold (0°C) solution of N-(tert-butoxycarbonyl)-2(S)-[2(S)-amino-3(S)-methyl]-pentyloxy-3-phenylpropionyl-methionine methyl ester (240 mg, 0.47 mmol) in ethyl acetate (25 ml) until a saturated solution was obtained. The resulting mixture was stirred at 0°C for 1 hr. The solution was purged with nitrogen and the mixture concentrated *in vacuo* to afford the title compound as a sticky foam (210 mg, 100%) which was used without further purification. NMR (CD₃OD) δ 0.84 (3H, d, J=6Hz), 0.93 (3H, t, J=6Hz), 1.20 (H, m), 1.40 (H, m), 1.60 (H, m), 2.08 (3H, s), 2.3-2.5 (2H, m), 2.98 (H, d of d, J=14, 7Hz), 3.11 (H, d of d, J=14, 5 Hz), 3.23 (H, m), 3.57 (H, d of d, J=10, 6Hz), 3.70 (H, d, J=3Hz), 3.73 (3H, s), 4.12 (H, d of d, J=8, 6Hz), 7.30 (5H, m).

Step H: Preparation of N-[2(S)-(2(S)-(Imidazol-4-yl)acetyl-amino)-3(S)-methylpentyloxy)-3-phenylpropionyl]-methionine methyl ester

- 94 -

Using standard peptide coupling reagents, imidazole-4-acetic acid was coupled to the product of Step G.

Anal Calcd for $C_{26}H_{38}N_4O_5S \cdot 0.75 H_2O$:

C, 58.67; H, 7.48; N, 10.53.

5 Found: C, 58.38; H, 7.18; N, 10.56.

EXAMPLE 10

10 Preparation of N-[2(S)-(2(S)-(Imidazol-4-yl)acetyl-amino)-3(S)-methylpentyl-oxy)-3-phenylpropionyl]-methionine

Using the method of Example 3, Step B, the methyl ester of the product of Example 9 was converted to the title compound.

Anal. Calcd for $C_{25}H_{36}N_4O_5S_2 \cdot 1.5 TFA$:

C, 49.77; H, 5.59; N, 8.29.

15 Found: C, 50.09; H, 5.72; N, 8.62.

EXAMPLE 11

20 Preparation of N-[2(S)-(2(S)-Pyroglutamyl-amino-3(S)-methylpentyl-oxy)-3-phenylpropionyl]-methionine methyl ester

Using the method of Example 9, substituting pyroglutamic acid for imidazole-4-acetic acid in Step H, the title compound was obtained.

Anal. Calcd for $C_{25}H_{39}N_3O_5S \cdot 0.25 CH_2Cl_2$:

25 C, 58.89; H, 7.73; N, 8.16.

Found: C, 59.01; H, 7.37; N, 7.87.

EXAMPLE 12

30 Preparation of N-[2(S)-(2(S)-Pyroglutamyl-amino-3(S)-methylpentyl-oxy)-3-phenylpropionyl]-methionine

Using the method of Example 3, Step B, the ester prepared in Example 11 was converted to the title compound.

Anal. Calcd for $C_{27}H_{37}N_3O_6S$:

- 95 -

C, 56.32; H, 7.03; N, 7.76.
Found: C, 56.15; H, 6.90; N, 7.80.

EXAMPLE 13

5

Preparation of N-[2(S)-(2(S)-((Imidazol-4-ylcarbonyl)amino-3(S)-
methylpentyl-oxy)-3-phenylpropionyl]-methionine methyl ester

Using the method for Example 9, substituting imidazole-4-
carboxylic acid for imidazole-4-acetic acid in Step H, the title compound
10 was obtained.

Anal. Calcd for C₂₅H₃₆N₄O₅S:

C, 58.45; H, 7.26; N, 10.91.
Found: C, 58.24; H, 6.97; N, 10.70.

15

EXAMPLE 14

Preparation of N-[2(S)-(2(S)-((Imidazol-4-ylcarbonyl)amino-3(S)-
methylpentyl-oxy)-3-phenylpropionyl]-methionine

Using the method of Example 3, Step B, the ester prepared
20 in Example 13 was converted to the title compound.

Anal. Calcd for C₂₄H₃₄N₄O₅S•1.25 TFA:

C, 50.17; H, 5.59; N, 8.82.
Found: C, 50.15; H, 5.68; N, 8.89.

25

EXAMPLE 15

Preparation of N-[2(S)-(2(S)-((3-Picolinyl)amino-3(S)-methylpentyl-
oxy)-3-phenylpropionyl]-methionine

30

Step A: Preparation of N-[2(S)-(2(S)-((3-Picolinyl)amino-3(S)-
methylpentyl-oxy)-3-phenylpropionyl]-methionine methyl
ester

A 100 mg (0.22 mmol) sample of 2(S)-Amino-3(S)-
methylpentyl-oxy)-3-phenylpropionyl-methionine methyl ester

- 96 -

hydrochloride, prepared as described in Example 9, Steps A-G, was dissolved in 5 mL of methanol and 3A molecular sieves were added. To this solution were added nicotinaldehyde (25 mL, 0.27 mmol), potassium acetate (80 mg, 0.22 mmol) and sodium cyanoborohydride (21 mg, 0.34 mmol). The mixture was stirred overnight at room temperature and filtered through a glass fiber disc. The mixture was concentrated and worked up in the standard manner to afford 110 mg of crude product. This material was further purified by chromatography on silica gel with 1-2% methanol in methylene chloride affording 65 mg of the title compound. The trifluoroacetate salt was characterized by FAB mass spectrum, $m/z = 502 (M+1)$.

Step B: Preparation of N-[2(S)-(2(S)-((3-Picolinyl)amino-3(S)-methylpentylloxy)-3-phenylpropionyl]-methionine

Using the method of Example 3, Step B, the ester obtained in Step A was converted to the title compound.

Anal. Calcd for $C_{26}H_{37}N_3O_4S \cdot 2.85 \text{ TFA}$:

C, 46.85; H, 4.94; N, 5.17.

Found: C, 46.81; H, 5.00; N, 5.55.

EXAMPLE 16

N-[2(S)-(2(S)-((Histidyl)amino-3(S)-methylpentylloxy)-3-phenylpropionyl]-methionine methyl ester

Using standard methods of solution phase peptide synthesis, 2(S)-(2(S)-Amino-3(S)-methyl)pentylloxy)-3-phenylpropionyl-methionine methyl ester hydrochloride, prepared as described in Example 9, Steps A-G, was coupled to histidine.

Anal. Calcd for $C_{27}H_{41}N_5O_4S \cdot 3 \text{ TFA}$:

C, 45.36; H, 5.08; N, 8.02.

Found: C, 45.41; H, 5.31; N 8.01.

- 97 -

EXAMPLE 17N-[2(S)-(2(S)-((Histidyl)amino-3(S)-methylpentyl-oxy)-3-phenyl-propionyl)-methionine

5 The product of Example 16 was saponified using the method of Example 3, Step B, to obtain the title compound.

Anal. Calcd for C₂₆H₃₉N₅O₅S•3 TFA:

C, 43.89; H, 4.83; N, 8.00.

10 Found: C, 44.16; H, 5.12; N, 8.01.

EXAMPLE 18

15 Preparation of N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)-amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester trifluoroacetate salt

Step A: Preparation of N-(2(S)-t-butoxycarbonylamino)-3-methylpentyl)glycine methyl ester

20 Glycine methyl ester hydrochloride (4.41 g, 0.035 mol) was dissolved in 1,2-dichloroethane (50 mL)- DMF (5 mL) and treated with 3A molecular sieves (10 g and N-t-butoxycarbonyl-isoleucinal (6.3 g, 0.029 mol) with stirring at 0°C. Sodium triacetoxyborohydride (9.27 g, 0.044 mol) was added, and the pH of the mixture was adjusted to 6 with triethylamine (3 mL, 0.022 mol). After stirring for 18 h the mixture was filtered, concentrated to a small volume and partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc 25 (2 x 50 mL). The combined organic phase was washed with aqueous saturated NaHCO₃ solution, brine, and dried (Na₂SO₄). Filtration and concentration gave 3.88g (54%) of the title compound after purification by chromatography (SiO₂, EtOAc: hexane, 1:3). ¹H NMR (CDCl₃) δ 30 4.69 (m, 1H), 3.72 (s, 3H), 3.48-3.62 (m, 1H), 3.42 (ABq, 2H), 2.65 (d, 2H, J=6Hz), 1.4-1.6 (m, 2H), 1.48 (s, 9H), 1.04-1.2 (m, 1H), 0.85-0.95 (m, 6H).

- 98 -

Step B: Preparation of N-[2(S)-t-Butoxycarbonylamino)-3-methylpentyl]-N-(1-naphthylmethyl)glycine methyl ester

N-[2(S)-t-Butoxycarbonylamino)-3-methylpentyl]-glycine methyl ester (2.00 g, 6.97 mmol) was dissolved in 1,2-dichloroethane (56 ml) and 3A molecular sieves were added followed by 1-naphthaldehyde (1.89 ml, 13.9 mmol) and sodium triacetoxyborohydride (6.65 g, 31.4 mmol). The mixture was stirred at ambient temperature for 16 h, and filtered through glass fiber paper and concentrated. The residue was partitioned between EtOAc and sat. NaHCO₃ (100 ml/25 ml). The aqueous layer was washed with EtOAc (3x50 ml). The organic layers were combined, dried with Na₂SO₄, filtered, and concentrated to give 5.0 g of crude product which was purified by chromatography (silica gel 1:6 to 1:3 ethyl acetate in hexane) to give 3.8 g of pure product. ¹H NMR (CD₃OD) δ 8.44-8.38 (d, 1H, J=6Hz), 7.88-7.77 (m, 2H), 7.55-7.35 (m, 4H), 6.34-6.27 (m, 1H), 4.25 (ABq, 2H), 3.66 (s, 3H), 3.40-3.23 (m, 1H), 2.95-2.85 (dd, 1H, J=6, 15Hz), 2.68-2.57 (dd, 1H, J=6, 15Hz), 1.57-1.46 (m, 1H), 1.43 (s, 9H), 1.34-1.18 (m, 2H), 1.06-0.85 (m, 1H), 0.85-0.71 (m, 6H).

Step C: Preparation of N-[2(S)-t-Butoxycarbonylamino)-3-methylpentyl]-N-(1-naphthylmethyl)glycine

N-[2(S)-t-Butoxycarbonylamino)-3-methylpentyl]-N-(1-naphthylmethyl)glycine methyl ester (2.61 g, 6.10 mmol) was dissolved in MeOH (50 ml) and 1N NaOH (24.4 ml, 24.4 mmol) was added. The mixture was stirred at ambient temperature for 4 h and concentrated. The resulting residue was dissolved in H₂O (25 ml) and neutralized with 1N HCl (24.4 ml). The aqueous layer was washed with EtOAc (3x50 ml). The organic layers were combined, dried with Na₂SO₄, filtered, and concentrated to give 2.29 g of product. ¹H NMR (CD₃OD); δ 8.48-8.39 (d, 1H, J=6Hz), 8.03-7.91 (t, 2H, J=6Hz), 7.75-7.48 (m, 4H), 5.00-4.93 (d, 1H, J=12Hz), 4.78-4.66 (d, 1H, J=12Hz), 3.80-3.58 (m, 3H), 3.49-3.40 (dd, 1H, J=3, 12Hz), 3.09-2.98 (dd, 1H, J=3, 12Hz), 1.42 (s, 9H), 1.37-1.28 (m, 2H), 1.80-1.00 (m, 1H), 0.94-0.78 (m, 6H).

- 99 -

Step D: Preparation of N-[2(S)-t-Butoxycarbonylamino]-3-methylpentyl]-N-(1-naphthylmethyl)glycine-methionine methyl ester

5 N-[2(S)-t-Butoxycarbonylamino]-3-methylpentyl]-N-(1-naphthylmethyl)glycine (2.29 g, 5.53 mmol), dissolved in DMF (20 mL), was treated with HOBt (0.822 g, 6.08 mmol), EDC (1.17 g, 6.08 mmol), and methionine methyl ester hydrochloride (1.21 g, 6.08 mmol). The pH was adjusted to 7.5 with Et₃N (1.7 mL, 12 mmol) and
10 the mixture was stirred at ambient temperature for 24 h. The mixture was concentrated, and the residue was partitioned between EtOAc (50 mL) and saturated NaHCO₃ solution (25 mL). The aqueous layer was extracted with EtOAc (1x30 mL). The organic layers were combined, washed with brine (1x25 mL), dried (Na₂SO₄), filtered, and
15 concentrated to give 3.2 g of crude product which was purified by chromatography (silica gel eluting with 1:3 to 1:2 ethyl acetate in hexane) to give 2.82 g of pure product. ¹H NMR (CD₃OD); δ 8.36-8.29 (d, 1H, J=6Hz), 7.93-7.86 (d, 1H, J=6Hz), 7.85-7.80 (d, 1H, J=6Hz), 7.61-7.39 (m, 4H), 6.60-6.52 (m, 1H), 4.32-4.06 (m, 2H), 3.90-
20 3.69 (m, 1H), 3.65 (s, 3H), 3.27-3.14 (m, 2H), 2.93-2.70 (m, 2H), 2.19-1.78 (m, 6H), 1.63-1.30 (m, 13H), 1.19-1.05 (m, 1H), 0.95-0.81 (m, 6H).

25 **Step E:** Preparation of N-[2(S)-amino-3-methylpentyl]-N-(1-naphthylmethyl)-glycyl-methionine methyl ester hydrochloride

N-[2(S)-(t-Butoxycarbonylamino)-3-methylpentyl]-N-(1-naphthylmethyl)-glycyl-methionine methyl ester (2.82 g, 5.04 mmol) was dissolved in EtOAc (50 mL) and cooled to -25°C. HCl was bubbled
30 through the mixture until TLC (95:5 CH₂Cl₂:MeOH) indicated complete reaction. Nitrogen was bubbled through the mixture to remove excess HCl and the mixture was then concentrated to give 2.68 g of the title compound. ¹H NMR (CD₃OD); δ 8.34-8.28 (d, 1H, J=6Hz), 8.00-7.92 (d, 2H, J=6Hz), 7.83-7.71 (m, 1H), 7.68-7.49 (m, 3H), 4.76-

- 100 -

4.55 (m, 4H), 3.84-3.75 (m, 2H), 3.71 (s, 3H), 3.59-3.70 (m, 1H), 3.21-3.00 (m, 2H), 2.57-2.38 (m, 3H), 2.17-2.04 (m, 4H), 1.97-1.81 (m, 1H), 1.63-1.50 (m, 1H), 1.39-1.20 (m, 1H), 1.19-1.00 (m, 1H), 0.95-0.79 (m, 6H).

5

Step F: Preparation of N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester trifluoroacetate salt

(S)-(-)Pyroglutamic acid (0.146 g, 1.13 mmol), dissolved in DMF (10 mL), was treated with HOBT (0.153 g, 1.13 mmol), EDC (0.217 g, 1.13 mmol), and N-[2(S)-amino-3-methylpentyl)-N-(1-naphthylmethyl)-glycyl-methionine methyl ester hydrochloride (0.500 g, 0.940 mmol). The pH was adjusted to 7.5 with Et₃N (0.45 mL, 3.0 mmol) and the mixture was stirred at ambient temperature for 24 h. The mixture was concentrated and the residue was partitioned between EtOAc (50 mL) and saturated NaHCO₃ solution (25 mL). The aqueous layer was extracted with EtOAc (1x30 mL). The combined organic layer was washed with brine (1x25 mL), dried (Na₂SO₄), filtered, and concentrated to give 0.589 g of crude product which was purified by chromatography (silica gel, eluting with 99:1 to 95:5 CH₂Cl₂:MeOH) to give 0.250 g of pure product. This material was converted to the trifluoroacetate salt by dissolving in 0.1% TFA in H₂O and lyophilization to give 0.289 g of the title compound. ¹H NMR (CD₃OD); δ 8.31-8.21 (d, 1H, J=9Hz), 7.91-7.76 (m, 2H), 7.62-7.35 (m, 4H), 4.42-4.30 (m, 1H), 4.25-3.99 (m, 4H), 3.69 (s, 3H), 2.94-2.74 (m, 2H), 2.55-2.48 (m, 1H), 2.40-1.78 (m, 7H), 1.95 (s, 3H), 1.66-1.53 (m, 2H), 1.50-0.99 (m, 3H), 0.95-0.78 (m, 6H).

Anal. Calcd for C₃₀H₄₁N₄O₅S•1 TFA•1.75 H₂O:

Found: C, 53.73; H, 6.41; N, 7.83.
C, 53.71; H, 6.04; N, 8.24.

30

- 101 -

EXAMPLE 19

Preparation of N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)-amino)-3(S)-methylpentyl]-glycyl-methionine trifluoroacetate salt

5 N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester (0.057 g, 0.10 mmol) was dissolved in MeOH (3 ml), cooled to 0°, and 1N NaOH (0.40 ml, 0.40 mmol) was added. The mixture was stirred at ambient temperature for 4 h and concentrated. The resulting residue was dissolved in H₂O (5
10 ml) and neutralized with 1N HCl (0.40 ml, 0.40 mmol). The aqueous layer was washed with EtOAc (3x10 ml). The organic layers were combined, dried with Na₂SO₄, filtered, and concentrated to give 0.048 g of crude product. Purification by preparative HPLC (Waters C-18 Prep Pak eluting with acetonitrile/0.1% TFA in H₂O gradient) gave
15 0.035 g of compound after lyophilization. ¹H NMR (CD₃OD); δ 8.39-8.32 (d, 1H, J=9Hz), 8.06-7.95 (m, 2H), 7.81-7.51 (m, 4H), 4.77-4.58 (m, 1H), 4.55-4.43 (m, 1H), 4.24-4.06 (m, 2H), 3.97-3.73 (m, 2H), 3.62-3.38 (m, 1H), 3.28-3.11, m, 1H), 2.50-2.17 (m, 6H), 2.13-1.94 (m, 1H), 2.03 (s, 3H) 1.88-1.71 (m, 2H), 1.68-1.55 (m, 1H), 1.53-1.38 (m,
20 1H), 1.27-1.12 (m, 1H), 1.03-0.83 (m, 6H).

Anal. Calcd for C₂₉H₄₀N₄O₅S•1.8 TFA:

C, 51.38; H, 5.53; N, 7.35.

Found: C, 51.10; H, 5.84; N, 7.75.

25

EXAMPLE 20

Preparation of N-(1-Naphthylmethyl)-N-[2(S)-((imidazol-4-ylacetyl)-amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester

30 4-Imidazoleacetic acid (0.064 g, 0.395 mmol), dissolved in DMF (5 mL) was treated with HOBt (0.053 g, 0.40 mmol), EDC (0.076 g, 0.40 mmol), and N-[2(S)-amino-3-methylpentyl]-N-(1-naphthylmethyl)-glycyl-methionine methyl ester hydrochloride (0.175 g, 0.329 mmol). The pH was adjusted to 7.5 with Et₃N (0.15 mL, 1.1 mmol) and the mixture was stirred at ambient temperature for 24 h.

- 102 -

After concentration, and the mixture was partitioned between EtOAc (20 mL) and saturated NaHCO₃ solution (10 mL). The aqueous layer was washed with EtOAc (1x20 mL). The organic layers were combined, washed with brine (1x10 mL), dried (Na₂SO₄), filtered and concentrated to give 0.170 g of crude product. Purification by chromatography (silica gel, eluting with 1 to 3% methanol in methylene chloride) gave 0.080 g of pure product. ¹H NMR (CD₃OD); δ 8.30-8.25 (d, 1H, J=9Hz), 7.91-7.86 (d, 1H, J=6Hz), 7.85-7.79 (d, 1H, J=9Hz), 7.56 (s, 1H), 7.55-7.38 (m, 4H), 6.9 (s, 1H), 4.37-4.27 (m, 1H), 4.23-4.04 (m, 3H), 3.67 (s, 3H), 3.49 (ABq, 2H), 3.25 (ABq, 2H), 2.90-2.70 (m, 2H), 2.21-1.97 (m, 2H), 1.95 (s, 3H), 1.88-1.74 (m, 1H), 1.64-1.46 (m, 2H), 1.44-1.25 (m, 1H), 1.14-.98 (m, 1H), 0.93-0.77 (m, 6H). FAB mass spectrum m/z = 568 (M+1).

15

EXAMPLE 21

Preparation of N-(1-Naphthylmethyl)-N-[2(S)-((imidazol-4-ylacetyl)-amino)-3-methylpentyl]-glycyl-methionine trifluoroacetate salt

N-(1-Naphthylmethyl)-N-[2(S)-((imidazol-4-ylacetyl)-amino)-3-methylpentyl]-glycyl-methionine methyl ester (0.058 g, 0.10 mmol) was dissolved in MeOH (3 mL), cooled to 0°C, and 1N NaOH (0.41 mL, 0.41 mmol) was added. The mixture was stirred at ambient temperature for 4 h and concentrated. The residue was dissolved in H₂O (5 mL) and neutralized with 1N HCl (0.41 mL, 0.41 mmol). The aqueous layer was extracted with EtOAc (3x10 mL). The organic layers were combined, dried with Na₂SO₄, filtered, and concentrated to give 0.042 g of crude product. The crude product was purified by preparative HPLC (Waters C-18 Prep Pak eluting with acetonitrile/0.1% TFA in H₂O gradient) to give 0.025 g of compound after lyophilization. ¹H NMR (CD₃OD); δ 8.75 (s, 1H), 8.31-8.21 (m, 1H), 7.98-7.87 (m, 2H), 7.64-7.40 (m, 4H), 7.34 (s, 1H), 4.73-4.55 (m, 1H), 4.51-4.35 (m, 2H), 4.18-4.06 (m, 1H), 3.75-3.50 (m, 4H), 3.33-3.19 (m, 1H), 3.13-2.97 (m, 1H), 2.39-2.13 (m, 2H), 2.08-1.86 (m, 1H),

- 103 -

1.99 (s, 3H), 1.8-1.51 (m, 2H), 1.49-1.35 (m, 1H), 1.24-1.08 (m, 1H),
0.95-0.79 (m, 6H).

Anal. Calcd for C₂₉H₃₉N₅O₄S•3 TFA:

C, 46.93; H, 4.73; N, 7.82.

5 Found: C, 47.01; H, 5.09; N, 8.03.

EXAMPLE 22

10 Preparation of N-(1-Naphthylmethyl)-N-[2(S)-((Imidazol-4-yl-
carbonyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester

Using the methods of Example 18, substituting imidazole-4-
carboxylic acid for pyroglutamic acid, the title compound was prepared.

Anal. Calcd for C₂₉H₃₉N₅O₄S•2 TFA•2H₂O:

C, 48.46; H, 5.55; N, 8.56.

15 Found: C, 48.22; H, 5.30; N, 8.73.

EXAMPLE 23

20 Preparation of N-(1-Naphthylmethyl)-N-[2(S)-((Imidazol-4-yl-
carbonyl)amino)-3(S)-methylpentyl]-glycyl-methionine

Using the method of Example 19, the product of Example
22 was converted to the title compound.

Anal. Calcd for C₂₈H₃₇N₅O₄S•2.25 TFA:

C, 49.02; H, 4.97; N, 8.80.

25 Found: C, 48.70; H, 5.05; N, 8.90.

EXAMPLE 24

30 Preparation of N-Benzyl-N-[2(S)-((Pyroglutamyl)amino)-3(S)-
methylpentyl]-glycyl-methionine methyl ester

Step A: Preparation of N-Benzyl-N-(2(S)-t-butoxy-
carbonylamino)-3-methylpentyl)glycine ethyl ester

- 104 -

N-t-Butoxycarbonylisoleucinal (1.1 g, 5.1 mmol), N-benzylglycine (0.94 mL, 5 mmol), and acetic acid (0.14 mL, 2.5 mmol) were dissolved in dichloroethane (50 mL) with stirring under argon at 0°C. 3A Molecular sieves (2 g) were added followed by sodium triacetoxymethylborohydride (1.52 g, 7.14 mmol). The mixture was stirred at ambient temperature for 6 h, then filtered, and concentrated to dryness. The residue was partitioned between EtOAc (50 mL) and aqueous saturated NaHCO₃ solution (50 mL). The organic layer was separated, washed with brine and dried (Na₂SO₄). Filtration and concentration gave 1.86 g (95%) of the title compound as a colorless oil. ¹H NMR (CDCl₃) δ 7.2-7.4 (m, 5H), 4.8-4.92 (m, 1H), 4.16 (d, 2H, J=7.2 Hz), 3.87 (d, 1H, J=13 Hz), 3.65-3.74 (m, 1H), 3.66 (d, 1H, J=13 Hz), 3.33 (s, 2H), 2.77 (dd, 1H, J=6, 13 Hz), 2.49 (dd, 1H, J=6, 14 Hz), 1.6-1.8 (m, 1H), 1.48 (s, 9H), 1.27 (t, 3H, J=7.2 Hz), 1.3-1.45 (m, 1H), 1.0-1.17 (m, 1H), 0.90 (t, 3H, J=7 Hz), 0.85 (d, 3H, J=7 Hz).

Step B: Preparation of N-Benzyl-N-[2(S)-((Pyroglutamyl)-amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester

The product of Step A was converted to the title compound by the methods described in Example 18, Steps B-F.

Anal. Calcd for C₂₆H₄₀N₄O₅S•1.9 TFA•0.3 CH₃CN:

C, 48.70; H, 5.75; N, 8.03.

Found: C, 48.58; H, 6.00; N, 8.33.

EXAMPLE 25

Preparation of N-Benzyl-N-[2(S)-((Pyroglutamyl)amino)-3(S)-methylpentyl]-glycyl-methionine

Using the method of Example 19, the product of Example 26 was converted to the title compound.

Anal. Calcd for C₂₅H₃₈N₄O₅S•1 TFA•2.5 H₂O:

C, 48.71; H, 6.66; N, 8.42.

Found: C, 48.68; H, 6.67; N, 8.40.

- 105 -

EXAMPLE 26

Preparation of N-Benzyl-N-[2(S)-((Imidazol-4-ylcarbonyl)amino)-3(S)-
methylpentyl]-glycyl-methionine methyl ester

5 The title compound was obtained using the method of
Example 26, substituting 4-imidazolecarboxylic acid for pyroglutamic
acid.

Anal. Calcd for $C_{25}H_{37}N_5O_4S \cdot 1.5$ TFA:

C, 49.70; H, 5.96; N, 10.59.

10 Found: C, 49.84; H, 5.75; N, 10.38.

EXAMPLE 27

15 Preparation of N-Benzyl-N-[2(S)-((imidazol-4-ylcarbonyl)amino)-3(S)-
methylpentyl]-glycyl-methionine

Using the method of Example 19, the product of Example
28 was converted to the title compound.

Anal. Calcd for $C_{24}H_{35}N_5O_4S \cdot 2$ TFA $\cdot 0.5$ H₂O:

C, 46.28; H, 5.27; N, 9.64.

20 Found: C, 46.13; H, 4.98; N, 9.77.

EXAMPLE 28

25 Preparation of N-Benzyl-N-[2(S)-((Imidazol-4-ylacetyl)amino)-3(S)-
methylpentyl]-glycyl-methionine methyl ester

The title compound was obtained using the method of
Example 26, substituting 4-imidazole acetic acid for pyroglutamic acid.
FAB mass spectrum $m/z = 518$ (M+1).

30

- 106 -

EXAMPLE 29Preparation of N-Benzyl-N-[2(S)-((Imidazol-4-ylacetyl)amino)-3(S)-methylpentyl]-glycyl-methionine

5 Using the method of Example 19, the product of Example 30 was converted to the title compound.

Anal. Calcd for $C_{25}H_{37}N_5O_4S \cdot 3 \text{ TFA} \cdot 0.5 \text{ CH}_3\text{CN}$:

C, 44.36; H, 4.83; N, 8.89.

10 Found: C, 44.67; H, 4.98; N, 9.03.

EXAMPLE 30Preparation of N-[1-(Pyroglutamylamino)cyclopent-1-ylmethyl]-N-(1-naphthylmethyl)-glycyl-methionine methyl ester

15 Step A: Preparation of 1-tert-(butyloxy)carbonylamino-cyclopentane-1-carboxaldehyde

The title compound was prepared by a Swern oxidation (3 equivalents of pyridine-sulfur trioxide complex and excess triethyl amine in DMSO/ CH_2Cl_2) of BOC protected 1-amino-1-hydroxymethyl-cyclopentane (Aldrich).

20 Step B: Preparation of N-[1-(Pyroglutamylamino)cyclopent-1-ylmethyl]-N-(1-naphthylmethyl)-glycyl-methionine methyl ester

25 Following the procedure described in Example 18, but substituting the 1-tert-(butyloxy)carbonylamino-cyclopentane-1-carboxaldehyde from Step A for N-t-butoxycarbonylisoleucinal provided the title compound.

30 Anal. Calcd for $C_{30}H_{40}N_4O_5S \cdot F_3\text{CCOOH} \cdot 0.4 \text{ EtOAc}$

C, 54.08; H, 5.73; N, 7.69.

Found: C, 54.08; H, 5.77; N, 8.07.

- 107 -

EXAMPLE 31

Preparation of N-[1-(Pyroglutamylamino)-cyclopent-1-ylmethyl]-N-(1-naphthyl-methyl)-glycyl-methionine

5 Following the procedure described in Example 19, but substituting the ester from Example 30 provided the title compound.

Anal. Calcd for C₂₉H₃₈N₄O₅S•0.5 EtOAc•1.75 H₂O

C, 59.07; H, 7.28; N, 8.89.

Found: C, 59.07; H, 6.67; N, 8.95.

10

EXAMPLE 32

Preparation of 2(S)-{2(S)-[2(S,R)-(Imidazol-4-yl)-2-aminoacetyl]-amino}-3(S)-methylpentyl-3-phenylpropionyl-methionine sulfone methyl ester and 2(S)-{2(S)-[2(R,S)-(Imidazol-4-yl)-2-aminoacetyl]-amino}-3(S)-methylpentyl-3-phenylpropionyl-methionine sulfone methyl ester

15

Step A: Preparation of racemic 2-(t-Butoxycarbonyl)amino-2-(N-t-butoxycarbonylimidazol-4-yl)acetic acid

20

To a solution of 1-(triphenylmethyl)imidazol-4-ylcarboxaldehyde (1.70 g, 5.02 mmol) and trimethylsilyl cyanide (1.36 mL, 9.9 mmol) in methylene chloride (75 ml) was added zinc iodide (159 mg, 0.497 mmol) and the mixture stirred at room temperature under argon for 24 h. The resulting mixture was evaporated *in vacuo* and the residue redissolved in methanol (75 ml) saturated with gaseous ammonia. This solution was heated at 48°C for 1 h. The solution was then evaporated *in vacuo* and the residue purified by flash chromatography (80 g SiO₂, 4% methanol saturated with ammonia/methylene chloride) to provide amino-1-(triphenylmethyl)-1H-imidazol-4-ylacetonitrile. This compound (0.80 g, 2.2 mmol) was dissolved in methylene chloride (19 ml) and treated with trifluoroacetic acid (10 ml) and triethylsilane (1 ml, 6.26 mmol) for 10 min. The solution was evaporated *in vacuo* and the residue partitioned between 5M HCl (10 ml) and diethyl ether (30 ml). The ether layer was

25

30

- 108 -

extracted with 5M HCl (10 ml). The combined aqueous extract was washed with diethyl ether (20 ml), diluted with 12M HCl (10 ml) and heated at reflux for 30 h. The resulting solution was evaporated *in vacuo* and dried under high vacuum to provide a white solid. The solid was dissolved in methanol and treated with triethylamine (920 μ l, 6.60 mmol) and di-*t*-butyl-dicarbonate (1.92 g, 8.80 mmol) and stirred at room temperature for 18 h. The resulting mixture was evaporated *in vacuo* and partitioned between 10% aq. citric acid (50 ml) and methylene chloride. The organic extract was washed with brine (20 ml), dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by flash chromatography (SiO₂, 10% methanol/methylene chloride) to provide the title compound.

¹H NMR(CD₃OD, 300MHz) δ 8.14 (1H, s), 7.36 (1H, s), 5.03 (1H, s), 1.64 (9H, s) and 1.43 (9H, s)ppm.

Step B: Preparation of 2(S)-{2(S)-[2(S,R)-(Imidazol-4-yl)-2-aminoacetyl]amino]-3(S)-methylpentylloxy}-3-phenylpropionyl-methionine sulfone methyl ester and 2(S)-{2(S)-[2(R,S)-(Imidazol-4-yl)-2-aminoacetyl]amino]-3(S)-methylpentylloxy}-3-phenylpropionyl-methionine sulfone methyl ester

The racemic amino acid was coupled with the intermediate prepared in Example 9, Step G using EDC and HOBT. The coupling was slow at room temperature and was accelerated by warming to 40-50°C. The Boc protecting groups were removed from the coupled product using TFA and the diastereomeric title compounds were purified by preparative HPLC.

2(S)-{2(S)-[2(S,R)-(Imidazol-4-yl)-2-aminoacetyl]amino]-3(S)-methylpentylloxy}-3-phenylpropionyl-methionine sulfone methyl ester

Anal. Calcd for C₂₆H₃₉N₅O₇S•2.5 TFA•0.45 H₂O:

C, 43.35; H, 4.98; N, 8.15.

Found: C, 43.33; H, 4.97; N, 8.15.

- 109 -

2(S)-{2(S)-[2(R,S)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-
methylpentylloxy}-3-phenylpropionyl-methionine sulfone methyl ester
 Anal. Calcd for C₂₆H₃₉N₅O₇S•2.35 TFA•0.55 H₂O:

C, 43.71; H, 5.07; N, 8.30.

5 Found: C, 43.71; H, 5.09; N, 8.27.

EXAMPLE 33

10 Preparation of N-(1-Naphthylmethyl)-N-[2(S)-(N'-(L-pyroglutamyl)-
 N'-methylamino)-3(S)-methylpentyl]-glycyl-methionine
trifluoroacetate salt

15 Step A: Preparation of N-[2(S)-(N'-t-Butoxycarbonyl-N'-
 methylamino)-3-methylpentyl]-N-(1-naphthyl-
 methyl)glycine

N-[2(S)-(t-Butoxycarbonylamino)-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycine (0.5 g, 1.21 mmol), dissolved in dry THF (2 mL), was cooled to 0°C and sodium bis(trimethylsilyl)amide (1M in THF, 2.5 mL, 2.5 mmol) was added. The mixture was stirred for
 20 5 min. The anion was added to a solution of iodomethane (0.375 mL, 6.03 mmol) in 1 mL dry THF at 0°C. The mixture was stirred overnight at ambient temperature. EtOAc (40 mL) was added and the organic solution was extracted with 1 N NaOH (30 mL) and water (30 mL). The aqueous layer was acidified with cold 1N HCl and
 25 extracted with EtOAc (3x30 mL). The organic layers were combined, washed with brine (25 mL), dried (MgSO₄), filtered, and concentrated to give the pure product. ¹H NMR (CDCl₃) δ 8.13 (d, 1H, J=8 Hz), 7.84 (d, 1H, J=8 Hz), 7.80 (d, 1H, J=7.5 Hz), 7.45-7.57 (m, 2H), 7.36-7.45 (m, 2H), 4.42 (d, 1H, J=13 Hz), 3.97-4.08 (m, 1H), 3.83 (d, 1H, J=13 Hz), 3.59 (d, 1H, J=15 Hz), 3.21 (d, 1H, J=15 Hz), 2.53-2.64 (m, 2H), 2.37 (br s, 1H), 1.89 (s, 3H), 1.44 (s, 9H),
 30 1.19-1.32 (m, 2H), 0.91-1.06 (m, 1H), 0.75-0.91 (m, 6H).

- 110 -

Step B: Preparation of N-[2(S)-(N'-t-Butoxycarbonyl-N'-methylamino)-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine methyl ester

5 N-[2(S)-(N'-t-Butoxycarbonyl-N'-methylamino)-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycine (0.295 g, 0.688 mmol), dissolved in CH₂Cl₂ (10 mL), was treated with HOBT (0.102 g, 0.757 mmol), EDC (0.198 g, 1.03 mmol), and methionine methyl ester hydrochloride (0.151 g, 0.757 mmol). The pH was adjusted to 7.5 with Et₃N (0.24 mL, 1.7 mmol) and the mixture was stirred at
10 ambient temperature for 4 h. The mixture was concentrated, and the residue was partitioned between EtOAc (40 mL) and 10% citric acid solution (25 mL). The aqueous layer was extracted with EtOAc (1x30 mL). The organic layers were combined, washed with water (25 mL), saturated NaHCO₃ solution (25 mL), brine (25 mL), dried
15 (MgSO₄), filtered, and concentrated to give a crude product, which was purified by chromatography (silica gel eluting with 1:3 ethyl acetate in hexane) to give the pure product. ¹H NMR (CD₃OD) was similar to N-[2(S)-(t-butoxycarbonylamino)-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine methyl ester with the addition of a
20 singlet at δ 2.41 for the N-methyl.

Step C: Preparation of N-[2(S)-(N'-methylamino)-3(S)-methylpentyl]-N-(1-naphthylmethyl)-glycyl-methionine methyl ester hydrochloride

25 N-[2(S)-(N'-t-Butoxycarbonyl-N'-methylamino)-3-methylpentyl]-N-(1-naphthylmethyl)-glycyl-methionine methyl ester (0.239 g, 0.416 mmol) was dissolved in EtOAc (5 mL) and cooled to 0°C. HCl was bubbled through the mixture for 5 min. The mixture was stirred for 2 h at which time the reaction was complete. Argon
30 was bubbled through the mixture to remove excess HCl and the mixture was then concentrated to give a solid which was triturated with ethyl ether to give the title compound. ¹H NMR (CD₃OD) was similar to N-[2(S)-amino-3-methylpentyl]-N-(1-naphthylmethyl)-

- 111 -

glycyl-methionine methyl ester hydrochloride with the addition of a singlet at δ 2.04 for the N-methyl.

5 **Step D:** Preparation of N-(1-Naphthylmethyl)-N-[2(S)-(N'-(L-pyroglutamyl)-N'-methylamino)-3(S)-methylpentyl]-glycyl-methionine methyl ester trifluoroacetate salt

10 L-Pyroglutamic acid (0.064 g, 0.495 mmol), dissolved in DMF (2 mL), was treated with BOP-Cl (0.252 g, 0.990 mmol), and N-[2(S)-(N'-methylamino)-3-methylpentyl]-N-(1-naphthylmethyl)-glycyl-methionine methyl ester hydrochloride (0.180 g, 0.330 mmol). The pH was adjusted to 7.5 with diisopropylethylamine (0.43 mL, 2.5 mmol) and the mixture was stirred at ambient temperature for 24 h. The mixture was concentrated and the residue was partitioned between EtOAc (60 mL) and 10% citric acid solution (30 mL). The aqueous layer was extracted with EtOAc (1x30 mL). The combined organic layer was washed with water (25 mL), saturated NaHCO₃ solution (25 mL), brine (25 mL), dried (MgSO₄), filtered, and concentrated to give a crude product. Purification by preparative HPLC (Waters C-18 Prep Pak eluting with acetonitrile/0.1% TFA in H₂O gradient) gave the title compound after lyophilization. ¹H NMR (CD₃OD) was similar to N-(1-naphthylmethyl)-N-[2(S)-((pyroglutamyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester trifluoroacetate salt with the addition of a singlet at δ 2.04 for the N-methyl.

25 **Step E:** Preparation of N-(1-Naphthylmethyl)-N-[2(S)-(N'-(pyroglutamyl)-N'-methylamino)-3(S)-methylpentyl]-glycyl-methionine trifluoroacetate salt

30 N-(1-Naphthylmethyl)-N-[2(S)-N'-(pyroglutamyl)-N'-methylamino)-3(S)-methylpentyl]-glycyl-methionine methyl ester trifluoroacetate salt (0.040 g, 0.057 mmol) was dissolved in MeOH (1 mL), cooled to 0°C, and 1N NaOH (0.287 mL, 0.287 mmol) was added. The mixture was stirred at ambient temperature for 4 h. The mixture was cooled to 0°C, and 1N HCl (0.287 mL, 0.287 mmol) was

- 112 -

added. The mixture was purified by preparative HPLC (Waters C-18 Prep Pak eluting with acetonitrile/0.1% TFA in H₂O gradient) to give the title compound after lyophilization. ¹H NMR (CD₃OD); δ 8.33 (d, 1H, J=8 Hz), 7.93-8.08 (m, 2H), 7.64-7.78 (m, 2H), 7.50-7.64 (m, 2H), 2.05 (s, 3H), 0.96 (d, 3H, 6 Hz), 0.85 (t, 3H, 6 Hz).
FAB MS m/z = 571 (M+1).

EXAMPLE 34

Employing the methods described in Examples 9, 18 and 32 the following compounds were prepared:

N-{2(S)-[2(S,R)-(Imidazol-4-yl)-2-aminoacetyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)-glycyl-methionine methyl ester
Anal. Calcd for C₃₀H₄₂N₆O₄S•3 TFA:

C, 46.75; H, 4.90; N, 9.09.

Found: C, 46.60; H, 5.07; N, 9.24.

N-{2(S)-[2(R,S)-(Imidazol-4-yl)-2-aminoacetyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)-glycyl-methionine methyl ester

2(S)-{2(S)-[2(S,R)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl-3-phenylpropionyl-methionine sulfone methyl ester

2(S)-{2(S)-[2(R,S)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl-3-phenylpropionyl-methionine sulfone methyl ester

2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl-3-methylbutanoyl-methionine methyl ester

Anal. Calcd for C₂₂H₃₉N₃O₆S•0.4 H₂O:

C, 54.95; H, 8.34; N, 8.74.

Found: C, 54.96; H, 8.18; N, 8.50.

- 113 -

2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentylloxy]-3-methylbutanoyl-methionine methyl ester

Anal. Calcd for $C_{22}H_{38}N_3O_5S \cdot 0.35 H_2O$:

C, 55.40; H, 8.18; N, 11.75.

5 Found: C, 55.51; H, 8.14; N, 11.36.

N-(Benzyl)-N-[2(S)-(2-oxopyrrolidin-5(R,S)-ylmethyl)amino-3(S)-methylpentyl]-glycyl-methionine methyl ester

10 N-(Benzyl)-N-[2(S)-[(D,L)-2-thiazolyl]alanyl]amino-3(S)-methylpentyl]-glycyl-methionine methyl ester

N-(Benzyl)-N-[2(S)-(3-pyridylmethyl)amino-3(S)-methylpentyl]-glycyl-methionine methyl ester

15 FAB MS $m/z = 501 (M+1)$.

2(S)-[2(S)-(2-Oxopyrrolidin-5(S)-ylmethyl)amino-3(S)-methylpentylloxy]-3-phenylpropionyl-methionine methyl ester

20 2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentylloxy]-3-(1-naphthyl)propionyl-methionine sulfone methyl ester

Anal. Calcd for $C_{30}H_{41}N_3O_8S \cdot 0.55 H_2O$:

C, 57.05; H, 7.04; N, 6.65.

25 Found: C, 57.07; H, 6.58; N, 6.66.

2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentylloxy]-3-(1-naphthyl)propionyl-methionine sulfone methyl ester

Anal. Calcd for $C_{30}H_{40}N_4O_7S \cdot 0.65 H_2O$:

C, 58.84; H, 6.80; N, 9.15.

30 Found: C, 58.85; H, 6.44; N, 8.91.

2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentylloxy]-3-(2-naphthyl)propionyl-methionine sulfone methyl ester

Anal. Calcd for $C_{30}H_{41}N_3O_8S \cdot 1.55 H_2O$:

- 114 -

C, 57.05; H, 7.04; N, 6.65.

Found: C, 57.07; H, 6.49; N, 6.54.

5 2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]-3-(2-naphthyl)propionyl-methionine sulfone methyl ester

¹H NMR was consistent with the structure of this compound.

10 N-(Benzyl)-N-[2(S)-(tetrazol-1-ylacetyl)amino-3(S)-methylpentyl]-glycyl-methionine methyl ester

N-(Benzyl)-N-[2(S)-nicotinoylamino-3(S)-methylpentyl]-glycyl-methionine methyl ester

15 N-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)-glycyl-methionine sulfoxide methyl ester

Anal. Calcd for C₃₀H₄₂N₄O₆S•2.45 TFA:

C, 48.39; H, 5.17; N, 6.47.

Found: C, 48.30; H, 5.42; N, 6.84.

20 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine isopropyl ester

Anal. Calcd for C₃₂H₄₆N₄O₅S:

C, 64.19; H, 7.74; N, 9.36.

Found: C, 63.78; H, 7.72; N, 9.32.

25 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(4-quinolylmethyl)glycyl-methionine methyl ester

Anal. Calcd for C₂₉H₄₁N₅O₅S•1.75 H₂O:

C, 57.73; H, 7.44; N, 11.61.

30 Found: C, 57.76; H, 6.98; N, 11.68.

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine t-butyl ester

Anal. Calcd for C₃₃H₄₈N₄O₅S•1.2 H₂O:

- 115 -

Found: C, 62.47; H, 8.01; N, 8.83.
C, 62.10; H, 7.62; N, 9.22.

5 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-glutamine t-butyl ester

Anal. Calcd for $C_{33}H_{47}N_5O_6 \cdot H_2O$:

C, 63.13; H, 7.87; N, 11.16.

Found: C, 62.90; H, 7.54; N, 11.12.

10 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-norleucine methyl ester

Anal. Calcd for $C_{31}H_{44}N_4O_5 \cdot 0.25 H_2O$:

C, 66.82; H, 8.05; N, 10.06.

Found: C, 66.54; H, 7.98; N, 10.16.

15 N-[2(S)-(3-pyridylmethyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine methyl ester

Anal. Calcd for $C_{31}H_{42}N_4O_3S \cdot 2.3 TFA \cdot 0.55 H_2O$:

C, 51.95; H, 5.56; N, 6.81.

20 Found: C, 51.94; H, 5.56; N, 6.84.

2(S)-{2(S)-[2-(Imidazol-4-yl)ethyl]amino-3(S)-methylpentyl}-3-phenylpropionyl-methionine sulfone methyl ester

Anal. Calcd for $C_{26}H_{40}N_4O_6S \cdot 2.9 TFA \cdot 0.05 H_2O$:

25 C, 43.99; H, 4.99; N, 6.45.

Found: C, 43.98; H, 4.90; N, 6.97.

30 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-serine methyl ester

Anal. Calcd for $C_{28}H_{38}N_4O_6 \cdot 0.75 H_2O$:

C, 62.26; H, 7.37; N, 10.37.

Found: C, 62.47; H, 7.29; N, 10.18.

- 116 -

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-homoserine lactone

Anal. Calcd for $C_{28}H_{36}N_4O_5 \cdot HCl \cdot 0.75 EtOAc$:

5 Found: C, 61.02; H, 6.94; N, 9.18.
Found: C, 60.52; H, 7.03; N, 9.45.

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(cinnamyl)glycyl-methionine methyl ester

Anal. Calcd for $C_{28}H_{42}N_4O_5S \cdot 1.75 TFA$:

10 Found: C, 50.69; H, 5.91; N, 7.51.
Found: C, 50.82; H, 6.04; N, 7.67.

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-alanine methyl ester

15 Anal. Calcd for $C_{28}H_{38}N_4O_5 \cdot 0.5 H_2O$:

Found: C, 64.71; H, 7.57; N, 10.78.
Found: C, 64.74; H, 7.20; N, 10.85.

N-{2(S)-[2-(Imidazol-4-yl)ethyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)glycyl-methionine methyl ester

20 FAB MS $m/z = 508 (M+1)$.

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-alanine methyl ester

25

N-[2(S)-(D-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine methyl ester

Anal. Calcd for $C_{30}H_{42}N_4O_5S \cdot 0.5 H_2O$:

30 Found: C, 62.15; H, 7.48; N, 9.66.
Found: C, 62.07; H, 7.52; N, 9.62.

2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl]-3-phenylpropionyl-methionine sulfone methyl ester

Anal. Calcd for $C_{26}H_{39}N_3O_8S \cdot 0.75 TFA \cdot 0.45 H_2O$:

- 117 -

Found: C, 51.03; H, 6.33; N, 6.49.
C, 51.04; H, 6.36; N, 6.72.

5 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-
methylenedioxybenzyl)glycyl-methionine methyl ester

Anal. Calcd for C₂₇H₄₀N₄O₇S•2.1 TFA:

C, 46.60; H, 5.28; N, 6.97.

Found: C, 46.46; H, 5.38; N, 7.09.

10 N-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]-N-(2,3-
dihydrobenzofuran-7-ylmethyl)glycyl-methionine methyl ester

Anal. Calcd for C₂₈H₄₁N₅O₅S•0.4 H₂O:

C, 59.32; H, 7.43; N, 12.35.

Found: C, 59.33; H, 7.31; N, 12.01.

15 N-[2(S)-[3-(3-Indolyl)propionyl]amino-3(S)-methylpentyl]-N-(1-
naphthylmethyl)glycyl-methionine methyl ester

Anal. Calcd for C₃₆H₄₆N₄O₄S•1.6 TFA:

C, 57.89; H, 5.90; N, 6.89.

20 Found: C, 57.94; H, 5.96; N, 6.83.

N-[2(S)-[3-(1-indolyl)propionyl]amino-3(S)-methylpentyl]-N-(1-
naphthylmethyl)glycyl-methionine methyl ester

Anal. Calcd for C₃₆H₄₆N₄O₄S•1.65 TFA:

25 C, 57.63; H, 5.86; N, 6.84.

Found: C, 57.73; H, 5.94; N, 6.82.

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-
naphthylmethyl)glycyl-histidine methyl ester

30 FAB MS m/z = 576 (M+1).

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(cyclopropyl-
methyl)glycyl-methionine methyl ester

FAB MS m/z = 484 (M+1).

- 118 -

N-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]-N-(cyclopropylmethyl)glycyl-methionine methyl ester
FAB MS m/z = 482 (M+1).

5

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-dihydrobenzofuran-7-ylmethyl)glycyl-methionine methyl ester
Anal. Calcd for $C_{28}H_{42}N_4O_6S \cdot 0.65 H_2O$:

C, 58.55; H, 7.60; N, 9.75.

10

Found: C, 58.54; H, 7.34; N, 9.46.

2(S)-[2(S)-N-(L-Pyroglutamyl)-N-methylamino-3(S)-methyl-pentyloxy-3-phenylpropionyl-methionine sulfone methyl ester
Anal. Calcd for $C_{26}H_{39}N_3O_6S \cdot 0.4 TFA \cdot 0.9 H_2O$:

15

C, 55.17; H, 7.12; N, 7.20.

Found: C, 55.12; H, 6.97; N, 7.59.

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-O-methylserine methyl ester

20

Anal. Calcd for $C_{29}H_{40}N_4O_6 \cdot 1.25 H_2O$:

C, 61.84; H, 7.61; N, 9.95.

Found: C, 61.62; H, 7.03; N, 9.94.

N-(1-Naphthylmethyl)-N-[2(S)-(N'-(L-pyroglutamyl)-N'-methylamino)-3(S)-methylpentyl]-glycyl-methionine methyl ester
FAB MS m/z = 585 (M+1).

25

N-[1-(Pyroglutamylamino)cyclopent-1-ylmethyl]-N-(1-naphthylmethyl)-glycyl-methionine methyl ester

30

Anal. Calcd for $C_{30}H_{40}N_4O_5S \cdot TFA \cdot 0.4 EtOAc$:

C, 54.08; H, 5.73; N, 7.69.

Found: C, 54.08; H, 5.77; N, 8.07.

- 119 -

N-[2(S)-(Pyridin-2-on-6-ylcarbonyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine methyl ester

Anal. Calcd for C₃₀H₄₀N₄O₅S•TFA•H₂O:

C, 55.61; H, 6.08; N, 7.86.

5 Found: C, 55.61; H, 5.83; N, 7.55.

EXAMPLE 35

10 The following compounds were prepared by the method described in Example 19 employing the corresponding ester from Example 27. When the physical data for the corresponding ester is described in Example 34 is not provided, the corresponding ester was converted to the acid without isolation or was not characterized by physical analysis.

15 N-{2(S)-[2(S,R)-(Imidazol-4-yl)-2-aminoacetyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)-glycyl-methionine

Anal. Calcd for C₂₉H₄₀N₆O₄S•3.15 TFA•1.45 H₂O:

C, 44.44; H, 4.87; N, 8.81.

20 Found: C, 44.44; H, 4.86; N, 8.87.

N-{2(S)-[2(R,S)-(Imidazol-4-yl)-2-aminoacetyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)-glycyl-methionine

Anal. Calcd for C₂₉H₄₀N₆O₄S•3.05 TFA•1.1 H₂O:

25 C, 45.03; H, 4.87; N, 8.98.

Found: C, 45.01; H, 4.87; N, 9.04.

2(S)-{2(S)-[2(S,R)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl-3-phenylpropionyl-methionine sulfone

30 This compound was prepared by in situ hydrolysis of the corresponding methyl ester.

2(S)-{2(S)-[2(R,S)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl-3-phenylpropionyl-methionine sulfone

- 120 -

This compound was prepared by in situ hydrolysis of the corresponding methyl ester.

5 2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl]oxy]-3-methylbutanoyl-methionine

Anal. Calcd for $C_{21}H_{37}N_3O_6S$:

C, 54.88; H, 8.12; N, 9.14.

Found: C, 54.79; H, 7.97; N, 8.85.

10 2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]oxy]-3-methylbutanoyl-methionine

Anal. Calcd for $C_{21}H_{36}N_4O_5 \cdot 1.45 \text{ TFA} \cdot 0.40 \text{ H}_2\text{O}$:

C, 45.63; H, 6.13; N, 8.91.

Found: C, 45.63; H, 6.10; N, 9.17.

15 N-(Benzyl)-N-[2(S)-(2-oxopyrrolidin-5(R,S)-ylmethyl)amino-3(S)-methylpentyl]-glycyl-methionine

Anal. Calcd for $C_{25}H_{40}N_4O_4S \cdot 2.65 \text{ HCl} \cdot 0.55 \text{ H}_2\text{O}$:

C, 50.19; H, 7.20; N, 9.37.

20 Found: C, 50.24; H, 7.21; N, 8.97.

N-(Benzyl)-N-[2(S)-[(D,L)-2-thiazolyl]alanyl]amino-3(S)-methylpentyl]-glycyl-methionine

Anal. Calcd for $C_{26}H_{33}N_5O_4S_2 \cdot 0.8 \text{ TFA} \cdot 2.45 \text{ H}_2\text{O}$:

25 C, 41.84; H, 4.52; N, 7.72.

Found: C, 41.85; H, 4.85; N, 7.66.

N-(Benzyl)-N-[2(S)-(3-pyridylmethyl)amino-3(S)-methylpentyl]-glycyl-methionine

30 Anal. Calcd for $C_{26}H_{38}N_4O_3S \cdot 2.35 \text{ TFA} \cdot 0.95 \text{ H}_2\text{O}$:

C, 47.78; H, 5.52; N, 7.26.

Found: C, 47.74; H, 5.50; N, 7.62.

- 121 -

2(S)-[2(S)-(2-Oxopyrrolidin-5(S)-ylmethyl)amino-3(S)-methylpentyloxy]-3-phenylpropionyl-methionine

This compound was prepared by in situ hydrolysis of the corresponding methyl ester

5

2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyloxy]-3-(1-naphthyl)propionyl-methionine sulfone

Anal. Calcd for C₂₉H₃₉N₃O₈S•1.5 TFA:

C, 50.52; H, 5.37; N, 5.52.

10

Found: C, 50.50; H, 5.17; N, 5.54.

2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyloxy]-3-(1-naphthyl)propionyl-methionine sulfone

Anal. Calcd for C₂₉H₃₈N₄O₇S•2 TFA•0.60 H₂O:

15

C, 48.01; H, 5.03; N, 6.79.

Found: C, 47.99; H, 5.02; N, 7.01.

2(S)-[2(S)-(L-Pyroglutamylamino)-3(S)-methylpentyloxy]-3-(2-naphthyl)propionyl-methionine sulfone

20

Anal. Calcd for C₂₉H₃₉N₃O₈S•1.55 TFA•0.15 H₂O:

C, 50.13; H, 5.35; N, 5.46.

Found: C, 50.12; H, 5.34; N, 5.60.

2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyloxy]-3-(2-naphthyl)propionyl-methionine sulfone

25

Anal. Calcd for C₂₉H₃₈N₄O₇S•1.2 TFA•1.25 H₂O:

C, 50.55; H, 5.63; N, 7.51.

Found: C, 50.54; H, 5.62; N, 7.22.

30

N-(Benzyl)-N-[2(S)-(tetrazol-1-ylacetyl)amino-3(S)-methylpentyl]-glycyl-methionine

Anal. Calcd for C₂₃H₃₅N₇O₄S•1.35 TFA•0.45 H₂O:

C, 46.23; H, 5.62; N, 14.69.

Found: C, 46.24; H, 5.61; N, 14.66.

- 122 -

N-(Benzyl)-N-[2(S)-nicotinoylamino-3(S)-methylpentyl]-glycyl-
methionine

Anal. Calcd for C₂₆H₃₆N₄O₄S•1.9 TFA:

5 C, 49.89; H, 5.33; N, 7.81.

Found: C, 49.69; H, 5.67; N, 8.15.

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(4-
quinolylmethyl)glycyl-methionine

10 Anal. Calcd for C₂₈H₃₉N₅O₅S•1.9 TFA:

C, 49.32; H, 5.32; N, 9.04.

Found: C, 49.34; H, 5.70; N, 9.23.

N-{2(S)-[(Imidazol-4-yl)methyl]amino-3(S)-methylpentyl}-N-(1-
naphthylmethyl)-glycyl-methionine

15 FAB MS m/z = 526 (M+1).

N-{2(S)-[3-(Imidazol-4-yl)propyl]amino-3(S)-methylpentyl}-N-(1-
naphthylmethyl)glycyl-methionine

20 Anal. Calcd for C₃₀H₄₃N₅O₃S•3 TFA•0.8 H₂O:

C, 47.50; H, 5.27; N, 7.69.

Found: C, 47.48; H, 5.27; N, 7.76.

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-
naphthylmethyl)glycyl-norleucine

25 Anal. Calcd for C₃₀H₄₂N₄O₅•1.5 TFA:

C, 55.84; H, 6.18; N, 7.89.

Found: C, 55.74; H, 6.42; N, 8.12.

30 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-
naphthylmethyl)glycyl-glutamine

Anal. Calcd for C₂₉H₃₉N₅O₆•1.75 TFA:

C, 51.82; H, 5.45; N, 9.30.

Found: C, 51.89; H, 5.73; N, 9.58.

- 123 -

N-[2(S)-(3-pyridylmethyl)amino-3(S)-methylpentyl]-N-(1-
naphthylmethyl)glycyl-methionine

Anal. Calcd for C₃₀H₄₀N₄O₃S•2.8 TFA•0.25 H₂O:

5 C, 49.69; H, 5.07; N, 6.51.

Found: C, 49.66; H, 5.05; N, 6.64.

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-
naphthylmethyl)glycyl-homoserine

10 This compound was prepared by in situ hydrolysis of the
corresponding lactone.

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-
naphthylmethyl)glycyl-(D,L)-serine

15 FAB MS m/z = 513 (M+1).

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-
naphthylmethyl)glycyl-(L,D)-serine

20 FAB MS m/z = 513 (M+1).

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-
(cinnamyl)glycyl-methionine

¹H NMR of this compound was consistent with the proposed structure.

25 2(S)-{2(S)-[2-(Imidazol-4-yl)ethyl]amino-3(S)-methylpentyl}-3-
phenylpropionyl-methionine sulfone

FAB MS m/z = 523 (M+1).

30 N-{2(S)-[2-(Imidazol-4-yl)ethyl]amino-3(S)-methylpentyl}-N-(1-
naphthylmethyl)glycyl-methionine

Anal. Calcd for C₂₉H₄₁N₅O₃S•2.35 TFA:

C, 50.11; H, 5.41; N, 8.67.

Found: C, 50.19; H, 5.42; N, 8.59.

- 124 -

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-alanine
FAB MS m/z = 497 (M+1).

5 N-[2(S)-(D-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine
Anal. Calcd for C₂₉H₄₀N₄O₅S•TFA•H₂O:
C, 54.05; H, 6.29; N, 8.14.
Found: C, 53.77; H, 6.18; N, 8.11.

10 2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyloxy]-3-phenylpropionyl-methionine sulfone
Anal. Calcd for C₂₅H₃₇N₃O₈S•0.65 TFA•0.15 H₂O:
C, 51.24; H, 6.21; N, 6.82.
15 Found: C, 51.23; H, 6.22; N, 6.97.

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-methylenedioxybenzyl)glycyl-methionine
Anal. Calcd for C₂₆H₃₈N₄O₇S•2.1 TFA:
20 C, 45.90; H, 5.12; N, 7.09.
Found: C, 45.84; H, 5.29; N, 7.43.

N-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]-N-(2,3-dihydrobenzofuran-7-ylmethyl)glycyl-methionine
25 FAB MS m/z = 546 (M+1).

N-{2(S)-[3-(3-indolyl)propionyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)glycyl-methionine
Anal. Calcd for C₃₅H₄₄N₄O₄S•0.4 EtOAc•0.75 H₂O:
30 C, 66.04; H, 7.38; N, 8.42.
Found: C, 66.03; H, 7.15; N, 8.41.

N-{2(S)-[3-(1-indolyl)propionyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)glycyl-methionine

- 125 -

Anal. Calcd for $C_{35}H_{44}N_4O_4S \cdot 0.8 \text{ EtOAc} \cdot 0.85 \text{ H}_2\text{O}$:

C, 65.30; H, 7.47; N, 7.97.

Found: C, 65.26; H, 7.11; N, 7.97.

5 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-
naphthylmethyl)glycyl-histidine

FAB MS m/z = 562 (M+1).

10 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-
(cyclopropylmethyl)glycyl-methionine

Anal. Calcd for $C_{22}H_{38}N_4O_5S \cdot 1.75 \text{ TFA} \cdot 0.45 \text{ H}_2\text{O}$:

C, 45.16; H, 6.04; N, 8.26.

Found: C, 45.12; H, 6.03; N, 8.59.

15 N-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]-N-
(cyclopropylmethyl)glycyl-methionine

FAB MS m/z = 468 (M+1).

20 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-
dihydrobenzofuran-7-ylmethyl)glycyl-methionine

FAB MS m/z = 549 (M+1).

25 2(S)-[2(S)-N-(L-Pyroglutamyl)-N-methylamino-3(S)-methyl-
pentyloxy]-3-phenylpropionyl-methionine sulfone

Anal. Calcd for $C_{25}H_{37}N_3O_6S$:

C, 51.24; H, 6.21; N, 6.82.

Found: C, 51.23; H, 6.22; N, 6.97.

30 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-
naphthylmethyl)glycyl-O-methylserine

Anal. Calcd for $C_{29}H_{40}N_4O_6$:

C, 62.34; H, 7.58; N, 10.01.

Found: C, 61.86; H, 7.06; N, 10.00.

- 126 -

N-(1-Naphthylmethyl)-N-[2(S)-(N'-(L-pyroglutamyl)-N'-methylamino)-
3(S)-methylpentyl]-glycyl-methionine

FAB MS $m/z = 571$ (M+1).

5 N-[1-(Pyroglutamylamino)-cyclopent-1-ylmethyl]-N-(1-
naphthylmethyl)-glycyl-methionine

FAB MS $m/z = 554$ (M+1).

10 N-[2(S)-(Pyridin-2-on-6-ylcarbonyl)amino-3(S)-methylpentyl]-N-(1-
naphthylmethyl)glycyl-methionine

This compound was prepared by in situ hydrolysis of the
corresponding methyl ester.

15 EXAMPLE 36

In vitro inhibition of ras farnesyl transferase

Assays of farnesyl-protein transferase. Partially purified bovine
FPTase and Ras peptides (Ras-CVLS, Ras-CVIM and RAS-CAIL) were
20 prepared as described by Schaber *et al.*, *J. Biol. Chem.* 265:14701-
14704 (1990), Pompliano, *et al.*, *Biochemistry* 31:3800 (1992) and
Gibbs *et al.*, *PNAS U.S.A.* 86:6630-6634 (1989), respectively. Bovine
FPTase was assayed in a volume of 100 μ l containing 100 mM N-(2-
hydroxy ethyl) piperazine-N'-(2-ethane sulfonic acid) (HEPES), pH 7.4,
25 5 mM MgCl₂, 5 mM dithiothreitol (DTT), 100 mM [³H]-farnesyl
diphosphate ([³H]-FPP; 740 CBq/mmol, New England Nuclear), 650
nM Ras-CVLS and 10 μ g/ml FPTase at 31°C for 60 min. Reactions
were initiated with FPTase and stopped with 1 ml of 1.0 M HCL in
ethanol. Precipitates were collected onto filter-mats using a TomTec
30 Mach II cell harvester, washed with 100% ethanol, dried and counted in
an LKB β -plate counter. The assay was linear with respect to both
substrates, FPTase levels and time; less than 10% of the [³H]-FPP was
utilized during the reaction period. Purified compounds were dissolved
in 100% dimethyl sulfoxide (DMSO) and were diluted 20-fold into the

- 127 -

assay. Percentage inhibition is measured by the amount of incorporation of farnesyl in the presence of the test compound when compared to the amount of incorporation in the absence of the test compound.

5 Human FPTase was prepared as described by Omer *et al.*, *Biochemistry* 32:5167-5176 (1993). Human FPTase activity was assayed as described above with the exception that 0.1% (w/v) polyethylene glycol 20,000, 10 μ M ZnCl₂ and 100 nM Ras-CVIM were added to the reaction mixture. Reactions were performed for 30 min.,
10 stopped with 100 μ l of 30% (v/v) trichloroacetic acid (TCA) in ethanol and processed as described above for the bovine enzyme.

The compounds of the instant invention were tested for inhibitory activity against human FPTase by the assay described above and were found to have IC₅₀ of < 10 μ M.

15

EXAMPLE 37

In vivo ras farnesylation assay

20 The cell line used in this assay is a v-ras line derived from either Rat1 or NIH3T3 cells, which expressed viral Ha-ras p21. The assay is performed essentially as described in DeClue, J.E. *et al.*, *Cancer Research* 51:712-717, (1991). Cells in 10 cm dishes at 50-75% confluency are treated with the test compound (final concentration of solvent, methanol or dimethyl sulfoxide, is 0.1%). After 4 hours at
25 37°C, the cells are labelled in 3 ml methionine-free DMEM supplemented with 10% regular DMEM, 2% fetal bovine serum and 400 mCi[³⁵S]methionine (1000 Ci/mmol). After an additional 20 hours, the cells are lysed in 1 ml lysis buffer (1% NP40/20 mM HEPES, pH 7.5/5 mM MgCl₂/1mM DTT/10 mg/ml aprotinen/2 mg/ml leupeptin/2 mg/ml
30 antipain/0.5 mM PMSF) and the lysates cleared by centrifugation at 100,000 x g for 45 min. Aliquots of lysates containing equal numbers of acid-precipitable counts are brought to 1 ml with IP buffer (lysis buffer lacking DTT) and immunoprecipitated with the ras-specific monoclonal antibody Y13-259 (Furth, M.E. *et al.*, *J. Virol.* 43:294-304,

- 128 -

(1982)). Following a 2 hour antibody incubation at 4°C, 200 ml of a 25% suspension of protein A-Sepharose coated with rabbit anti rat IgG is added for 45 min. The immunoprecipitates are washed four times with IP buffer (20 mM HEPES, pH 7.5/1 mM EDTA/1% Triton X-100.0.5% deoxycholate/0.1%/SDS/0.1 M NaCl) boiled in SDS-PAGE sample buffer and loaded on 13% acrylamide gels. When the dye front reached the bottom, the gel is fixed, soaked in Enlightening, dried and autoradiographed. The intensities of the bands corresponding to farnesylated and nonfarnesylated ras proteins are compared to determine the percent inhibition of farnesyl transfer to protein.

EXAMPLE 38

In vivo growth inhibition assay

To determine the biological consequences of FPTase inhibition, the effect of the compounds of the instant invention on the anchorage-independent growth of Rat1 cells transformed with either a *v-ras*, *v-raf*, or *v-mos* oncogene is tested. Cells transformed by *v-Raf* and *v-Mos* maybe included in the analysis to evaluate the specificity of instant compounds for Ras-induced cell transformation.

Rat 1 cells transformed with either *v-ras*, *v-raf*, or *v-mos* are seeded at a density of 1×10^4 cells per plate (35 mm in diameter) in a 0.3% top agarose layer in medium A (Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum) over a bottom agarose layer (0.6%). Both layers contain 0.1% methanol or an appropriate concentration of the instant compound (dissolved in methanol at 1000 times the final concentration used in the assay). The cells are fed twice weekly with 0.5 ml of medium A containing 0.1% methanol or the concentration of the instant compound. Photomicrographs are taken 16 days after the cultures are seeded and comparisons are made.

- 129 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANTS: deSolms, S. Jane
Garsky, Victor M.
Giuliani, Elizabeth A.
Gomez, Robert P.
Graham, Samuel L.
Stokker, Gerald E.
Wiscount, Catherine M.

(ii) TITLE OF INVENTION: Inhibitors of Farnesyl-Protein
Transferase

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: David A. Muthard
(B) STREET: P.O. Box 2000, 126 E. Lincoln Avenue
(C) CITY: Rahway
(D) STATE: NJ
(E) COUNTRY: U.S.A.
(F) ZIP: 07065

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Muthard, David A.
(B) REGISTRATION NUMBER: 35,297
(C) REFERENCE/DOCKET NUMBER: 190671A

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 908-594-3903
(B) TELEFAX: 908-594-4720

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- 130 -

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Xaa Val Phe Met

1

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:


Xaa Val Ile Met

1

- 131 -

WHAT IS CLAIMED IS:

1. A compound which inhibits Ras farnesyl-transferase having the formula I:



wherein:

R¹ is selected from:

- a) heterocycle, and
- b) C₁-C₁₀ alkyl, which is substituted with heterocycle and which is optionally substituted with one or more of C₁-C₄ alkyl, hydroxy or amino groups;

R^{2a} and R^{2b} are independently selected from:

- a) a side chain of a naturally occurring amino acid,
- b) an oxidized form of a side chain of a naturally occurring amino acid which is:
 - i) methionine sulfoxide, or
 - ii) methionine sulfone,
- c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
- d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocycle and C₃-C₁₀ cycloalkyl; or

R^{2a} and R^{2b} are combined to form - (CH₂)_s -;

- 132 -

R³ and R⁴ are independently selected from:

- 5 a) a side chain of a naturally occurring amino acid,
b) an oxidized form of a side chain of a naturally occurring
amino acid which is:
- 10 i) methionine sulfoxide, or
ii) methionine sulfone, and
c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀
alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,
wherein the substituent is selected from F, Cl, Br,
N(R⁸)₂, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-,
CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃,
-N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
15 d) C₁-C₆ alkyl substituted with an unsubstituted or
substituted group selected from aryl, heterocyclic and C₃-
C₁₀ cycloalkyl; or

R³ and R⁴ are combined to form - (CH₂)_s - ;


20 R^{5a} and R^{5b} are independently selected from:

- a) a side chain of a naturally occurring amino acid,
b) an oxidized form of a side chain of a naturally occurring
amino acid which is:
- 25 i) methionine sulfoxide, or
ii) methionine sulfone,
c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀
alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocycle group,
wherein the substituent is selected from F, Cl, Br,
N(R⁸)₂, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-,
30 CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃,
-N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
d) C₁-C₆ alkyl substituted with an unsubstituted or
substituted group selected from aryl, heterocyclic and C₃-
C₁₀ cycloalkyl; or


- 133 -

R^{5a} and R^{5b} are combined to form $-(CH_2)_S-$ wherein one of the carbon atoms is optionally replaced by a moiety selected from: O, S(O)_m, -NC(O)-, and -N(COR⁸)-;


5 X-Y is




10




15



20



25



R^{7a} is selected from

- 30 a) hydrogen,
 b) unsubstituted or substituted aryl,
 c) unsubstituted or substituted heterocyclic,
 d) unsubstituted or substituted cycloalkyl, and
 e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

- 134 -

R^{7b} is selected from

- a) hydrogen,
- b) unsubstituted or substituted aryl,
- 5 c) unsubstituted or substituted heterocyclic,
- d) unsubstituted or substituted cycloalkyl,
- e) C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl,
- 10 f) a carbonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl, and
- 15 g) a sulfonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl;

20

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

R⁹ is independently selected from C₁-C₆ alkyl and aryl;

25 R¹⁰ is independently selected from hydrogen and C₁-C₆ alkyl;

Z is independently H₂ or O;


30 m is 0, 1 or 2; and

s is 4 or 5;

or a pharmaceutically acceptable salt thereof.

- 135 -

2. A prodrug of a compound of Claim 1 having the formula II:



II

10

wherein:

R¹ is selected from:

15

- a) heterocycle, and
- b) C₁-C₁₀ alkyl, which is substituted with heterocycle and which is optionally substituted with one or more of C₁-C₄ alkyl, hydroxy or amino groups;

R^{2a} and R^{2b} are independently selected from:

20

- a) a side chain of a naturally occurring amino acid,
- b) an oxidized form of a side chain of a naturally occurring amino acid which is:
 - i) methionine sulfoxide, or
 - ii) methionine sulfone,
- c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,

25

wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
- d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocycle and C₃-C₁₀ cycloalkyl; or

30

R^{2a} and R^{2b} are combined to form - (CH₂)_s - ;

R³ and R⁴ are independently selected from:

- 136 -

a) a side chain of a naturally occurring amino acid,
b) an oxidized form of a side chain of a naturally occurring amino acid which is:

i) methionine sulfoxide, or

ii) methionine sulfone, and

c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,

wherein the substituent is selected from F,

Cl, Br, N(R⁸)₂, NO₂, R⁸O-, R⁹S(O)_m-,

R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-,

R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂,

R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and

d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl; or

R³ and R⁴ are combined to form - (CH₂)_s - ;

R^{5a} and R^{5b} are independently selected from:

a) a side chain of a naturally occurring amino acid,

b) an oxidized form of a side chain of a naturally occurring amino acid which is:

i) methionine sulfoxide, or

ii) methionine sulfone,

c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocycle group,

wherein the substituent is selected from F, Cl, Br,

N(R⁸)₂, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-,

CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃,

-N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and

d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl; or

- 137 -


R^{5a} and R^{5b} are combined to form - (CH₂)_s - wherein one of the carbon atoms is optionally replaced by a moiety selected from: O, S(O)_m, -NC(O)-, and -N(COR⁸)- ;

5 R⁶ is

a) substituted or unsubstituted C₁-C₈ alkyl, wherein the substituent on the alkyl is selected from:

- 1) aryl,
- 2) heterocycle,
- 10 3) -N(R⁹)₂,
- 4) -OR⁸, or

b)



20


25

30


- 138 -

X-Y is



5




10



15



20

R^{7a} is selected from

25

- a) hydrogen,
- b) unsubstituted or substituted aryl,
- c) unsubstituted or substituted heterocyclic,
- d) unsubstituted or substituted cycloalkyl, and
- e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

30

R^{7b} is selected from

- a) hydrogen,
- b) unsubstituted or substituted aryl,

- 139 -

- c) unsubstituted or substituted heterocyclic,
d) unsubstituted or substituted cycloalkyl,
e) C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl,
f) a carbonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl, and
g) a sulfonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl;

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

R⁹ is independently selected from C₁-C₆ alkyl and aryl;

R¹⁰ is independently selected from hydrogen and C₁-C₆ alkyl;

R¹¹ is independently selected from C₁-C₆ alkyl;

Z is independently H₂ or O;


m is 0, 1 or 2; and

s is 4 or 5;

or a pharmaceutically acceptable salt thereof.

3. A compound which inhibits Ras farnesyl-transferase
having the formula III:

- 140 -



III

wherein:

10 R1 is selected from:

- a) heterocycle, and
- b) C1-C10 alkyl, which is substituted with heterocycle and which is optionally substituted with one or more of C1-C4 alkyl, hydroxy or amino groups;

15

R2a and R2b are independently selected from:

- a) a side chain of a naturally occurring amino acid,
- b) an oxidized form of a side chain of a naturally occurring amino acid which is:
 - 20 i) methionine sulfoxide, or
 - ii) methionine sulfone,
- c) substituted or unsubstituted C1-C20 alkyl, C2-C20 alkenyl, C3-C10 cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO2, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C1-C20 alkyl, and
- d) C1-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocycle and C3-C10 cycloalkyl; or
- 30 R2a and R2b are combined to form - (CH₂)_s -;

25

30

R3 and R4 are independently selected from:

- a) a side chain of a naturally occurring amino acid,

- 141 -

b) an oxidized form of a side chain of a naturally occurring amino acid which is:

i) methionine sulfoxide, or

ii) methionine sulfone, and

c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,

wherein the substituent is selected from F,

Cl, Br, N(R⁸)₂, NO₂, R⁸O-, R⁹S(O)_m-,

R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-,

R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂,

R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and


d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl; or

R³ and R⁴ are combined to form - (CH₂)_s - ;


- 142 -

X-Y is


5




10



15



20

R^{7a} is selected from

25

- a) hydrogen,
- b) unsubstituted or substituted aryl,
- c) unsubstituted or substituted heterocyclic,
- d) unsubstituted or substituted cycloalkyl, and
- e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

30

R^{7b} is selected from

- a) hydrogen,
- b) unsubstituted or substituted aryl,

- 143 -

- 5 c) unsubstituted or substituted heterocyclic,
d) unsubstituted or substituted cycloalkyl,
e) C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl,
f) a carbonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
10 heterocyclic and cycloalkyl, and
g) a sulfonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
15 heterocyclic and cycloalkyl;

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

20 R⁹ is independently selected from C₁-C₆ alkyl and aryl;

R¹⁰ is independently selected from hydrogen and C₁-C₆ alkyl;

Z is H₂ or O;


25 m is 0, 1 or 2;
n is 0, 1 or 2; and
s is 4 or 5;

30 or a pharmaceutically acceptable salt thereof.

- 144 -

4. A prodrug of a compound of Claim 3 of the formula

IV:



IV

wherein:

R¹ is selected from:

- a) heterocycle, and
- b) C₁-C₁₀ alkyl, which is substituted with heterocycle and which is optionally substituted with one or more of C₁-C₄ alkyl, hydroxy or amino groups;

R^{2a} and R^{2b} are independently selected from:

- a) a side chain of a naturally occurring amino acid,
- b) an oxidized form of a side chain of a naturally occurring amino acid which is:
 - i) methionine sulfoxide, or
 - ii) methionine sulfone,
- c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
- d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocycle and C₃-C₁₀ cycloalkyl; or

R^{2a} and R^{2b} are combined to form - (CH₂)_s -;

- 145 -

R³ and R⁴ are independently selected from:

a) a side chain of a naturally occurring amino acid,
b) an oxidized form of a side chain of a naturally occurring
amino acid which is:

i) methionine sulfoxide, or

ii) methionine sulfone, and

c) substituted or unsubstituted C₁-C₂₀ alkyl, C₂-C₂₀
alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,

wherein the substituent is selected from F, Cl, Br,

N(R⁸)₂, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-,

CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃,

-N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and


d) C₁-C₆ alkyl substituted with an unsubstituted or
substituted group selected from aryl, heterocyclic and C₃-
C₁₀ cycloalkyl; or

R³ and R⁴ are combined to form - (CH₂)_s - ;


- 146 -

X-Y is


5





10



15



20

R^{7a} is selected from

25

- a) hydrogen,
- b) unsubstituted or substituted aryl,
- c) unsubstituted or substituted heterocyclic,
- d) unsubstituted or substituted cycloalkyl, and
- e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

30

R^{7b} is selected from

- a) hydrogen,
- b) unsubstituted or substituted aryl,

- 147 -

- 5 c) unsubstituted or substituted heterocyclic,
d) unsubstituted or substituted cycloalkyl,
e) C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl,
f) a carbonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl, and
10 g) a sulfonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
unsubstituted or substituted group selected from aryl,
15 heterocyclic and cycloalkyl;

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

20 R⁹ is independently selected from C₁-C₆ alkyl and aryl;

R¹⁰ is independently selected from hydrogen and C₁-C₆ alkyl;


Z is H₂ or O;

25 m is 0, 1 or 2;
n is 0, 1 or 2; and
s is 4 or 5;

30 or a pharmaceutically acceptable salt thereof.

5. The compound according to Claim 1 having the
formula I:

- 148 -



5

wherein:

R¹ is selected from:

10

- a) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and isoquinolinyl, and
- b) C₁-C₁₀ alkyl, which is substituted with a heterocycle and which is optionally substituted with one or more of C₁-C₄ alkyl, hydroxy or amino groups;

15

wherein the heterocycle is selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and isoquinolinyl;

20

R^{2a} is selected from:

25

- a) a side chain of a naturally occurring amino acid, wherein the amino acid is selected from alanine, leucine, isoleucine and valine;
- b) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸-, C₁-C₂₀ alkyl, and
- c) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl;

30

R^{2b} is selected from hydrogen and C₁-C₆ alkyl; or

- 149 -

R^{2a} and R^{2b} are combined to form - (CH₂)_s -;

R³ and R⁴ are independently selected from:

- 5 a) a side chain of a naturally occurring amino acid,
 b) an oxidized form of a side chain of a naturally occurring
 amino acid which is:
 i) methionine sulfoxide, or
 ii) methionine sulfone,
10 c) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀
 alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,
 wherein the substituent is selected from F, Cl, Br, NO₂,
 R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-,
 R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸-, C₁-
15 C₂₀ alkyl, and
 d) C₁-C₆ alkyl substituted with an unsubstituted or
 substituted group selected from aryl, heterocyclic and C₃-
 C₁₀ cycloalkyl;

20 R^{5a} is selected from:

- a) a side chain of a naturally occurring amino acid,
 wherein the amino acid is selected from methionine
 and glutamine,
 b) an oxidized form of a side chain of a naturally occurring
25 amino acid which is:
 i) methionine sulfoxide, or
 ii) methionine sulfone, and
 c) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀
 alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,
30 wherein the substituent is selected from F, Cl, Br,
 NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-
 C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂,
 R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and


- 150 -

d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl;


5 R^{5b} is selected from:

- a) hydrogen, and
b) C₁-C₃ alkyl;


10 X-Y is




15




20



25



, or



R^{7a} is selected from

30

- a) hydrogen,
b) unsubstituted or substituted aryl,
c) unsubstituted or substituted heterocyclic,
d) unsubstituted or substituted cycloalkyl, and

- 151 -

e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

wherein heterocycle is selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl;

R^{7b} is selected from

a) hydrogen,

b) unsubstituted or substituted aryl,

c) unsubstituted or substituted heterocyclic,

d) unsubstituted or substituted cycloalkyl,

e) C₁-C₆ alkyl substituted with hydrogen or an

unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl,

f) a carbonyl group which is bonded to an unsubstituted or substituted group selected from aryl, heterocyclic, cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl, and

g) a sulfonyl group which is bonded to an unsubstituted or substituted group selected from aryl, heterocyclic, cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

wherein heterocycle is selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl;

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

R⁹ is independently selected from C₁-C₆ alkyl and aryl;

- 152 -


Z is independently H₂ or O;

m is 0, 1 or 2; and

s is 4 or 5;

or a pharmaceutically acceptable salt thereof.

6. The compound according to Claim 2 having the formula II:



II

wherein:

R¹ is selected from:

- a) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and isoquinolinyl, and
- b) C₁-C₁₀ alkyl, which is substituted with a heterocycle and which is optionally substituted with one or more of C₁-C₄ alkyl, hydroxy or amino groups;

wherein the heterocycle is selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and isoquinolinyl;

R^{2a} is selected from:

- a) a side chain of a naturally occurring amino acid, wherein the amino acid is selected from alanine, leucine, isoleucine and valine; and

- 153 -

- b) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
- c) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl;

R_{2b} is selected from hydrogen and C₁-C₆ alkyl; or

R_{2a} and R_{2b} are combined to form - (CH₂)_s -;

R₃ and R₄ are independently selected from:

- a) a side chain of a naturally occurring amino acid,
b) an oxidized form of a side chain of a naturally occurring amino acid which is:
i) methionine sulfoxide, or
ii) methionine sulfone,
c) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl;

R_{5a} is selected from:

- a) a side chain of a naturally occurring amino acid, wherein the amino acid is selected from methionine and glutamine,

- 154 -

b) an oxidized form of a side chain of a naturally occurring amino acid which is:

i) methionine sulfoxide, or

ii) methionine sulfone, and

c) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,

wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and

d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl;

R^{5b} is selected from:

a) hydrogen, and

b) C₁-C₃ alkyl;

R⁶ is

a) substituted or unsubstituted C₁-C₈ alkyl, wherein the substituent on the alkyl is selected from:


1) aryl,

2) heterocycle,

3) -N(R⁹)₂,


4) -OR⁸, or

b)



- 155 -

X-Y is



20

R^{7a} is selected from

- 25
- a) hydrogen,
 - b) unsubstituted or substituted aryl,
 - c) unsubstituted or substituted heterocyclic,
 - d) unsubstituted or substituted cycloalkyl, and
 - e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

30

wherein heterocycle is selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl;

R^{7b} is selected from

- a) hydrogen,

- 156 -

- b) unsubstituted or substituted aryl,
c) unsubstituted or substituted heterocyclic,
d) unsubstituted or substituted cycloalkyl,
e) C₁-C₆ alkyl substituted with hydrogen or an
5 unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl,
f) a carbonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
10 unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl, and
g) a sulfonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
15 unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl;
wherein heterocycle is selected from pyrrolidinyl,
imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-
oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl,
20 and thienyl;

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

25 R⁹ is independently selected from C₁-C₆ alkyl and aryl;

R¹⁰ is independently selected from hydrogen and C₁-C₆ alkyl;

30 R¹¹ is independently selected from C₁-C₆ alkyl;

Z is independently H₂ or O;


m is 0, 1 or 2; and

s is 4 or 5;

- 157 -

or a pharmaceutically acceptable salt thereof.

7. The compound according to Claim 3 having the
 5 formula III:



III

wherein:

15 R1 is selected from:

- a) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and isoquinolinyl, and
- b) C1-C10 alkyl, which is substituted with a heterocycle and which is optionally substituted with one or more of C1-C4 alkyl, hydroxy or amino groups;

20 wherein the heterocycle is selected from
 pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl,
 pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and
 25 isoquinolinyl;

R2a is selected from:

- a) a side chain of a naturally occurring amino acid,
 30 wherein the amino acid is selected from alanine,
 leucine, isoleucine and valine;
- b) substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, C3-C10 cycloalkyl, aryl or heterocyclic group,
 wherein the substituent is selected from F, Cl, Br,
 NO2, R8O-, R9S(O)m-, R8C(O)NR8-, CN, (R8)2N-

- 158 -

C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂,
R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and
d) C₁-C₆ alkyl substituted with an unsubstituted or
substituted group selected from aryl, heterocyclic and C₃-
C₁₀ cycloalkyl;

R_{2b} is selected from hydrogen and C₁-C₆ alkyl; or

R_{2a} and R_{2b} are combined to form - (CH₂)_s -;

R₃ and R₄ are independently selected from:

a) a side chain of a naturally occurring amino acid,
b) an oxidized form of a side chain of a naturally occurring
amino acid which is:


i) methionine sulfoxide, or
ii) methionine sulfone,

c) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀
alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group,
wherein the substituent is selected from F, Cl, Br,
NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-,
C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂,
R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and

d) C₁-C₆ alkyl substituted with an unsubstituted or
substituted group selected from aryl, heterocyclic and C₃-
C₁₀ cycloalkyl;

- 159 -

X-Y is



20

R7a is selected from

- 25
- a) hydrogen,
 - b) unsubstituted or substituted aryl,
 - c) unsubstituted or substituted heterocyclic,
 - d) unsubstituted or substituted cycloalkyl, and
 - e) C1-C6 alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

30

wherein heterocycle is selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinoliny, isoquinoliny, and thienyl;

R7b is selected from

- a) hydrogen,

- 160 -

- 5 b) unsubstituted or substituted aryl,
 c) unsubstituted or substituted heterocyclic,
 d) unsubstituted or substituted cycloalkyl,
 e) C₁-C₆ alkyl substituted with hydrogen or an
 unsubstituted or substituted group selected from aryl,
 heterocyclic and cycloalkyl,
 f) a carbonyl group which is bonded to an unsubstituted or
 substituted group selected from aryl, heterocyclic,
10 cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
 unsubstituted or substituted group selected from aryl,
 heterocyclic and cycloalkyl, and
 g) a sulfonyl group which is bonded to an unsubstituted or
 substituted group selected from aryl, heterocyclic,
15 cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
 unsubstituted or substituted group selected from aryl,
 heterocyclic and cycloalkyl;
 wherein heterocycle is selected from pyrrolidinyl,
 imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-
20 oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl,
 and thienyl;

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

25 R⁹ is independently selected from C₁-C₆ alkyl and aryl;


Z is independently H₂ or O;

30 m is 0, 1 or 2;
 n is 0, 1 or 2; and
 s is 4 or 5;

or a pharmaceutically acceptable salt thereof.

- 161 -

8. The compound according to Claim 4 having the formula IV:



IV

wherein:

R¹ is selected from:

- a) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and isoquinolinyl, and
- b) C₁-C₁₀ alkyl, which is substituted with a heterocycle and which is optionally substituted with one or more of C₁-C₄ alkyl, hydroxy or amino groups;

wherein the heterocycle is selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, and isoquinolinyl;

R^{2a} is selected from:

- a) a side chain of a naturally occurring amino acid, wherein the amino acid is selected from alanine, leucine, isoleucine and valine;
- b) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸- and C₁-C₂₀ alkyl, and

- 162 -

c) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl;

5 R_{2b} is selected from hydrogen and C₁-C₆ alkyl; or


R_{2a} and R_{2b} are combined to form - (CH₂)_s -;

R₃ and R₄ are independently selected from:

- 10 a) a side chain of a naturally occurring amino acid,
b) an oxidized form of a side chain of a naturally occurring amino acid which is:
- 15 i) methionine sulfoxide, or
ii) methionine sulfone,
- 15 c) substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, aryl or heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R⁸O-, R⁹S(O)_m-, R⁸C(O)NR⁸-, CN, (R⁸)₂N-C(NR⁸)-, R⁸C(O)-, R⁸OC(O)-, N₃, -N(R⁸)₂, R⁹OC(O)NR⁸-, C₁-C₂₀ alkyl, and
- 20 d) C₁-C₆ alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and C₃-C₁₀ cycloalkyl;
- 25
- 30

- 163 -

X-Y is



20

R^{7a} is selected from

- 25
- a) hydrogen,
 - b) unsubstituted or substituted aryl,
 - c) unsubstituted or substituted heterocyclic,
 - d) unsubstituted or substituted cycloalkyl, and
 - e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocyclic and cycloalkyl;

30

wherein heterocycle is selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl;

R^{7b} is selected from

- a) hydrogen,

- 164 -

- b) unsubstituted or substituted aryl,
c) unsubstituted or substituted heterocyclic,
d) unsubstituted or substituted cycloalkyl,
e) C₁-C₆ alkyl substituted with hydrogen or an
5 unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl,
f) a carbonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
10 unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl, and
g) a sulfonyl group which is bonded to an unsubstituted or
substituted group selected from aryl, heterocyclic,
cycloalkyl and C₁-C₆ alkyl substituted with hydrogen or an
15 unsubstituted or substituted group selected from aryl,
heterocyclic and cycloalkyl;
wherein heterocycle is selected from pyrrolidinyl,
imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-
oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl,
20 and thienyl;

R⁸ is independently selected from hydrogen, C₁-C₆ alkyl and aryl;

25 R⁹ is independently selected from C₁-C₆ alkyl and aryl;

Z is independently H₂ or O;

m is 0, 1 or 2;

30 n is 0, 1 or 2; and

s is 4 or 5;

or a pharmaceutically acceptable salt thereof.

- 165 -

9. A compound which inhibits farnesyl-protein transferase which is:

- 5 Pyroglutamyl-valyl-isoleucyl-methionine;
- Pyroglutamyl-valyl-isoleucyl-methionine methyl ester;
- Nicotinoyl-isoleucyl-phenylalanyl-methionine;
- 10 Nicotinoyl-isoleucyl-phenylalanyl-methionine methyl ester;
- N-[2(S)-(L-Pyroglutamylamino)-3-methylbutyl]phenylalanyl-methionine;
- 15 N-[2(S)-(L-Pyroglutamylamino)-3-methylbutyl]phenylalanyl-methionine methyl ester;
- N-[5(S)-(L-Pyroglutamylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine;
- 20 N-[5(S)-(L-Pyroglutamylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine methyl ester;
- N-[5(S)-((Imidazol-4-yl)acetylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine;
- 25 N-[5(S)-((Imidazol-4-yl)acetylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine methyl ester;
- 30 N-[5(S)-((Imidazol-4-ylcarbonylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine;
- N-[5(S)-((Imidazol-4-ylcarbonylamino)-6(S)-methyl-2(R)-butyl-3,4(E)-octenoyl]-methionine methyl ester;

- 166 -

N-[2(S)-(2(S)-(Imidazol-4-yl)acetylamino)-3(S)-methylpentylloxy)-3-phenylpropionyl]-methionine;

5 N-[2(S)-(2(S)-(Imidazol-4-yl)acetylamino)-3(S)-methylpentylloxy)-3-phenylpropionyl]-methionine methyl ester;

10 N-[2(S)-(2(S)-Pyroglutamylamino-3(S)-methylpentylloxy)-3-phenylpropionyl]-methionine;

N-[2(S)-(2(S)-Pyroglutamylamino-3(S)-methylpentylloxy)-3-phenylpropionyl]-methionine methyl ester;

15 N-[2(S)-(2(S)-Imidazol-4-ylcarbonyl)amino)-3(S)-methylpentylloxy)-3-phenylpropionyl]-methionine;

N-[2(S)-(2(S)-Imidazol-4-ylcarbonyl)amino)-3(S)-methylpentylloxy)-3-phenylpropionyl]-methionine methyl ester;

20 N-[2(S)-(2(S)-((3-Picolinyl)amino)-3(S)-methylpentylloxy)-3-phenylpropionyl]-methionine;

25 N-[2(S)-(2(S)-((3-Picolinyl)amino)-3(S)-methylpentylloxy)-3-phenylpropionyl]-methionine methyl ester;

N-[2(S)-(2(S)-((Histidyl)amino)-3(S)-methylpentylloxy)-3-phenylpropionyl]-methionine;

30 N-[2(S)-(2(S)-((Histidyl)amino)-3(S)-methylpentylloxy)-3-phenylpropionyl]-methionine methyl ester;

N-Benzyl-N-[2(S)-((Imidazol-4-ylcarbonyl)amino)-3(S)-methylpentyl]-glycyl-methionine;

- 167 -

N-Benzyl-N-[2(S)-((Imidazol-4-ylcarbonyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester;

5 N-Benzyl-N-[2(S)-((Imidazol-4-ylacetyl)amino)-3(S)-methylpentyl]-glycyl-methionine;

N-Benzyl-N-[2(S)-((Imidazol-4-ylacetyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester;

10 N-Benzyl-N-[2(S)-((Pyroglutamyl)amino)-3(S)-methylpentyl]-glycyl-methionine;

15 N-Benzyl-N-[2(S)-((Pyroglutamyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester;

N-(1-Naphthylmethyl)-N-[2(S)-((imidazol-4-ylcarbonyl)amino)-3(S)-methylpentyl]-glycyl-methionine;

20 N-(1-Naphthylmethyl)-N-[2(S)-((imidazol-4-ylcarbonyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester;

N-(1-Naphthylmethyl)-N-[2(S)-((imidazol-4-ylacetyl)amino)-3(S)-methylpentyl]-glycyl-methionine;

25 N-(1-Naphthylmethyl)-N-[2(S)-((imidazol-4-ylacetyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester;

30 N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)amino)-3(S)-methylpentyl]-glycyl-methionine;

N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester;

- 168 -

N-[1-(Pyroglutamylamino)cyclopent-1-ylmethyl]-N-(1-naphthylmethyl)-glycyl-methionine methyl ester;

5 N-[1-(Pyroglutamylamino)-cyclopent-1-ylmethyl]-N-(1-naphthylmethyl)-glycyl-methionine;

N-(2(S)-L-Histidylamino-3(S)-methylpentyl)-N-(benzylmethyl)glycyl-methionine methyl ester;

10 N-(2(S)-L-Histidylamino-3(S)-methylpentyl)-N-(benzylmethyl)glycyl-methionine;

15 N-(2(S)-L-Histidylamino-3(S)-methylpentyl)-N-(1-naphthylmethyl)-glycyl-methionine methyl ester;

N-(2(S)-L-Histidylamino-3(S)-methylpentyl)-N-(1-naphthylmethyl)-glycyl-methionine;

20 2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyloxy]-3-methylbutanoyl-methionine methyl ester;

2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyloxy]-3-methylbutanoyl-methionine;

25 2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyloxy]-3-methylbutanoyl-methionine methyl ester;

30 2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyloxy]-3-methylbutanoyl-methionine;

N-(Benzyl)-N-[2(S)-(2-oxopyrrolidin-5(R,S)-ylmethyl)amino-3(S)-methylpentyl]-glycyl-methionine methyl ester;

- 169 -

N-(Benzyl)-N-[2(S)-(2-oxopyrrolidin-5(R,S)-ylmethyl)amino-3(S)-methylpentyl]-glycyl-methionine;

5 N-(Benzyl)-N-{2(S)-[[(D,L)-2-thiazolyl]alanyl]amino}-3(S)-methylpentyl]-glycyl-methionine methyl ester;

N-(Benzyl)-N-{2(S)-[[(D,L)-2-thiazolyl]alanyl]amino}-3(S)-methylpentyl]-glycyl-methionine;

10 N-(Benzyl)-N-[2(S)-(3-pyridylmethyl)amino-3(S)-methylpentyl]-glycyl-methionine methyl ester;

15 N-(Benzyl)-N-[2(S)-(3-pyridylmethyl)amino-3(S)-methylpentyl]-glycyl-methionine;

2(S)-[2(S)-(2-Oxopyrrolidin-5(S)-ylmethyl)amino-3(S)-methylpentyl]oxy]-3-phenylpropionyl-methionine methyl ester;

20 2(S)-[2(S)-(2-Oxopyrrolidin-5(S)-ylmethyl)amino-3(S)-methylpentyl]oxy]-3-phenylpropionyl-methionine ;

2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl]oxy]-3-(1-naphthyl)propionyl-methionine sulfone methyl ester;

25 2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl]oxy]-3-(1-naphthyl)propionyl-methionine sulfone;

30 2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl]oxy]-3-(2-naphthyl)propionyl-methionine sulfone methyl ester;

2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl]oxy]-3-(2-naphthyl)propionyl-methionine sulfone;

- 170 -

2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]oxy]-3-(1-naphthyl)propionyl-methionine sulfone methyl ester;

5 2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]oxy]-3-(1-naphthyl)propionyl-methionine sulfone;

2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]oxy]-3-(2-naphthyl)propionyl-methionine sulfone methyl ester;

10 2(S)-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]oxy]-3-(2-naphthyl)propionyl-methionine sulfone;

15 N-(Benzyl)-N-[2(S)-(tetrazol-1-ylacetyl)amino-3(S)-methylpentyl]-glycyl-methionine methyl ester;

N-(Benzyl)-N-[2(S)-(tetrazol-1-ylacetyl)amino-3(S)-methylpentyl]-glycyl-methionine;

20 N-(Benzyl)-N-[2(S)-nicotinoylamino-3(S)-methylpentyl]-glycyl-methionine methyl ester;

N-(Benzyl)-N-[2(S)-nicotinoylamino-3(S)-methylpentyl]-glycyl-methionine;

25 N-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)-glycyl-methionine sulfoxide methyl ester;

30 N-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)-glycyl-methionine sulfoxide;

2(S)-{2(S)-[2(S,R)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl]oxy}-3-phenylpropionyl-methionine sulfone methyl ester;

- 171 -

2(S)-{2(S)-[2(S,R)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl-oxy}-3-phenylpropionyl-methionine sulfone;

5 2(S)-{2(S)-[2(R,S)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl-oxy}-3-phenylpropionyl-methionine sulfone methyl ester;

2(S)-{2(S)-[2(R,S)-(Imidazol-4-yl)-2-aminoacetyl]amino}-3(S)-methylpentyl-oxy}-3-phenylpropionyl-methionine sulfone;

10 N-{2(S)-[2(S,R)-(Imidazol-4-yl)-2-aminoacetyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)-glycyl-methionine methyl ester;

15 N-{2(S)-[2(S,R)-(Imidazol-4-yl)-2-aminoacetyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)-glycyl-methionine;

N-{2(S)-[2(R,S)-(Imidazol-4-yl)-2-aminoacetyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)-glycyl-methionine methyl ester;

20 N-{2(S)-[2(R,S)-(Imidazol-4-yl)-2-aminoacetyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)-glycyl-methionine;

N-{2(S)-[(Imidazol-4-yl)methyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)-glycyl-methionine methyl ester;

25 N-{2(S)-[(Imidazol-4-yl)methyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)-glycyl-methionine;

30 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine isopropyl ester;

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine t-butyl ester;

- 172 -

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(4-quinolyl-methyl)glycyl-methionine methyl ester;

5 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(4-quinolyl-methyl)glycyl-methionine;

N-{2(S)-[3-(Imidazol-4-yl)propyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)glycyl-methionine methyl ester;

10 N-{2(S)-[3-(Imidazol-4-yl)propyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)glycyl-methionine;

15 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-norleucine;

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-norleucine methyl ester;

20 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-glutamine;

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-glutamine t-butyl ester;

25 N-[2(S)-(3-pyridylmethyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-methionine methyl ester;

30 N-[2(S)-(3-pyridylmethyl)amino-3(S)-methylpentyl]-N-(1-naphthyl-methyl)glycyl-methionine;

2(S)-{2(S)-[2-(Imidazol-4-yl)ethyl]amino-3(S)-methylpentyloxy}-3-phenylpropionyl-methionine sulfone methyl ester;

- 173 -

2(S)-{2(S)-[2-(Imidazol-4-yl)ethyl]amino-3(S)-methylpentyl}-3-phenylpropionyl-methionine sulfone;

5 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-serine methyl ester;

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-(D,L)-serine;

10 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-(L,D)-serine;

15 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-homoserine lactone;

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-homoserine;

20 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(cinnamyl)glycyl-methionine methyl ester;

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(cinnamyl)glycyl-methionine;

25 N-[2(S)-[2-(Imidazol-4-yl)ethyl]amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine methyl ester;

30 N-[2(S)-[2-(Imidazol-4-yl)ethyl]amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine;

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-alanine methyl ester;

- 174 -

- N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-alanine;
- 5 N-[2(S)-(D-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine methyl ester;
- N-[2(S)-(D-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine;
- 10 2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl]-3-phenylpropionyl-methionine sulfone methyl ester;
- 2(S)-[2(S)-(L-Pyroglutamyl)amino-3(S)-methylpentyl]-3-phenylpropionyl-methionine sulfone;
- 15 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-methylenedioxybenzyl)glycyl-methionine methyl ester;
- 20 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-methylenedioxybenzyl)glycyl-methionine;
- N-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]-N-(2,3-dihydrobenzofuran-7-ylmethyl)glycyl-methionine methyl ester;
- 25 N-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]-N-(2,3-dihydrobenzofuran-7-ylmethyl)glycyl-methionine;
- N-{2(S)-[3-(3-indolyl)propionyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)glycyl-methionine methyl ester;
- 30 N-{2(S)-[3-(3-indolyl)propionyl]amino-3(S)-methylpentyl}-N-(1-naphthylmethyl)glycyl-methionine;

- 175 -

N-[2(S)-[3-(1-indolyl)propionyl]amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine methyl ester;

5 N-[2(S)-[3-(1-indolyl)propionyl]amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine;

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-histidine methyl ester;

10 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-histidine;

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(cyclopropylmethyl)glycyl-methionine methyl ester;

15 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(cyclopropylmethyl)glycyl-methionine;

20 N-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]-N-(cyclopropylmethyl)glycyl-methionine methyl ester;

N-[2(S)-(Imidazol-4-ylacetyl)amino-3(S)-methylpentyl]-N-(cyclopropylmethyl)glycyl-methionine;

25 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-dihydrobenzofuran-7-ylmethyl)glycyl-methionine methyl ester;

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-dihydrobenzofuran-7-ylmethyl)glycyl-methionine;

30 2(S)-[2(S)-N-(L-Pyroglutamyl)-N-methylamino-3(S)-methylpentyloxy]-3-phenylpropionyl-methionine methyl ester;

- 176 -

2(S)-[2(S)-N-(L-Pyroglutamyl)-N-methylamino-3(S)-methylpentyl]-3-phenylpropionyl-methionine;

5 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-O-methylserine methyl ester;

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-O-methylserine;

10 N-(1-Naphthylmethyl)-N-[2(S)-(N'-(L-pyroglutamyl)-N'-methylamino)-3(S)-methylpentyl]-glycyl-methionine methyl ester;

N-(1-Naphthylmethyl)-N-[2(S)-(N'-(L-pyroglutamyl)-N'-methylamino)-3(S)-methylpentyl]-glycyl-methionine;

15 N-[1-(Pyroglutamylamino)cyclopent-1-ylmethyl]-N-(1-naphthylmethyl)-glycyl-methionine methyl ester;

20 N-[1-(Pyroglutamylamino)-cyclopent-1-ylmethyl]-N-(1-naphthylmethyl)-glycyl-methionine;

N-[2(S)-(Pyridin-2-on-6-ylcarbonyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine methyl ester;

25 N-[2(S)-(Pyridin-2-on-6-ylcarbonyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine;

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(3-chlorobenzyl)glycyl-methionine methyl ester;

30 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(3-chlorobenzyl)glycyl-methionine;

- 177 -

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-O-methylhomoserine methyl ester;

5 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-O-methylhomoserine;

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-dimethylbenzyl)glycyl-methionine methyl ester;

10 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(2,3-dimethylbenzyl)glycyl-methionine;


15 N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-(2-thienyl)alanine methyl ester; or

N-[2(S)-(L-pyroglutamyl)amino-3(S)-methylpentyl]-N-(1-naphthylmethyl)glycyl-(2-thienyl)alanine;

20 or a pharmaceutically acceptable salt thereof.

10. A compound which inhibits farnesyl-protein transferase which is:

25 N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)amino)-3(S)-methylpentyl]-glycyl-methionine




or the pharmaceutically acceptable salts thereof.

- 178 -

11. A compound which inhibits farnesyl-protein transferase which is:


N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)amino)-3(S)-methyl-pentyl]-glycyl-methionine methyl ester



or the pharmaceutically acceptable salt thereof.

12. A compound which inhibits farnesyl-protein transferase which is:

N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)amino)-3(S)-methyl-pentyl]-glycyl-methionine isopropyl ester




or the pharmaceutically acceptable salt thereof.

13. A compound which inhibits farnesyl-protein transferase which is:


N-(1-Naphthylmethyl)-N-[2(S)-((pyroglutamyl)amino)-3(S)-methyl-pentyl]-glycyl-methionine t-butyl ester

- 179 -




or the pharmaceutically acceptable salt thereof.

14. A compound which inhibits farnesyl-protein transferase which is:
N-(1-Naphthylmethyl)-N-[2(S)-((imidazol-4-ylacetyl)amino)-3(S)-methylpentyl]-glycyl-methionine



or the pharmaceutically acceptable salt thereof.

15. A compound which inhibits farnesyl-protein transferase which is:
N-(1-Naphthylmethyl)-N-[2(S)-((imidazol-4-ylacetyl)amino)-3(S)-methylpentyl]-glycyl-methionine methyl ester



- 180 -

or the pharmaceutically acceptable salt thereof.

5 16. A pharmaceutical composition comprising a
pharmaceutical carrier, and dispersed therein, a therapeutically effective
amount of a compound of Claim 1.

10 17. A pharmaceutical composition comprising a
pharmaceutical carrier, and dispersed therein, a therapeutically effective
amount of a compound of Claim 2.

15 18. A pharmaceutical composition comprising a
pharmaceutical carrier, and dispersed therein, a therapeutically effective
amount of a compound of Claim 3.

 19. A pharmaceutical composition comprising a
pharmaceutical carrier, and dispersed therein, a therapeutically effective
amount of a compound of Claim 4.

20 20. A pharmaceutical composition comprising a
pharmaceutical carrier, and dispersed therein, a therapeutically effective
amount of a compound of Claim 9.

25 21. A method for inhibiting farnesylation of Ras protein
which comprises administering to a mammal in need thereof a
therapeutically effective amount of the composition of Claim 16.

30 22. A method for inhibiting farnesylation of Ras protein
which comprises administering to a mammal in need thereof a
therapeutically effective amount of the composition of Claim 17.

 23. A method for inhibiting farnesylation of Ras protein
which comprises administering to a mammal in need thereof a
therapeutically effective amount of the composition of Claim 18.

- 181 -

24. A method for inhibiting farnesylation of Ras protein which comprises administering to a mammal in need thereof a therapeutically effective amount of the composition of Claim 19.

5

25. A method for inhibiting farnesylation of Ras protein which comprises administering to a mammal in need thereof a therapeutically effective amount of the composition of Claim 20.

10

26. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 16.

15

27. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 17.

20

28. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 18.

25

29. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 19.

30

30. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 20.